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ABSTRACT 
 
Despite many efforts, the molecular mechanisms underlying the pathophysiology of neurodegenerative 
disorders have not been fully understood. Results published in literature highlight that different 
neurodegenerative diseases share common features: protein aggregation in neuronal tissue; oxidation of 
neuronal tissue mediated by redox-active metal ions interaction with a target protein; and functional 
demise. So, unveiling the physiological function of protein that aggregate in neurodegenerating tissues, 
as well as their interplay with metal ions, becomes a prominent issue, in order to understand the 
etiological trigger and to define a possible therapeutic strategy.  
Metal ions are essential elements for cellular processes, but at the same they are potentially dangerous 
since they can give rise to Fenton reaction and oxidative/nitrosative stress. So, their homeostasis is 
strictly regulated in each district of the organism, but in particular in the brain. The brain, having the 
highest metabolic rate and depending predominantly on oxidative metabolism for its energy, has 
developed fine mechanisms to compartmentalize, distribute, uptake and excrete the different ionic 
species. Alterations in one of these mechanisms can lead to great neuronal damages, and maybe 
neurodegenerative disorders.  
This work has been focused on the cellular prion protein (PrPC), whose conformational isoform, the 
scrapie prion protein (PrPSc) is the causative agent of prion disordes and whose function has not been 
clearly defined, yet. Metal ions are a common denominator to all the cellular pathways in which PrPC 
seems to be actively involved. In particular, metal ions homeostasis maintainance, neuroprotection in 
excitotoxic condition and ionotropic receptor modulation have been studied.  
In the first part of the project, PrPC role in metal ion homeostais maintainance has been investigated. 
To this aim, copper, manganese, zinc and iron content, as well as metal binding proteins expression 
have been measured in a PrP knockout murine model, compared to wild-type. The results describe the 
global rearrangement occurring in the expression of metal binding proteins to maintain trace metals 
homeostasis, trying to compensate PrPC absence. At the same time, a pronounced decrease in 
Ceruloplasmin ferroxidase activity has been detected in PrP null mouse serum, pointing out a global 
impairment in copper metabolism in PrPC absence.  
In the second part of the project, the importance of the interaction between PrPC and copper ions in 
excitotoxic conditions and in synapses functionality has been studied. It has been published that PrP 
null mice show higher levels of neuronal cell death in stressful conditions and when subjected to toxic 
treatment with glutamate receptor agonists. Moreover, these mice show altered kinetics of N-methyl-
D-aspartate (NMDA) receptor current. These alterations appears to be due to an inhibitory regulation 
that PrPC exerts on NMDA receptors via copper ions, lacking in PrP null hippocampi. First, the 
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enhanced suceptibility to excitotoxicity of PrP knockout mice has been verified and characterised in 
organotypic hippocampal cultures upon treatment with NMDA. Higher neuronal cell death levels have 
been detected in all the investigated hippocampal regions. To identify which cellular regulatory 
mechanism is alterd in PrPC absence, the expression of the proteins mainly involved in excitotoxicity 
has been compared between PrP knockout and wild-type hippocampi. Among other minor differences, 
a different modulation of calcium transporters expression has been identified in PrP knockout 
hippocampi and brains. This global alteration appears to be necessary to maintain calcium homeostasis, 
since calcium content measurements did not reveal any strong difference between PrP null and wild-
type samples.   
NMDA receptors can be S-nitrosylated on extracellular cysteines and this reaction is always inhibitory. 
S-nytrosilation requires an electron acceptor to occur, for this reason copper ions are often involved in 
these kind of reactions. Moreover, copper ions are known to modulate NMDA receptor activity, but 
the precise mechanism has not been described, yet. Since PrPC is known to support the S-nitrosylation 
of other membrane proteins, the S-nitrosylation levels of NMDA receptor subunits GluN1 and 
GluN2A have been measured in PrP knockout hippocampi from adult mice and compared to wild-type 
ones. Results show that the S-nitrosylated fractions of both GluN1 and GluN2A are reduced in PrP 
absence. So, this reveals that PrPC modulates NMDA receptor activity providing the copper ions 
necessary to support their inhibitory S-nitrosylation reaction. Through this mechanism, PrPC 
contributes to inhibit NMDA receptor currents, as well as to protect neurons in excitotoxic conditions.  
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INTRODUCTION 
 
During last century, neurodegenerative diseases have become a prominent health issue because of their 
increasing impact on modern society. Despite many efforts, the molecular mechanisms responsible for 
the pathophysiology of this group of disorders have not been fully understood. In a review published in 
the year 2000, it was observed that all neurodegenerative diseases share common features: protein 
aggregation in neuronal tissue; oxidation of neuronal tissue mediated by redox-active metal ions 
interaction with a target protein; and functional demise (Bush, 2000). The author proposed that at least 
certain disorders, like Alzheimer’s disease (AD), familial amyotrophic lateral sclerosis (fALS) and 
Creutzfeldt-Jakob disease (CJD), are caused by abnormal interaction of metals that are enriched in 
neuronal tissue with specific proteins that are vulnerable to such interactions. According to the author’s 
opinion, these abnormal metal-protein interactions are the etiological trigger of such disorders, together 
with the generation of microanatomical stress that triggers the damage of the cell site where the 
abnormal metal-protein interaction occurs. The author’s theory is summarized in Table 1 (modified 
from (Bush, 2000)). 
Cu/Fe-mediated degenerative diseases  
Specific protein 
Non-pathological Pathological 
Adverse metal Specific tissue Specific disease 
APP Aβ Cu, Fe, possible loss of Zn Neocortex AD 
PrPC PrPSc Cu Neocortex CJD 
SOD1 SOD1 Cu, loss of Zn Motor neuron fALS 
α-Crystallin α-Crystallin Cu, Fe Lens Cataracts 
 
Table 1. List of the neurodegenerative diseases that share the same molecular pathogenic mechanism proposed in (Bush, 
2000). Amyloid precursor protein (APP), Amyloid β (Aβ), cellular Prion Protein (PrPC) scrapie Prion Protein (PrPSc), 
Superoxide dismutase 1 (SOD1). 
Among all, prion disorders represent a prominent biological and pathological question. This class of 
diseases also known as transmissible spongiform encephalopaties (TSEs) can be either sporadic or 
genetic or infective (Prusiner, 2001). Infectivity is properly the peculiar characteristic of prions. Prion 
diseases include bovine spongiform encephalopaty (BSE) in cattle, scrapie in ovine, chronic wasting 
disease (CWD) in deer, moose and elk, and Kuru, CJD, fatal familial insomnia (FFI) and Gerstmann, 
Sträussler and Scheinker syndrome (GSS) in humans (Table 2 (Aguzzi et al., 2004)). 
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Table 2. Spectrum of prion diseases of human and animals (Aguzzi et al., 2004) 
All prion diseases affect primarly the nervous system, but the clinical features can be variable according 
to the different TSEs forms. These differences regard the etiology (whether sporadic, genetic or 
infective), the incidence of the disease, the brain region affected by replicating prions deposits, the 
manifested clinical symptoms and the disease time-course (Prusiner, 1992; Prusiner and DeArmond, 
1994). Despite these differences, all TSEs are generally characterized by spongiosis, resulting in brain 
tissue vacuolated appearance, neuronal loss and diffused astrocytic gliosis (Figure 1 (Aguzzi et al., 
2001)). At the present, all prions diseases are fatal, progressive and without cure, dramatic features 
shared by all others neurodegenerative disorders.  
 
Figure 1. Neuropathological features of TSEs. Histological and immunohistochemical analysis of frontal cortex samples 
from the brain of a patient who died of non-cerebral causes (upper row) and a patient suffering from CJD (lower row). 
Brain sections were stained with hematoxylin-eosin (H-E, left panels), with antibodies against glial fibrillar acidic protein 
(GFAP, middle panels) and with antibodies against the prion protein (PrP, right panels). Neuronal loss and prominent 
spongiosis are visible in the H-E stain. Strong proliferation of reactive astrocytes (gliosis) and perivacuolar prion protein 
deposits are detectable in the GFAP and PrP immunostaining of the CJD brain samples (from Aguzzi et al., 2001).   
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PRION CONCEPT 
The term “prion” was coined by Prusiner in 1982 and stands for “proteinaceus infectious particle”, to 
underline the exclusively proteinaceous property of these disorders causative, infective agent: this 
proposition lead to the so called “protein-only hypothesis” (Prusiner, 1982). According to Prusiner’s 
theory, the infective particle responsible for scrapie disease is primarily composed of a protein able to 
transmit the infection and replicate itself without requirement of nucleic acids. The protein 
identification and the sequencing revealed it was encoded by an endogenous cellular gene (in mouse 
Prnp, in humans PRNP) whose translational product was called cellular prion protein (PrPC) (Oesch et 
al., 1985). Prions are the product of a posttranslational conformational remodelling event converting 
PrPC into the disease-associated infectious form PrPSc. PrPC and PrPSc differ for some biochemical 
characteristics: PrPC is mainly α-helical, while PrPSc is highly enriched in β-sheet (Caughey et al., 1991; 
Gasset et al., 1993). In prion disease inherited forms, a genetic mutation in the PrP encoding gene 
occurs and destabilizes the protein tertiary structure, promoting its conversion to the scrapie form as 
well as the aggregation process. In infective forms, a preformed PrPSc-aggregate directly triggers the 
conversion of endogenous PrPC. In sporadic disease, PrPC tertiary structure is likely to be perturbed by 
unknown biochemical modifications, favouring PrPSc formation. However, the mechanisms underlying 
sporadic TSEs are yet to be clarified (Prusiner, 1991, 1994).  
PRION TOXICITY 
The mechanism by which prions damage the central nervous system (CNS) remains unknown. The 
infectious particle may correspond to either a single molecule of a prion or a small PrPSc oligomer, but 
which species triggers the toxic effects is still under debate (Aguzzi and Falsig, 2012). In the case of 
prion diseases, it is known that PrPC is required for the pathology development (Bueler et al., 1993; 
Watts and Westaway, 2007). Nevertheless, mice expressing low levels of glycosylphosphatidylinositol 
(GPI) lacking PrPC, named PrP(ΔGPI), remained healthy and exhibited little or no neuropathologic 
changes, while neuronal expression of PrP(ΔGPI) at 1.7× levels compared with PrPC expression in 
wild-type mice resulted in late-onset, spontaneous neurologic illness accompanied by a profound CNS 
amyloidosis resembling GSS (Chesebro et al., 2005; Stohr et al., 2011). Moreover, the pathology can be 
reversed by acute PrPC ablation in vivo during the neurotoxic phase of prion replication (Mallucci et al., 
2003) leading to a hypothetical switch off of PrPC endogenous expression as a cure to prion diseases. In 
light of all these findings, it is still unclear whether prion toxicity is due either to a gain-of-function of 
oligomeric species or to a lack-of-function of PrPC. To answer all these questions, it is crucial to 
understand which is PrPC physiological function.  
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THE CELLULAR PRION PROTEIN - PrPC 
The cellular prion protein, PrPC, is an endogenously encoded protein composed of 254 amino acids in 
mouse. As described in Figure 2, it is a sialoglycoprotein that is attached to the outer leaf of the plasma 
membrane via a C-terminal GPI anchor (Stahl et al., 1990). It can be expressed in un-, mono- or di-
glycosilated forms, corresponding to the variable occupancy of the residues Asn180 and Asn196 in 
mice (Haraguchi et al., 1989). The globular domain of the protein contains three α-helices interspersed 
with an antiparallel β-sheet. One disulfide bridge is present between Cys178 and Cys213. The N-
terminal portion is a flexible, unstructured domain containing the octapeptide repeat (OR) that is 
preceded and followed by two positively charged clusters, CC1 and CC2. The N- and the C-terminals 
are linked by a hydrophobic amino acidic stretch, also named hydrophobic core (HC) (Zahn et al., 
2000).  
 
Figure 2. Mouse prion protein scheme. This protein is anchored to the cell membrane by a glycosylphosphatidylinositol 
(GPI) anchor. The signal peptide for entry into the endoplasmic reticulum and the GPI signal peptide are cleaved before the 
protein reaches the cell surface. Glycosylation can occur on one, two or none of the Asn residues indicated. A hydrophobic 
region envelops a cleavage point (N-terminal cleavage) where the protein is cleaved during normal metabolic breakdown. A 
disulfide bridge links two regions of the protein that form separate α-helices in the three dimensional structure of the 
protein. The complete octameric repeats can bind up to four copper atoms, most mammals also have an incomplete repeat 
located upstream of this (Brown, 2001).   
COPPER- BINDING TO PrPC 
One of the most salient features of PrPC is its ability to bind divalent cations such as copper (Cu) ions 
(Arena et al., 2012). The major Cu binding site has been identified at the N-terminus OR domain 
composed of four sequential repeats of the sequence PHGGGWGQ between residues 59-90, while 51-
58 residues constitute a nonarepeat lacking the histidine residue (Brown et al., 1997a; Hornshaw et al., 
1995). Cu binding importance for PrPC physiological function is reflected in the high OR conservation 
degree among different mammalian and avian species (Vassallo and Herms, 2003). Beside Cu, the OR 
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region is able to bind other divalent cations like Zn, Ni, Fe and Mn (Jackson et al., 2001; Singh et al., 
2010; Stockel et al., 1998). However, at physiological pH Cu shows the highest binding affinity and 
specific Cu concentrations are sensed by transitioning from a multi-His binding mode at low Cu levels 
to a single-His, amide nitrogen bond at high Cu levels (Chattopadhyay et al., 2005; Liu et al., 2011). The 
OR region cooperatively binds up to four Cu ions with 5-8µM affinity (Kramer et al., 2001; Whittal et 
al., 2000). These values are compatible with the physiological Cu concentration released in the synaptic 
cleft during synaptic vesicle release (15µM) and during neuronal depolarization (100-300µM) (Hartter 
and Barnea, 1988). Moreover, histidines at positions 96 and 111 create a high affinity Cu binding site 
(10-14M) (Jackson et al., 2001; Jones et al., 2004). Both the low and high occupancy copper binding 
mode support the reduction of Cu(II) to Cu(I), thus, protecting against the production of reactive 
oxygen species from unregulated Fenton type reactions (Liu et al., 2011). Despite many studies trying 
to understand the physiological relevance of PrPC Cu binding, a defined consensus has been elusive.  
PrPC EXPRESSION AND SUBCELLULAR LOCALIZATION 
Though PrPC is mostly expressed in the nervous system, it is also present in many non-neuronal tissues, 
for instance blood lymphocytes, gastroepithelial cells, heart, kidney and muscles (Fournier et al., 1998; 
Horiuchi et al., 1995). This pattern of expression implies that PrPC function is not limited to the 
nervous tissue, despite the fact that the high expression in the CNS suggests a special relevance for 
neurons. The protein PrPC is particularly abundant in the developing and in the mature nervous system 
and it is expressed in both neuronal and glial cells. PrPC expression starts from early embryonic stages 
and is developmentally regulated (Benvegnu et al., 2010; Lazarini et al., 1991; Manson et al., 1992; 
Mobley et al., 1988; Sales et al., 2002). In the brain, its expression increases during the initial postnatal 
weeks up to the synaptogenetic process completion (coincident with one month of age), and afterwards 
it remains stable at plateau during adulthood. In particular, the olfactory bulb and the hippocampus, 
which are both characterized by neuronal renewal also in adulthood, show the higher PrPC expression 
levels (Sales et al., 2002). The protein levels may decrease with aging.  
The polypeptide expression levels vary among distinct brain regions, cell types and neurochemical 
phenotypes (Benvegnu et al., 2010; Linden et al., 2008). While several controversial results concerning 
PrPC subcellular localization (cell body, axonal, dendritic, synaptic compartment) have been reported, it 
is widely accepted that its expression is concentrated at synapses, both presynaptically and 
postsynaptically (Fournier et al., 1998; Haeberle et al., 2000; Herms et al., 1999; Linden et al., 2008; 
Moya et al., 2000; Sales et al., 1998). Many lines of evidence suggest that PrPC transport along the axon 
to the presynaptic or the postsynaptic bouton depends on the different glycoforms of the protein 
(Rodolfo et al., 1999). Moreover, the diglycosilated PrPC can be isolated in detergent insoluble rafts 
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(Naslavsky et al., 1997). These are specialized plasma membrane areas enriched in cholesterol, 
sphingolipids and proteins, functioning in membrane trafficking and signalling (Simons and Ikonen, 
1997). Accumulating evidence has shown that both the presynaptic and postsynaptic sites are highly 
enriched in lipid rafts, which are likely to organize and maintain synaptic proteins in their precise 
localization. For example, both ionotropic and metabotropic glutamate receptor are specifically 
localized in rafts (Sebastiao et al., 2013).  
PrP KNOCKOUT AND TRANSGENIC MURINE MODELS 
To understand PrPC physiological function, several knockout and transgenic murine lines for the Prnp 
gene have been created. The first generation of knockout mice, namely Prnp0/0 (ZurichI) and Prnp-/- 
(Edimburgh) (Bueler et al., 1992; Manson et al., 1994) showed normal development as well as no 
pathological signs during their lifespan. Subsequently, other three Prnp0/0 were created, namely Ngsk 
Prnp-/- (Nagasaki), Rcm0 and Prnp-/-(Zurich II), which revealed loss of Purkinje cells and cerebellar 
degeneration (Moore et al., 1999; Rossi et al., 2001; Sakaguchi et al., 1996). These results were due to 
another gene, Prnd, located 16kb downstream to Prnp gene, which resulted to be overexpressed in 
Ngsk, Rcm0 and ZurichII, but not in ZurichI and Edimburgh (Moore et al., 1999). This gene encodes 
for a protein, named Doppel (Dpl, Mus musculus nomenclature), which is not usually expressed in the 
brain and resulted expressed in the second generation of PrP knockout mice, because of an accidental 
deletion of a splice acceptor site, leading to exon skipping phenomenon and, in turn, to the generation 
of chimeric Prnp-Prnd mRNA. This brought Dpl expression under the control of Prnp promoter, so 
highly expressed in the brain. Dpl ectopic expression in the brain causes cerebellar granule ataxia and 
degeneration that could be rescued by Prnp gene re-introduction (Nishida et al., 1999). This latter result 
shows PrPC acting as an antagonist of Dpl, counteracting its neurotoxic effects in vivo and in vitro 
(Didonna et al., 2012).  
Additionally, murine models carrying PrPC deletion mutants have been created aiming at identifying 
functional domains of the protein (Figure 3). For example, an initial report of Prnp0/0 mice expressing 
PrPC lacking amino acid residues 32-121 or 32-134 (PrPΔ32-121 and PrPΔ32-134) revealed how the 
expression of these truncated PrP caused severe ataxia and neuronal cell death limited to the granular 
layer of the cerebellum, as well as widespread gliosis and demyelination in the brain stem, similar to the 
phenotype elicited by Dpl ectopic expression (Shmerling et al., 1998). Gliosis and demyelination could 
be rescued by oligodendrocyte-specific PrPC expression, but not cerebellar neurodegeneration. 
Viceversa, neuron-specific PrPC expression can partially rescue cerebellar granule cell degeneration, but 
not demyelination (Radovanovic et al., 2005).  Thus, white matter disease and cerebellar granule cell 
degeneration are independent and distinct in these models and wild-type PrPC expression is required in 
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both neurons and glia to completely revert the degenerative phenotype. Neurodegeneration and myelin 
damage are two distinct pathological phenotypes induced by distinct PrP mutants. Mice on a Prnp0/0 
background and expressing PrPC lacking amino acid residues 32-93 (PrPΔ32-93) within the OR region 
do not show pathological phenotypes: this may indicate that the lack of the central domain (CD, 
residues 94-134) creates a toxic protein isoform. The CD domain includes the positively charged CC2 
cluster and the HC core, previously described. To analyse the two domains different contributions to 
the pathological phenotype, other Prnp transgenic models have been created deleting the entire central 
domain, PrPΔ94-134 (Baumann et al., 2007). Mice entirely lacking CD showed a drastic 
neuropathological phenotype with vacuolar degeneration, astrogliosis, extensive central and peripheral 
nervous system (PNS) and death within 20-30 days (Baumann et al., 2007). Despite the similar myelin 
damage, this model lacks cerebellar degeneration observed in PrPΔ32-121 and PrPΔ32-134 expressing 
mice. Furthermore, mice lacking residues 105-125 (referred to as ΔCR) develop an even more dramatic 
phenotype, developing a severe neurodegeneration that becomes lethal within the first post-natal week 
(Li et al., 2007). Expression of ΔCR PrP induces a strong ion channel activity in transfected cells that 
can be detected by patch-clamping techniques (Solomon et al., 2010; Solomon et al., 2011). Each of 
these phenotypes can be rescued co-expressing the wild-type PrPC in a dose-dependent manner 
according to the mutant PrP expression level and the severity of the pathology elicited (Baumann et al., 
2007; Li et al., 2007). According to the model proposed by Baumann and colleagues and shown in 
Figure 4, PrPC and its deletion mutants can compete for a common ligand, maybe a receptor that 
regulate signal transduction.  
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Figure 3. Deletions within the central region of the prion protein (PrP) are associated with neurotoxicity in transgenic mice. 
(a) Deletions up to residue 106 have no adverse effect (Shmerling et al., 1998), whereas deletions extending to residues 121 
or 134 cause spontaneous neurodegenerative illness in the absence of endogenous PrPC (Shmerling et al., 1998). Additional 
deletions (Δ94-134 (Baumann et al., 2007) and Δ105-125 (Li et al., 2007)) narrow the critical neurotoxicity-determining 
region to a highly conserved segment of 21 amino acids in the central region (105-125). Schematics show the structures of 
wild-type (WT) mouse PrP and each of the deletion mutants (with the deleted region indicated by broken lines). The 
column labelled “Onset” gives the age (in weeks) at which spontaneous neurological illness occurs in mice expressing the 
corresponding deletion mutant. The column labelled “WT PrP rescue” gives the fold expression WT PrPC needed to 
prevent the appearance of neurological illness. A minus symbol (-) indicated that no spontaneous disease is observed. (b) 
The graph, which is a representation of the data shown in the first two columns, shows the inverse correlation between age 
of onset in the different mouse lines and the amount of WT PrP expression required for rescuing the neurological 
phenotype (Biasini et al., 2012).   
 
Figure 4. A model showing the effects of PrPC deletion mutants. (A) Schematic diagram of wild-type PrPC and its several 
deletion mutants. SP, signal peptide; octarepeats are indicated in blue; CC, charged cluster; HC, hydrophobic core; H1, H2, 
H3 Helix 1, 2 and 3, respectively; GPI, GPI-anchor addition sequence (B). PrP (purple) consist of a globular C-terminal 
domain (hexagon) and a N-terminal flexible tail (arch) encompassing the octapeptide repeats (circle). The model rests on the 
following assumptions: (1) PrP activates a hitherto unidentified receptor (PrPR) which transmits myelin maintainence signal 
(flashes); (2) in the absence of PrP, PrPR exerts some residual activity, either constitutively or by recruiting a surrogate 
ligand; (3) the activity of PrP and its mutants requires homo- or heterodimerization, and induces dimerization of PrPR; and 
(4) PrP dimers containing PrPΔCD or PrPΔCD trap PrPR in an inactive dominat-negative state (from (Steele et al., 2007)). 
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PHYSIOLOGICAL FUNCTION OF PrPC 
Though the precise PrPC role in cellular physiology has not properly been established, this protein has 
been linked to many cellular processes in the nervous system: neuronal survival, neurite outgrowth, 
synapse formation, maintenance and functionality, as well as formation and maintenance of myelinated 
fibers (Figure 5 (Aguzzi et al., 2008) and Table 3 (Caughey and Baron, 2006)).  Another function that 
has been proposed for PrPC concerns a role in metal ion homeostasis and metabolism (Singh et al., 
2009b; Singh et al., 2010).  
Hereafter, some of the proposed functions of PrPC will be described, according to the topic and the 
aim of this Ph.D. project and thesis.  
 
 
 
Figure 5. Physiological processes involving PrPC. Several processes in the nervous system have been influenced by PrPC. 
Neurite ougrowth, including growth of axons and dendrites, was observed to be reuced in neurons lacking PrPC. PrPC has 
often been reported to promote neuronal survival, in particular following apoptotic or oxidative stress. Cerebellar granule 
cell apoptosis was observed in mice expressing toxic N-terminal deletion mutants of PrP. In addition, tha latter transgenic 
mice show an impaired maintenance of myelinated axons in the white matter. Another site of PrPC action might be the 
synapse, which is often affected in the first stage of prion diseases and whose formation was found to be reduced in 
neuronal cultures devoid of PrPC. Furthermore, electrophysiological studies indicate a role of PrPC in synapse function, 
especially in neurotrasmitter release (Aguzzi et al., 2008).  
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Table 3. The cellular distribution and activities of PrPC in cell types in which known or putative functions have been 
described (Caughey and Baron, 2006).  
FUNCTIONS OF PrPC AND METALS INTERACTION  
The importance of understanding the interaction between PrPC and metals relies on the physiological 
and pathological implications it has.  In normal conditions, PrPC mediates Cu and Fe uptake (Brown, 
2003; Singh et al., 2009b). PrPSc has a higher affinity for Ni, decreasing the binding of Zn and Mn 
(Jackson et al., 2001). All essential metals metabolic pathways are strictly related and interconnected. So, 
for instance, it is likely that Cu and Fe uptake is impaired in prion disease due to this shift in metal 
binding affinity of PrPSc.  
The PrPC-Cu interaction is the best characterized, as described above. Observations from 
neuroblastoma cells suggest that PrPC contributes to Cu uptake since it binds extracellular Cu ions and 
delivers them to the endocytic compartment, thus increasing antioxidant enzymes activity (Brown and 
Harris, 2003; Pauly and Harris, 1998; Rachidi et al., 2003). Moreover, the OR region plays a role in the 
reduction of Cu(II) to Cu(I) before transporting the metal across the endosomal membrane to the 
cytosol (Miura et al., 2005). Thus, PrPCmay function as a Cu uptake and delivery protein, although 
results concerning Cu content in the brain of wild-type, PrPC null, PrPC overexpressing and scrapie 
infected mice reported in literature are discordant, leaving PrPC influence on the global brain Cu 
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content an unsettled matter (Singh et al., 2010). For instance, some results show no differences in Cu 
content upon PrPC ablation (Giese et al., 2005; Waggoner et al., 2000), but others highlight a reduced 
Cu amount in the CNS of PrPC null mice (Brown et al., 1997a; Brown et al., 1998). Concerning the role 
of the protein at the synapses, it has been proposed by Vassallo and Herms in 2003 that PrPC acts as a 
buffer of Cu(II) ions released in the synaptic cleft. In this way, PrPC protects synapses from Fenton 
redox reaction that Cu(II) can produce. Furthermore, in the presynaptic bouton, PrPC has a role in the 
redistribution of Cu ions that are released together with neurotransmitters, contributing to  
synaptosomal Cu concentration maintenance. This likely occurs by transferring of Cu to membrane 
transporters that have higher affinity compared to PrPC. A similar mechanism may occur in the 
postsynaptic bouton where PrPC is also expressed (Moya et al., 2000) and Cu ions are released from the 
trans-Golgi network (TGN) upon activation of glutamate ionotropic receptors (Schlief et al., 2005; 
Schlief et al., 2006). Vassallo and Herms hypothesis explains why Cu content in Prnp0/0 mice is almost 
unchanged: PrPC absence affects Cu distribution but not its overall content (Vassallo and Herms, 2003).  
Using cells expressing PrPC mutants and Prnp0/0 mice, it has been shown that the protein has a 
fundamental role in Fe metabolism (Singh et al., 2009b; Singh et al., 2009c). PrP null cells have a lower 
Fe content as well as a lower ferritin saturation level. Even increasing Fe concentration in the 
extracellular medium, Fe uptake and storage remains unchanged, thus indicating a dominant effect of 
PrPC ablation. On the contrary, cells overexpressing PrPC increase the intracellular Fe pool, saturating 
ferritin molecules. In addition, Prnp0/0 mice show a lower Fe content in the brain, probably due to an 
impaired intestinal absorption, while, re-establishing PrPC expression in PrPC null mice, the phenotype 
is reversed indicating the specificity of PrPC functional role (Singh et al., 2009b). Presently, it has not 
been clarified whether PrPC mediates Fe uptake by using a novel pathway or by interacting with 
conventional Fe uptake and transport pathways (Singh et al., 2010). It has been proposed that it can 
interact with the transferrin/transferrin receptor pathway or functions as a ferric reductase, facilitating 
the transport of Fe(III) from endosomes to cytosolic ferritin (Singh et al., 2009c). However, since Fe 
content is just mildly affected in Prnp0/0 mice, it is likely that PrPC absence modulates others Fe uptake 
proteins or compensatory mechanisms occur. Concerning a direct binding between PrPC and Fe, results 
are still contradictory and preliminary (Singh et al., 2010).  
In 2010, Aguzzi’s group reported that PrPC expression on neuronal cells, but not on Schwann’s cells, is 
fundamental to maintain myelination and prevent chronic demyelinating polyneuropathy (CDP) in the 
PNS (Bremer et al., 2010). Their results better characterised what previously observed by Nishida and 
colleagues (Nishida et al., 1999). It has been known that metal ions, in particular Cu and Fe are 
necessary to both myelin formation and maintainance (Benetti et al., 2010; Skripuletz et al., 2008). So, it 
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is likely that PrPC function in these processes can be due to both a direct molecular mechanism, as 
suggested in (Benvegnu et al., 2011), and to an alteration in Cu and Fe homeostasis that triggers CDP.   
Though with a lower affinity, PrPC also binds Zn. However, in cell models Zn is able to alter the 
distribution of PrPC-Cu complex (Watt and Hooper, 2003), indicating that, given the relevant Zn 
concentration in the brain, PrPC-Zn interaction may be more significant than expected (Kenward et al., 
2007; Qin et al., 2002; Walter et al., 2007; Watt and Hooper, 2003). Concerning PrPC role in Zn uptake, 
controversial results has been published. Rachidi and colleagues observed that PrPC protects from Zn 
toxicity in cell cultures without affecting Zn uptake. Thus, a Zn re-localization effect of PrPC 
expression together with an increased expression of metallothioneins (Mt) were supposed to mediate 
protection from Zn toxicity (Rachidi et al., 2009). On the contrary, Watt and colleagues recently 
reported that PrPC enhances the uptake of zinc into neuronal cells (Watt et al., 2012). The transport 
requires PrPC ORs and amino-terminal polybasic region, but not its endocytosis. PrPC-mediated Zn 
uptake occurs upon  activation of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) 
receptors. Evidences of a physiological consequence of this process were also provided: Zn-sensitive 
intracellular tyrosine phosphatase activity is decreased in wild-type cells and increased in the brains of 
PrPC null mice. Moreover, PrPC-mediated Zn uptake is ablated in cells expressing familial associated 
mutants of the protein and in prion-infected cells. These data suggest that alterations in Zn uptake may 
contribute to neurodegeneration in prion and other neurodegenerative diseases. 
Recombinant PrP has been shown to bind Mn in place of Cu with the same or weaker affinity on the 
N-terminal OR region, and Mn2+ binds also at a second site near His 96 or His111 (Brown et al., 2000; 
Jackson, 2001). However, after binding, Mn switches PrPC conformation into a PrPSc similar form with 
increased β-sheet content and reduced antioxidant activity (Brown et al., 2000; Tsenkova et al., 2004). 
A switch of PrPC to a protease-resistant and detergent-isoluble conformation has been also observed 
after Cu addition to PrPC extracted from transgenic mouse brain and transfected cells (Quaglio et al., 
2001). As in case of Mn, Cu-treated PrPC resulted to be structurally distinct from PrPSc. The authors 
observed that metal binding to the N-terminal region of PrP affects its biochemical properties. This 
suggests a potential roles in prion diseases and in the physiological function of PrPC. 
ESSENTIAL METALS METABOLISM AND HOMEOSTASIS 
Biometals are essential for a wide range of biological functions, from electrochemical gradients 
generation to enzyme active sites formation. Based on instability constant values of their complexes 
with biological ligands, metals are classified as weak (e.g. sodium and potassium, Kinst ≥ 10
-1 M), 
moderate (e.g. calcium and magnesium, Kinst ≥ 10
-8 M) and strong (e.g. transition metals, Kinst ≤ 10
-15 
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M). Both alkali metals and alkaline earth metal, also called hard ions, generates weak and moderate 
complexes because of their poor polarizability. They give rise to highly dynamic complexes, preferring 
oxygen over nitrogen and sulphur ligands. On the contrary, transition metals, also called soft ions and 
characterized by multiple valences, present an incomplete inner electron shell that is highly polarizable, 
allowing stable complexes formation, such as those of prosthetic groups. That is the reason why 
transition metals prefer nitrogen and sulphur ligands. While hard ions are indicated as macronutrients 
because of their large amounts in biological systems, soft ions are known as micronutrients. However, 
iron, copper, zinc, manganese, cobalt, nickel, chromium and molybdenum provide essential 
biochemical activities and structural scaffolding to a multitude of proteins including enzymes and other 
cellular constituents. Moreover, free ionic or exchangeable Zn and Cu are released in the glutamatergic 
synaptic cleft of hippocampus and cortex to inhibit N-Methyl-D-Aspartate (NMDA) receptor activity 
(Schlief et al., 2005). At the same time, increasing evidences suggest that Zn can be a second messenger, 
like calcium (Frederickson et al., 2005).  
Iron is the most abundant transition metal and it is used by both Fe-sulphur cluster and porphyrin 
conjugates containing proteins, primarily heme. Fe-containing proteins include haemoglobin and 
myoglobin which function in oxygen transport, cytochromes which are necessary for both respiration 
and detoxification, aconitase and other proteins which are required for oxidative metabolism, 
ribonucleotide reductase which catalyzes the rate-limiting step in DNA synthesis, and many others 
(Hower et al., 2009). Iron is required in different CNS metabolic processes as neurotransmitter 
production or nitric oxide metabolism (Ponka, 1999). Its oxidation states range from –II to +VI, 
though the two most biologically relevant are Fe(II) and Fe(III) (Bleackley and Macgillivray, 2011). 
Iron, as the other transition metals, is a redox active element and it can promote free radicals formation 
through the Fenton reaction, with potential highly toxic effects. To minimize this risk, organisms have 
developed efficient systems for properly uptake, transport, load on proteins and store Fe ions, 
summarized in Figure 6 (Kambe et al., 2008). Considering the whole organism, Fe homeostasis is 
regulated at absorption, utilization and storage sites; no regulated excretion pathways have been 
developed (De Domenico et al., 2008). Major sites of regulation are: duodenum for dietary Fe 
absorption; bone marrow for red blood cells production; liver for Fe storage; spleen and other cells of 
the reticuloendothelial system (RES) for red blood cells catabolism and Fe recycling. Cell types 
involved in Fe homeostasis are the enterocyte in the duodenum, reticulocyte in the bone marrow, and 
macrophages in the spleen, liver and RES (De Domenico et al., 2008). Briefly, Fe is oxidized to Fe3+ in 
the intestinal lumen and in the serum, but to be transported into cells it needs to be reduced to Fe2+, 
likely by DCytb. So, upon extracellular reduction, Fe2+ is transported into enterocytes by divalent metal 
transporter 1 (Dmt1), it is exported by ferroportin (Fpn) and subsequently oxidized to Fe3+ by 
membrane bound copper-dependent ferroxidases hephaestin and ceruloplasmin (Cp). In the serum, 
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Fe3+ is bound to transferrin (Tf) that delivers it to cells. Upon transferrin receptor (TfR) binding, the 
Fe3+–Tf complex is internalized and iron is released from Tf in acidified endosomes, reduced by a six 
transmembrane epithelial antigen of the prostate (Steap) metalloreductase and then transported into the 
cytoplasm by Dmt1. Apo-Tf and the TfR are returned to circulation and plasma membrane, 
respectively, via the recycling endosome pathway. Cytosolic Fe is translocated into mitochondria via 
mitoferrin and loaded into Fe-S cluster by frataxin. Fe-S cluster is released into cytoplasm by ATP-
binding cassette transporter Abcb7. In the cytoplasm, Fe is stored as a complex with ferritin. In 
erythroblast, mitochondrial Fe is primarily used for heme synthesis. Fe recycling occur via reticulo-
endothelial macrophages, which engulf aged red blood cells and release it in the extracellular 
environment via Fpn. Released Fe is newly oxidized by GPI-linked Cp and loaded on Tf (Kambe, 
Weaver, & Andrews, 2008). 
Copper is an essential nutrient for all eukaryotic organisms due to its function as cofactor in a broad 
range of critical processes that include respiration (cytochrome C oxidase), neuropeptide maturation 
(peptidyl-α-mono-oxygenase), protection from oxidative stress (Cu,Zn-dependent superoxide 
dismutase, Sod1), neurotransmitter biogenesis (dopamine β-hydroxylase), pigmentation (tyrosinase), Fe 
absorption (Cp), connective tissue maturation (lysyl oxidase), and other key biological functions (Gupta 
and Lutsenko, 2009; Nose et al., 2006). Copper oxidation states range from +I to +III, though the 
biologically relevant oxidation states are +I and +II. Cuprous ions (Cu+) prefer sulphur atoms as a 
ligand, while cupric ions (Cu2+) prefer nitrogen ones. Copper is also able to generate free radical 
species, and its homeostasis is strictly regulated. The metabolic pathway responsible for Cu homeostasis 
is summarized in Figure 7 (Kambe et al., 2008). Copper is oxidized in the intestinal lumen and serum, 
but it requires to be reduced to Cu+ before transport into cells. The Steap ferric/cupric reductases 
(Steaps 2, 3, and 4) are essential for the Cu reduction, as well as for Fe reduction (Ohgami et al., 2006). 
Although mechanisms involved in enterocytes Cu uptake are not completely defined, several studies 
suggested a role for the high-affinity copper-transporter 1 (Ctr1). From enterocytes, Cu is exported into 
the bloodstream by Atp7a for further distribution to tissues (Gupta and Lutsenko, 2009). So, Cu can 
reach the liver, the primary copper homeostasis organ. In the hepatocyte, Atp7b is devoted both to the 
excess Cu excretion into the bile and to Cu translocation into the TGN where it is loaded on Cp, the 
primary copper-binding protein in serum. In the cytoplasm, Cu serves copper chaperones, Cox17/19, 
Atox1 and Ccs, which deliver it respectively to: mitochondria and cytochrome C oxidase; Atp7a in the 
TGN for activation of lysyl oxidase, tyrosinase, peptidylglycine α-amidating mono-oxygenase; and 
Sod1. 
Zinc is one of the most abundant elements within cells (King, 2011). It serves structural and/or 
catalytic roles in hundreds of proteins involved in cellular metabolism and gene expression, such as 
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metalloproteases and zinc finger proteins (Bleackley and Macgillivray, 2011; Tapiero and Tew, 2003). 
Since Zn2+ ion has a full d orbital, it does not give rise to multiple valences under physiological 
conditions and it does not participate in redox reactions (Williams, 1987). Twenty four different genes 
encode proteins that may be involved in Zn uptake (Zip genes) or efflux (ZnT genes) in a cell-specific, 
developmentally regulated, and Zn-regulated manner (Figure 8 (Kambe et al., 2008)). Dietary Zn 
absorption is mainly mediated by Zip4, though other transporters should have important roles. ZnT1 is 
responsible for Zn export into the portal blood or into the conceptus being localized on the basolateral 
membrane. Other ZnT proteins (eg. ZnT4) likely play a role in this process. Zip5 is localized on 
enterocytes, endoderm cells and pancreatic acinar cells basolateral membranes, where it may serve to 
remove Zn from the blood when it is abundantly supplied. In peripheral tissues, various plasma 
membrane Zip transporters likely mediate Zn uptake. Inside the cell, free Zn levels are kept low 
through Mt binding or transport into secretory vesicles, endosomes/lysosomes or zincosomes by ZnT2 
and ZnT4. To control excess content, Zn activates Zn-sensing transcription factors. ZnTs2–7 
participate in Zn delivery to the secretory pathway, whereas Zip7 may transport zinc out of the Golgi 
apparatus into the cytoplasm. ZnT3 transports Zn into glutamate containing vesicles in the brain 
whereas ZnT8 transports zinc into pancreatic β-cell insulin secretory granules. 
Manganese is an essential metal that is found in all tissues and is required for normal amino acid, lipid, 
protein, and carbohydrate metabolism. Manganese is fondamental for immune system functioning, for 
blood sugars and cellular energy regulation, bone growth, defense against free radicals, and, together 
with vitamin K, blood clotting. Manganese functions as a cofactor in several enzymes: arginase (urea 
formation), glutamine synthetase (critical for brain ammonia metabolism), phosphoenolpyruvate 
decarboxylase (gluconeogenesis), and manganese superoxide dismutase (antioxidant, Sod2) (Erikson et 
al., 2005). In humans and animals, Mn is a cofactor of several enzymes necessary for neuronal and glial 
cell function, as well as enzymes involved in neurotransmitter synthesis and metabolism (Bowman et 
al., 2011). Manganese oxidation states range from –III to +VII, though the three major biologically-
relevant oxidation states are Mn(II), Mn(III) and Mn(IV) (Bleackley and Macgillivray, 2011). When 
bound to enzymes, Mn(III) is predominant, while Mn(II) and Mn(IV) are the most commonly taken 
into the body. Ceruloplasmin oxidases Mn(II) to Mn(III), resulting in a shift of Mn bound to α2-
macroglubulin to Tf, that is relevant since Mn bound to α2-macroglubulin is more rapidly cleared 
compared to the Tf-bound form (Aschner, 2006; Gibbons et al., 1976).  Manganese 
oxidation/reduction rate and its association to proteins are a key determinants for its retention and 
delivery in the body (Davidsson et al., 1989). Yeast Mn metabolism is summarized in Figure 9 
(Bleackley and Macgillivray, 2011). In the large intestine Mn is transported by simple diffusion, while it 
is absorbed by active transport in the small intestine. Excess of Mn is eliminated via bile. A plethora of 
plasma proteins or ligands have been implicated as specific Mn carrier proteins, including 
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transglutaminase, β1-globulin, albumin, and transferrin. In fact, approximately 80% of plasma Mn is 
bound to β1-globulin. Several transporters are involved in cellular uptake and release of Mn, for 
instance Fpn1, Dmt1, TfR, Zip8 and voltage-gated Ca2+ channels, each one being also involved in other 
metal ions transport. Intracellular Mn is transported via Ca2+ uniporter to the mitochondria, where it is 
loaded onto Sod2. In the brain, Mn(III) enters via TfR, while Mn(II) is readly transported into the CNS 
either as a free ion species or as a nonspecific protein-bound species (Aschner and Gannon, 1994; 
Rabin et al., 1993). Also Dmt1 has been found to be involved in Mn uptake in the brain (Chua and 
Morgan, 1997). However, the main form entering the brain seems to be manganese citrate (Crossgrove 
and Yokel, 2004). Concerning its efflux, a lack of active Mn transport from the CNS to the systemic 
circulation has been suggested: a slow diffusion process likely occurs (Yokel and Crossgrove, 2004; 
Yokel et al., 2003).  
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Figure 6. Overview of Fe homeostasis. Fe is oxidized in the intestinal lumen and in the serum, but is reduced before 
transport into cells. Fe is transported into enterocytes by Dmt1 after extracellular reduction perhaps by DCytb. Fe uptake by 
visceral endoderm cells is apparently not dependent on Dmt1 and could require the transferrin uptake system. Fe is 
transported out of cells by Ferroportin and is thought to be subsequently oxidized by membrane bound Hephaestin and 
Ceruloplasmin. Fe, inflammation and hypoxia regulate Hepcidin, a polypeptide hormone made by the hepatocyte. Hepcidin 
binds to Ferroportin resulting in degradation of the transporter. In the serum, Fe3+ binds to Transferrin. Developing 
erithrobrast and many other cell types take up Fe via the transferrin-mediated endocytic pathway. After binding to the 
transferrin receptor, the Fe–transferrin complex is internalized and Fe is released from transferrin in the acidified endosome, 
reduced by a Steap metalloreductase and then transported into the cytoplasm by Dmt1. Apo-transferrin and the transferrin 
receptor are returned to circulation and plasma membrane, respectively, via the recycling endosome pathway. All 
nonerythroid cells store Fe complexed with the ferritin heavy and light chains (Ferritin) which can store up to 4,000 atoms 
of Fe per molecule. Cytoplasmic Fe is transported into mitochondria by mitoferrin where it is loaded into Fe-S clusters in a 
process that requires Frataxin. A substrate essential for Fe-S assembly in the cytoplasm is transported out of the 
mitochondria by the ATP-binding cassette transporter Abcb7. In the erythroblast, mitochondrial Fe is primarily utilized for 
heme synthesis. A major fraction of Fe is recycled by the reticulo-endothelial macrophage which phagocytoses aged red 
blood cells (RBC). The Fe is solubilized in the lysosomes, reduced by a Steap metalloreductase and exported out of the 
lysosome by Nramp1. Fe is released from the macrophage by ferroportin, subsequently reoxidized by Ceruloplasmin, and 
conveyed again via transferrin through the systemic circulation. (Kambe et al., 2008) 
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Figure 7. Overview of Cu homeostasis. Cu is oxidized in the intestinal lumen and in the serum, but is reduced to Cu1+ 
before transport into cells. The Steap ferric/cupric reductases (Steaps 2, 3, and 4) are localized to endosomes/lysosomes 
and the plasma membrane and may be essential for the reduction of Cu, as well as the reduction of iron (Ohgami et al., 
2006). Cu is transported into enterocyte/endoderm cells by unknown mechanisms (endocytosis?). Ctr1 is essential for the 
acquisition of dietary Cu but its function in the enterocyte is unknown. In many other cell types, Cu is taken up by Ctr1 
localized to the plasma membrane and perhaps also by Ctr2 (Slc31a2). Cu taken up by enterocyte/endoderm is exported 
into portal blood/conceptus, respectively, by Atp7a (Menkes’s disease protein, MNK) which is localized to vesicles 
trafficking toward the basolateral membrane and to the basolateral membrane. Cu exported to portal blood is taken up into 
the liver, the primary organ that regulates Cu homeostasis. In the hepatocyte, Atp7b (Wilson’s disease protein, WND) 
effluxes excess Cu into the bile and puts Cu into the trans-Golgi network (TGN) where it is loaded into ceruloplasmin, a 
ferroxidase that is the primary Cu binding protein in serum. Inside the cell, Cu is distributed to cytoplasmic Cu chaperones 
(Cox17/19, Atox1, Ccs) which, in turn, deliver Cu to mitochondrial inner membrane and ultimately cytochrome C oxidase 
(Cco) or to Atp7a in the TGN, and cytoplasmic Sod1, respectively. Atp7a transports Cu into the TGN and activates Cu 
containing secretory and membrane-bound proteins [lysyl oxidase, tyrosinase, peptidylglycine α-amidating monooxygenase 
(PAM)]. It should be noted that the cellular localization and abundance of Ctr1, Atp7a, and Atp7b are dynamically regulated 
by Cu availability, which is not reflected in this static cartoon. (Kambe et al., 2008). 
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Figure 8. Overview of Zn homeostasis. Twenty four different genes encode proteins that may be involved in the uptake 
(Zip genes) or efflux (ZnT genes) of this metal in a cell-specific, developmentally regulated, and Zn-regulated manner. The 
functions of many of these genes remain to be determined. Therefore, this cartoon provides only a superficial and static 
view of Zn homeostasis. Zip4 plays a critical role in the absorption of dietary Zn by enterocyte/endoderm cells when Zn is 
limiting, but other transporters must also play important roles. Zn is thought to be exported into portal blood or into the 
conceptus by ZnT1 localized on the basolateral membrane. Other ZnT proteins (i.e. ZnT4) also likely play a role in this 
process. Zip5 is localized to the basolateral membranes of enterocytes, endoderm cells and pancreatic acinar cells where it 
may serve to remove Zn from the blood when Zn is replete. In peripheral tissues, Zn is probably taken up by various Zip 
transporters localized on the plasma membrane. To date ZIPs1, 2, 3, 6, 8, 10, and 14 have each been shown to have Zn 
transport activity in transfection or oocyte injection studies, and most show tissue-specific patterns of expression. Inside the 
cell, free Zn levels are kept low and Zn can be bound to Mt or transported into secretory vesicles, endosomes/lysosomes or 
Znosomes by ZnT2 and ZnT4. Zn activates the Zn-sensing transcription factor Mtf-1 which regulates transcription of the 
mouse Mt-I/II and Znt1 genes and represses expression of Zip10 in an effort to control excess Zn. ZnTs2–7 participate in 
the delivery of Zn into the secretory pathway, whereas Zip7 may transport Zn out of the Golgi apparatus into the 
cytoplasm. ZnT3 transports Zn into glutamate containing vesicles in the brain whereas ZnT8 transports Zn into pancreatic 
β-cell insulin secretory granules. ZIP4 is expressed in β-cells, but its localization in those cells has not been reported (Kambe 
et al., 2008). 
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Figure 9. Manganese homeostasis in S. cerevisiae. Transporters are shown in red. (Bleackley and Macgillivray, 2011) 
 
Although metals are often considered individually, there are significant interactions between them and 
alterations of each metal metabolism can affect the others. Interferences among transition metals occur 
at different levels: absorption inhibition, compartmental displacement and enzymatic impairment, 
including both competition for the binding site, as well as catalytic functionality. This can be 
understood also by the fact that they share several common transporters. Fe and Cu metabolisms are 
intricately interconnected (Cherukuri et al., 2005; Ohgami et al., 2006). Cu has a dual effect on iron 
metabolism: a synergistic one due to its requirement for ferroxidases (Cp, hephaestin) activity, but a 
competitive one, due to common absorption mechanisms, when Cu is in excess. Competitive inhibition 
of Fe absorption by Zn and Mn has also been shown (Rossander-Hulten et al., 1991). Zn exerts its 
antagonistic effect also on Cu absorption (Fischer et al., 1981; L'Abbe and Fischer, 1984). High Zn 
dietary levels cause a reduction of Cu-dependent enzymes activity similar to that observed during Cu 
deficiency. Competition between Mn and Fe at the gastrointestinal tract has been documented, and it is 
most likely mediated by Dmt1. Moreover, a small fraction of Mn3+ is also bound to the Tf (Aschner, 
2006). These interferences can also lead to enzymatic impairment, with subsequent alterations of 
biological processes. 
METAL IONS AND NEURODEGENERATION 
For a long time, it has been commonly thought that the neurological syndromes in which metals are 
implicated are hypothetically caused either by toxicological exposure or by deficiency. For functioning, 
the brain requires high concentrations of metal ions and its oxidative metabolic rate is elevated. 
Therefore, the brain must have efficient homeostatic mechanisms and buffering systems to prevent the 
abnormal discompartmentalization of metal ions and control their availability (Bush, 2000). Also, the 
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blood–brain barrier (BBB) is relatively impermeable to fluctuating levels of plasma metal ions. It is 
known that several of the metal regulatory transport systems are energy dependent (e.g. Atp7b). 
Therefore, damage to the BBB or energy compromise in the brain are two characteristics of several 
neurodegenerative disorders that could perturb metal levels and lead to deranged protein behavior 
(Bush, 2000). In principle, two main generic reactions relevant to neurodegenerative disease can occur. 
First, a metal–protein association leads to protein aggregation; this reaction can involve redox-inert 
metal ions such as Zn2+, or redox-active metal ions such as Cu2+ and Fe3+. Second, a metal-catalyzed 
protein oxidation leads to protein damage and denaturation; this reaction involves a redox-active metal 
ion such as Cu2+, Fe3+, or Mn2+ (Bush, 2000). Copper and iron can accept or donate electrons, triggering 
radical formation, reactive nitrogen species (RNS) and reactive oxygen species (ROS) formation and 
oxidative attack of tissue components contributing to disease and aging. On the contrary, Zn generally 
acts as an antioxidant, maintaining its valence, but it can give several toxic effects, e.g. Aβ precipitation 
(Bertoni-Freddari et al., 2008; Frederickson et al., 2005). Concerning Mn, its neurotoxicity seems to be 
primarily due to oxidation of important cellular component by Mn3+. In fact, intracellularly Mn2+ is 
oxidized to Mn3+ reacting with the superoxide anion produced by the mitochondrial electron transport 
chain. In the mitochondria, Mn can inhibit the complex I, leading to altered oxidative phosphorylation. 
In particular, Mn3+ toxic effects are likely to occur in dopaminergic cells (Archibald and Tyree, 1987; 
Aschner, 2006).  Paradoxically, both metal ions loss and accumulation can bring to neurological 
diseases (Lovell, 2009). For this reason, their content in the brain is tightly regulated and no passive flux 
of metals through the BBB occurs. However, Fe, Cu and Zn involvement in several interactions with 
the major protein components of neurodegenerative diseases is not due to increased exposure to 
metals, but rather to a breakdown in the homeostatic mechanisms that compartmentalize and regulate 
them (Barnham and Bush, 2008).  
The dominant risk factor associated with neurodegeneration is ageing increasing. It has been reported 
that brain Cu levels rise from youth to adulthood, then from middle age onwards they drops markedly, 
leading to a loss of Cu-dependent enzymes activity, e.g. Sod1 and Cp (Adlard and Bush, 2006; Religa et 
al., 2006). Moreover, Fe levels increase in the brain in an age-related manner (Hardy et al., 2005; Suh et 
al., 2005) and failure of ubiquitous ferroxidases Cp, FtH and frataxin cause neurodegenerative disorders 
(Chinnery et al., 2007; Mantovan et al., 2006; Zecca et al., 2004).  
Different neurodegenerative disorders, due to genetic origin, involve mutations in metal ion 
metabolism proteins. An example is the Menkes’ disease that is caused by loss-of-function mutations in 
the Atp7a encoding gene (Chelly et al., 1993; Mercer et al., 1993; Vulpe et al., 1993). The disease results 
from the impaired activity of specific cuproenzymes caused by the impaired Atp7a function. Moreover, 
as will be better described in next paragraph, without Cu release in synapses upon NMDA receptor 
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activation, excitotoxic events are likely to occur (Schlief et al., 2005). Systemic Cu treatment is not 
effective in patients with Menkes disease because Cu transport into the brain is dependent on Atp7a 
(Madsen and Gitlin, 2007). Another pathology resulting from Cu transporter loss-of-function is 
Wilson’s disease. It involves mutations in the Atp7b encoding gene, resulting in biliary Cu excretion 
impairment and consequent hepatocyte Cu accumulation. This accumulation damages the liver and 
activates cell-death pathways, inducing Cu leakage into the plasma and following overload in all tissues. 
Even though Atp7b is expressed in some brain regions, the disease results from liver accumulation of 
Cu (Gitlin, 2003; Tao et al., 2003). Moreover, in absence of Atp7b activity, Cu will not be delivered to 
Cp. Apo-ceruloplasmin is rapidly degraded in the plasma, resulting in a lack of ferroxidase activity and 
consequently alterations in Fe metabolism. Wilson’s disease affected patients develop severe 
Parkinsonian symptoms, due to basal ganglia Cu accumulation and neuronal cell death, together with 
behavioural problems and psycosis (Dening, 1991; Oder et al., 1991). These symptoms are the result of 
Cu accumulation, since treatment with Cu chelators improve the neuropathology (Schlief and Gitlin, 
2006). A further example of genetic disorder due to loss-of-function of a metal binding protein is 
aceruloplasminemia. As the name indicates, this autosomal recessive disorder is caused by a mutation in 
the Cp encoding gene (Harris et al., 1995). So, Cp is absent in the serum, as well as serum Fe levels are 
decreased inducing anemia and brain Fe accumulation (Kono and Miyajima, 2006). Loss of Cp results 
also in non-Tf bound Fe that rapidly accumulates in liver, pancreas and other tissue after Dmt1 
removal from plasma membrane (Andrews, 2002; Hentze et al., 2004). Accumulation of Fe in the brain 
is unique to aceruloplasminemia, suggesting that the GPI-anchored Cp isoform present in astrocytes is 
a ferroxidase that facilitates the rate of Fe release from storage cells in the CNS (Madsen and Gitlin, 
2007). 
PrPC ANTIOXIDANT ACTIVITY 
An overlap between systems controlling redox-active metals homeostasis and oxygen radicals 
metabolism has been extensively documented (Avery, 2001). The physiological connection between 
transition metals and oxidative stress is exemplified by the activities of metal-detoxifying proteins and 
antioxidant enzymes (Vassallo and Herms, 2003).  It has been suggested that PrPC is associated with 
cellular systems that control redox balance and protects from oxidative stress (Brown et al., 2002). Lack 
of PrPC results in increased neuronal sensitivity to oxidative stress (Brown et al., 1997b; Rachidi et al., 
2003). PrPC knock down decreased Sod1 activity because of a reduced Cu incorporation, not linked to 
alterations in the copper chaperon for superoxide dismutase (Ccs) (Brown and Besinger, 1998; 
Kralovicova et al., 2009). Moreover, Prnp0/0 brains present higher levels of lipids and protein oxidation 
(Wong et al., 2001). Indeed, PrPC expression is increased in a variety of stress related conditions, 
including heat shock, hypoxia, ischemia and hypoglycaemia, as well as in stroke models (McLennan et 
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al., 2004; Mitsios et al., 2007; Shyu et al., 2005; Shyu et al., 2000; Shyu et al., 2004). Moreover, a knock 
down of any Sod proteins triggers PrPC expression, on the contrary shutting down PrPC increases 
extracellular-Sod expression and Sod2 activity (Brown and Besinger, 1998; Kralovicova et al., 2009). 
This connection between PrPC and Sod proteins indicates a common cell protection pathway. 
Furthermore, in vitro experiments revealed that PrPC has Sod-like activity with a dismutation constant 
rate similar to Sod2’s one (Brown et al., 2001; Brown et al., 1999; Cui et al., 2003; Treiber et al., 2007). 
Sod activity is dependent on Cu(II) incorporation and it probably involves Cu(II) reduction (Brown et 
al., 2001).  It should be also noted that PrPC is cleaved at the end of its Cu-binding OR through the 
action of ROS, a process termed β-cleavage. β-cleavage is considered an early and critical event in the 
mechanism by which PrPC protects cells against oxidative stress. If a PrP construct lacks the OR, the 
protein will fail to undergo ROS-mediated β-cleavage, as occurs with the two mutant forms of PrP, 
PG14, and A116V, associated with human prion diseases (Watt et al., 2005). 
In their review, Vassallo and Hermes state that the most likely candidate as intracellular messenger for 
PrPC-mediated protection is calcium. Intracellular calcium is a critical component of the signalling 
pathways that lead to neuron structural and functional changes. The calcium signal usually corresponds 
to an elevation of the intracellular calcium concentration as a consequence of synaptic activity-induced 
depolarization. Indeed, in PrP null conditions neuron calcium homeostasis is impaired (Krebs et al., 
2007). Hence, PrPC may influence both neuron survival and synaptic physiology regulating calcium 
homeostasis (Vassallo and Herms, 2003). The model proposed is reported in Figure 10. 
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Figure 10. Schematic representation of the physiological role of prion protein (PrPC) in copper homeostasis and redox 
signalling. Cu2+ ions released during neurotransmitter vesicles exocytosis are buffered by PrPC, and subsequentially returned 
to the pre-synaptic cytosol. This can occur either by transfer of copper to copper transporter proteins (CTR) within the 
membrane, or in case of high copper concentrations in the synaptic cleft, via PrPC-mediated endocytosis (◇represent an 
octarepeat; ◆represent an octarepeat bound to copper(II) ion). Further, copper-loaded PrPC may interact with ROS, 
including H2O2 and O2•-, triggering redox signalling and subsequently activation of Ca2+-dependent signalling cascade. 
Changes in the intracellular Ca2+ levels lead to a modulation of synaptic activity and neuroprotection. (from (Vassallo and 
Herms, 2003)). 
PrPC AND SYNAPTIC FUNCTIONALITY 
Electrophysiology studies suggest a role for PrPC in the regulation of ion channels and neuronal 
excitability. PrPC localizes at synapses, together with a plethora of ion channels, and evidence supports 
that this is important for normal synaptic development and functionality (Kanaani et al., 2005; Moya et 
al., 2000). A variety of electrophysiological abnormalities have been observed in cerebellum or 
hippocampus of PrP null mice (Carleton et al., 2001; Colling et al., 1996; Collinge et al., 1994; 
Fuhrmann et al., 2006; Herms et al., 2001; Lazzari et al., 2011; Maglio et al., 2004; Mallucci et al., 2002; 
Manson et al., 1995; Prestori et al., 2008).  However, the most compelling evidence for a functional 
interaction between PrPC and ion channels concerns glutamate excitatory receptors, in particular 
NMDARs (Khosravani et al., 2008b; You et al., 2012). First, Zamponi’s group reported that adult PrP 
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null mice exhibit greater basal excitability in the CA1 region of the hippocampus. In particular, synaptic 
NMDAR-mediated current was altered, showing slowed deactivation kinetics. They obtained the same 
results also in neuronal cultures transfected with PrPC siRNA, confirming that PrPC is a negative 
regulator of NMDAR function in hippocampal neurons. In the same work, they showed that Prnp0/0 
neurons are also more susceptible to NMDAR-mediated cell death, both in vitro and in vivo (Khosravani 
et al., 2008b). More recently, the same group published an article concerning the crucial role of Cu, 
PrPC and NMDAR in mediating amyloid β (Aβ) neurotoxic effect. Their interdependent role consists 
in the induction of a pathologically large non-desensitizing steady-state NMDAR current. They also 
showed that the same electrophysiologial alteration is observed in both PrP null hippocampus and in 
wild-type hippocampus treated with a Cu chelator. Copper addition re-establishes NMDAR current in 
both Aβ-treated and PrP null neurons, meaning that PrP-mediated modulation of NMDAR occurs via 
Cu ions and Aβ oligomers block this modulation, maybe interfering with Cu-PrPC binding. The authors 
propose that PrP regulates NMDARs by decreasing glycine affinity for the receptor, so diminishing its 
agonistic effect (You et al., 2012).  
 
NMDA RECEPTORS: FUNCTION, SUBUNIT COMPOSITION AND REGULATION 
NMDARs, together with other glutamate ionotropic receptors, are key mediators of the excitatory 
synaptic transmission in the brain. These glutamate-gated cation channels convert a chemical signal 
(glutamate released from the presynaptic terminal) into an electric signal (a membrane voltage change 
due to cation flow through the channels) (Yashiro and Philpot, 2008). NMDARs have critical roles in 
excitatory synaptic transmission, plasticity and excitotoxicity in the CNS. The involvement of 
NMDARs in these diverse processes reflects their unique features, which include voltage-sensitive 
block by extracellular Mg2+, a high permeability to Ca2+ and unusually slow ‘activation/deactivation’ 
kinetics. Moreover, the co-agonist glycine binding is required for NMDAR activation, whereas 
physiological levels of protons suppress receptor’s opening (Cull-Candy et al., 2001). Several and 
distinct NMDAR subtypes have been identified in CNS, differing in their sensitivity to endogenous and 
exogenous ligands, permeation and block by divalent ions, kinetic properties, and interaction with 
intracellular proteins. So NMDARs functional properties are determined by their subunit composition 
(Cull-Candy et al., 2001). A variety of NMDAR subunits have been identified: the ubiquitously 
expressed GluN1 subunit (formerly known as NR1); a family of four distinct GluN2A-D subunits 
(formerly NR2A-D); and two GluN3A-B subunits (formerly NR3A-B) (Das et al., 1998; Moriyoshi et 
al., 1991; Sugihara et al., 1992). The diversification is also increased by the different splicing isoforms 
each subunit presents (Dingledine et al., 1999). In situ hybridization studies have shown that mRNAs 
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for NMDAR subunits are differentially distributed throughout the brain, with patterns of expression 
that change strikingly during development (Akazawa et al., 1994; Monyer et al., 1994). GluN2B and 
GluN2D subunits predominate in the neonatal brain, but over the course of development these are 
supplemented with, or replaced by, GluN2A and in some regions GluN2C subunits. All NMDARs 
appear to function as heteromeric assemblies composed of multiple GluN1 subunits in combination 
with at least one type of GluN2. The GluN3 subunit does not form functional receptors alone, but can 
co-assemble with GluN1/GluN2 complexes (Das et al., 1998; Perez-Otano et al., 2001). As each of the 
constituent subunits confers distinct properties to the receptor assembly, to a greater or lesser extent, 
many of the important functional attributes of the native receptors are determined by the expression of 
the various subunits and isoforms, as it is shown in Figure 11 (Cull-Candy et al., 2001). NMDARs are 
found both at synaptic and extrasynaptic sites including the cell soma and the dendritic shaft. 
Extrasynaptic NMDARs are activated not only at pathological situations, but also by burst of activity 
that can occur under physiological conditions (Hardingham et al., 2002; Harris and Pettit, 2008). 
Therefore, extrasynaptic NMDARs are involved in stimulus-dependent synaptic modifications, and 
they are likely activated in a manner that is distinct from the activation of synaptic NMDARs. The 
possibility that NMDARs subunit composition differs between synaptic and extrasynaptic sites is also 
controversial. It has been proposed that GluN2A-containing NMDARs occupy the central portion of 
synapses, while GluN2B-containing ones are preferentially targeted to peripheral portions of synapses 
or to extrasynaptic sites (Cull-Candy et al., 2001). Although diheteromeric GluN2A-, GluN2B- and 
GluN2C-containing NMDARs participate in synaptic transmission, there is no evidence for 
GluN1/GluN2D-containing receptors at any central synapse. Distinct single-channel properties of 
GluN1/GluN2D receptors have enabled their identification in the extrasynaptic membrane of several 
cell types. As reviewed by Cull-Candy et al., in 2001, many studies led to conclude that GluN2D-
containing NMDARs are absent from synaptic sites.  
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Figure 11. Functional properties of NMDARs conferred by specific subunits. (a) Representative single-channel records of 
recombinant NMDARs expressed in Xenopus oocytes, showing the high-conductance openings of NR2A- and NR2B-
containing receptors, and the low-conductance openings of NR2C- and NR2D-containing receptors. Solid lines indicate the 
closed state, and dotted lines indicate open states. Numbers indicate conductance in picosiemens (Behe et al., 1999). (b) 
Example of single-channel records of native NMDARs from cerebellar granule cells, a dorsal horn neuron of the spinal 
cord, and a cerebellar Purkinje cell, showing openings of high- and low-conductance (Farrant et al., 1994; Momiyama et al., 
1996). In these examples, the high-conductance channels are thought to arise from NR1/NR2B receptors and the low-
conductance channels from GluN1/GluN2D receptors in spinal cord and Purkinje cells, and from NR1/NR2C receptors in 
granule cells. (c) Macroscopic currents from recombinant NMDARs expressed in HEK293 cells, illustrating the NR2 
subunit-dependent deactivation seen in response to 1-ms applications of 1 mM glutamate (Vicini et al., 1998). (d) 
Macroscopic currents from recombinant NMDARs illustrating the influence of NR1 splice varaiants on deactivation (4-ms 
applications of 1 mM glutamate; (Rumbaugh et al., 2000)). τw is the weighted deactivation time constant. 
 
Since NMDARs play crucial roles in physiological processes, like learning and memory (Collingridge, 
1987), as well as in the pathophysiology of CNS disorders, like ischemia, epilepsy, many 
neurodegenerative diseases and even also neuropsychiatric disorders, such as schizofrenia (Aarts et al., 
2002; Lipton and Rosenberg, 1994; Loftis and Janowsky, 2003), several regulatory mechanisms have 
been identified, reviewed by (Dingledine et al., 1999). For example, activating phosphorylation can 
occur on serine and threonine residues by mean of protein kinase A (Pka), protein kinase C (Pkc) and 
Ca2+/calmodulin-dependent protein kinase II (CamkII), while deactivating dephosphorylation occurs 
via Ca2+/calmodulin-dependent phosphatase calcineurin. Activating phosphorylation can occur also on 
tyrosine residues, by mean of Src and Fyn kinases. Other regulatory mechanisms involve glycosylation, 
covalent bound to lipids, as well as proteolytic degradation mainly mediated by calpain.  
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In 1996, it was published that in hippocampal neurons Cu can modulate NMDARs (Vlachova et al., 
1996). In fact, upon depolarization ionic Cu is released into the cleft reaching 100µM concentration 
(Kardos et al., 1989). Copper release is dependent on Ca2+ influx from NMDARs that activates TGN 
vesicles containing Cu accumulated by the Atp7a (Schlief et al., 2005; Schlief et al., 2006). Vlachova and 
colleagues showed that Cu ions are high-affinity, voltage-dependent, NMDAR antagonists. The 
inhibitory properties of Cu suggest an extracellular binding site, out of the membrane electric field. 
However, this binding site has not been discovered, and also the precise mechanism of Cu inhibition 
on NMDARs has not currently been defined.  
Lipton and colleagues have argued that modulation of NMDAR activity involves sulfhydryl reactions 
of at least seven cysteine residues with redox reagents, Zn2+ or nitric oxide (NO) (Lipton et al., 2002) 
(see Box 1). The various involvement of these cysteine residues (some involve a single protein thiol 
group, whereas others involve the recruitment of multiple thiol groups to the reaction mechanism) can 
be summarized in a Venn diagram that shows each cysteine residue can influence high-affinity Zn2+ 
inhibition, redox modulation or S-nitrosylation (reaction with NO) of the NMDA receptor (Figure 12). 
Because a single sulfhydryl group can, in some cases, react with an oxidizing agent, NO or Zn2+, these 
thiol groups are capable of multiple tasks. Upon transport into vesicles by mean of ZnT3, Zn ions are 
released from the presynaptic bouton together with glutamate (Assaf and Chung, 1984; Howell et al., 
1984). However, Zn-mediated modulation does not occur via a direct binding to cystein thiols.  In fact, 
it was shown that the thiol groups enhance high-affinity Zn2+ inhibition of the NMDA receptor when 
in their oxidized state (i.e. when part of a disulfide bond). Hence, it can be concluded that the redox 
status of these thiol groups modulates the effect of Zn2+ allosterically, rather than by direct binding to 
Zn2+. In fact, high-affinity Zn2+-coordination site involves three histidines and one glutamate, rather 
than cysteine, residues (Choi and Lipton, 1999; Fayyazuddin et al., 2000; Low et al., 2000; Paoletti et al., 
2000). Five cysteine thiol groups are involved in S-nitrosylation: Cys744 and Cys798 of GluN1, and 
Cys87, Cys320 and Cys399 of GluN2A (Choi et al., 2000). In all cases, S-nitrosylation of receptor thiol 
is inhibitory – that is, it decreases the amplitude of NMDA-evoked responses by decreasing the number 
of channel openings. The allosteric inhibition is mediated by a single crucial thiol group (Cys399 of 
GluN2A) while the other four cysteine residues only contribute to this reaction when they are in a free 
thiol conformation (i.e. in their chemically reduced state) and have not been oxidized to disulfide (Choi 
et al., 2000). Moreover, Cys399 on GluN2A also plays a role in Zn2+ inhibition that is mechanistically 
distinct from those of the other four cysteine residues (Paoletti et al., 2000). Exposure to NO enhances 
GluN1/GluN2A receptor sensitivity to high-affinity Zn2+-mediated inhibition, and this effect is 
completely abrogated in the GluN1/GluN2A Cys399Ala mutant. Furthermore, it has been shown that 
the inhibitory effect of Zn2+ is exerted by enhanced glutamate affinity that results in receptor 
desensitization (Zheng et al., 2001). Based on all these findings, together with the analogy to the effects 
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of S-nitrosylation on hemoglobin, Lipton and colleagues proposes a model in which S-nitrosylation of 
Cys399 on GluN2A allosterically affects the quaternary organization of the receptor, resulting in 
enhanced glutamate binding and receptor desensitization (Lipton et al., 2002). 
 
 
 
  
 
PrPC AND EXCITOTOXICITY 
The PrP-medited regulation of NMDARs is confirmed by the enhanced susceptibility reported for PrP 
null mice in excitotoxic conditions. It has been reported that PrP ablated mice are more susceptible to 
excitotoxic stimulation (Rangel et al., 2007; Spudich et al., 2005; You et al., 2012). Following 
intraluminal middle cerebral artery occlusion, PrP null mice showed a 200% increased infarct size, 
Box 1. Potential reactions of protein thiol with 
nitric oxide, Zn2+ and redox reagents (Lipton 
et al., 2002).   
Figure 12.Effect of individual cysteine residues on 
the NMDA receptor. Depending on the exact site on 
the receptor, various individual cysteine residues can 
react with redox reagents, undergo S-nitrosylation or 
influence high-affinity Zn2+ inhibition. The Venn 
diagram summarizes the effect of each cysteine 
residue on the NR1 (currently named GluN1) and 
NR2A (currently named GluN2A) subunits, based on 
site-directed mutagenesis experiments. (Modified 
from (Lipton et al., 2002))  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together with enhanced levels of active caspase 3 (Casp3) (Spudich et al., 2005). A similar result was 
obtained both in vivo and in vitro with organotypic hippocampal cultures (OHCs) following stimulation 
with kainic acid. In particular, mice injected with kainic acid showed higher seizure behaviour together 
with increased neuronal cell death. Using OHCs they confirmed the increased susceptibility in the 
pyramidal layer cells. Moreover, they found an involvement of NMDARs in the apoptotic process since 
adding the synaptic NMDARs antagonist MK-801 neuronal cell death was significantly reduced (Rangel 
et al., 2007).  
EXCITOTOXICY AND MAJOR PLAYERS INVOLVED IN ITS MECHANISMS  
Excitotoxicity is a pathological process that kills or damages neurons following an excessive excitatory 
stimulation and that occurs in spinal cord injury, stroke, traumatic brain injury, hearing loss (through 
noise overexposure or ototoxicity) and in neurodegenerative diseases of the CNS such as multiple 
sclerosis, Alzheimer's disease, amyotrophic lateral sclerosis (ALS), Parkinson's disease, alcoholism or 
alcohol withdrawal, and Huntington's disease. As illustrated in Figure 13, excitotoxicity is caused by 
glutamate overstimulation of its ion channel receptors that provokes an intracellular calcium overload. 
The massive Ca2+ entrance activates a cascade that leads to neuronal cell death. In fact, two paradoxical 
roles are played by Ca2+: one in physiological states and another one in CNS disease. Glutamatergic 
neurotransmission is dependent upon cytosolic and nuclear Ca2+-dependent signaling by 
Ca2+/calmodulin-dependent kinase IV, ras-extracellular signal–regulated kinase 1/2 pathway, and cyclic 
adenosine monophosphate response element binding protein (Creb)-dependent transcription of brain-
derived neurotropic factor. This signalling pathway is essential for neuronal survival. Thus, it is 
important to differentiate between physiological Ca2+ transients mediated by synaptic glutamatergic 
neurotransmission needed for survival, antagonism of which causes cell death by apoptosis, and the 
more sustained and larger Ca2+ increases that result from pathological activation of extrasynaptic and 
synaptic glutamatergic receptors (Dong et al., 2006; Hardingham and Bading, 2003). The most 
common disease paradigm is stroke, where increased glutamate synaptic vesicular release, failure of 
cellular transporters, and glutamate release from dying cells lead to high extracellular glutamate, high 
glutamate receptors activation, and massive Na+ and Ca2+ influx (Dong et al., 2006) 
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Figure 13. Excitotoxic injury in neurons. Binding of glutamate results in Na+ and Ca2+ influx through plasma membrane 
glutamate receptors (GR). Consequently, cytosolic Na+ and Ca2+ increase. Increased cytosolic Na+ results in the 
consumption of adenosine triphosphate (ATP), and therefore decreases of the nucleotide. Increased Ca2+ leads to the 
activation of hydrolytic enzymes such as calpain. Ligation of glutamate to GR also stimulates production of nitric oxide 
(NO) by nitric oxide synthase (NOS). From the cytosol, Ca2+ is transported across the mitochondrial inner membranes 
through a Ca2+ uniporter into the mitochondrial matrix. This requires a proton-motive force (mitochondrial potential, Δψm) 
across the inner membrane. As long as Δψm remains above threshold levels, and cytosolic Ca2+ is high, Ca2+ continues to 
be transported into the mitochondrial matrix. Increasing accumulation of Ca2+ leads to the formation of calcium precipitates 
within mitochondria, generation of reactive oxygen species (ROS), phospholipid hydrolysis, and, eventually, decrease of 
Δψm and ATP, formation of mitochondrial permeability transition (MPT) pores in the inner membrane, and leakage of the 
accumulated Ca2+ back into the cytosol. Together with the failure of ATP-dependent Ca2+ pumps, and possibly with the 
participation of calcium-induced calcium release (CICR) from the endoplasmic reticulum, mitochondrial release of 
accumulated Ca2+ causes a catastrophic, delayed Ca2+ increase, which kills the cell. Increased cytosolic Na+ may also be 
expected to inhibit Na+ and Ca2+ exchange across the plasma membrane through the Na+/ Ca2+ exchanger (NCX) in the 
physiological mode, and, in addition, drive reverse exchange of Na+ and Ca2+ and thus exacerbate Ca2+ increase in the 
cytosol. Proteolysis of the exchanger by calpain may also inhibit Na+/ Ca2+exchange. Depending on the intensity and speed 
of Ca2+-dependent injury, determined in part by oxidant damage through ROS generation and concomitant NO production, 
cell death occurs by necrosis or apoptosis (from (Dong et al., 2006). 
 
As described in Figure 14, in excitotoxic conditions neuronal nitric oxide synthase (nNOS) is activated, 
leading to an increased generation of NO. NO interacts with many intracellular targets and triggers a 
variety of signal transduction pathways, resulting in stimulatory or inhibitory output signals. Upon 
excitotoxic insult, NO can play a neuroprotective function, for example inhibiting NMDAR by S-
nitrosylation. However, NO becomes noxious whether produced in excess and, if a cell is in a pro-
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oxidant state, NO can undergo oxidative-reductive reactions to form toxic compounds, RNS. In the 
last decade, the term “nitrosative stress” has been used to indicate the cellular damage elicited by 
excessive NO and RNS (Calabrese et al., 2007). NO and RNS have been implicated in the pathogenesis 
of neurodegenerative disorders. In fact, extreme nitrosative/oxidative stress can facilitate protein 
misfolding and aggregation, and very likely viceversa. The mechanism underlying this phenomenon is 
still elusive. It has been proposed that NO-related species may significantly participate in the protein 
misfolding process through S-nitrosylation (and nitration, also) under degenerative conditions (Gu et 
al., 2010). Moreover, together with the production of toxic species like peroxynitrite, high levels of NO 
are thought to stimulate neurotoxic pathways through the S-nitrosylation of a number of targets, 
activating neuronal cell death, as described in Figure 14 (Nakamura and Lipton, 2011).  
 
 
 
Figure 14. Representative examples of S-nitrosylated proteins that can regulate neuronal function. NO generated in the 
nervous system modulates the activity of various proteins via S-nitrosylation (or further oxidation) controlling (a) redox 
responses, (b) synaptic function, (c) protein quality control, (d) mitochondrial function, (e) transcriptional regulation, and (f) 
cell death and injury. Depending on the level of NO, S-nitrosylation of these proteins can mediate either neuroprotective or 
neurodestructive pathways (Nakamura and Lipton, 2011).  
 
Other key proteins in excitotoxic mechanisms are calcium trasporters. In the resting excitable cell, 
when intracellular Ca2+ concentrations rise and the cell requires the return to resting levels, this 
exchange transport mechanism couples the uphill extrusion of Ca2+ to the influx of Na+ ions into the 
cells down their electrochemical gradient (Carafoli, 1985). This mode of operation, defined as forward 
mode, keeps the 104-fold difference in Ca2+ concentrations across the cell membrane (Blaustein and 
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Santiago, 1977). Several studies indicate that seizure-induced changes are accompanied by changes in 
the expression and/or function of calcium extrusion proteins (Garcia et al., 1997; Keele et al., 2000; 
Parsons et al., 2000). Three calcium pumps have been analyzed for this Ph.D. project: Na+/Ca2+ 
exchanger 1 (Ncx1), plasma membrane Ca2+ ATPase (Pmca) and sarco(endo)plasmic reticulum Ca2+ 
ATPase 2 (Serca2).  
The Ncx family if composed of three identified members: Ncx1, Ncx2 and Ncx3. As reviewed by 
Carafoli in 1987 (Carafoli, 1987), Ncx is particularly active in excitable plasma membranes where an 
electrically exchange of 3 Na+ per 1 Ca2+ occurs (Baker et al., 1969; Blaustein and Hodgkin, 1969). The 
antiporter is activated in the range of submicromolar concentrations (0.1-0.3µM) of intracellular Ca2+ 
(DiPolo, 1979). Ncx has a low affinity and it does not bind very tightly to Ca2+. However, it has high 
capacity, so it can move ions rapidly, transporting up to five thousand Ca2+ ions per second. Therefore, 
it requires large concentrations of Ca2+ to be effective, but it is useful for ridding the cell of large 
amounts of Ca2+ in a short time, as it is needed in a neuron after an action potential (Carafoli et al., 
2001). 
The Ca2+ pumps belong to the family of P-type ATPases, which is characterized by the temporary 
conservation of ATP energy in the form of a phosphorylated enzyme intermediate (hence P-type) 
formed between the γ-phosphate of hydrolized ATP and an invariant D-residue in a highly conserved 
sequence in P-type ATPases (Pedersen and Carafoli, 1987). This pumps are high-affinity enzymes, 
which interact with Ca2+ with a Km well below 1µM, but which transport Ca
2+ with a low total capacity: 
about 0.5nmoles of Ca2+ transported per mg of membrane per sec (Caroni and Carafoli, 1981). The first 
ATP-driven Ca2+ transport system, which was later identified as the Serca pump, was discovered in 
1961-1962 in a skeletal muscle fraction, known at the time as the Marsh relaxing factor. Studies in the 
early period showed that the pump transports 2 Ca2+ ions per ATP hydrolized and that it 
countertransports H+ in exchange for Ca2+. As reviewed in 2008 by Carafoli and colleagues, contrary to 
Serca, Pmca can transport 1 Ca2+ ion per ATP hydrolized, per 1 H+(Di Leva et al., 2008). One of its 
major characteristics is the stimulation by calmodulin, not via phosphorylation, but through a direct 
interaction that moves the autoinhibitory domain calmodulin binding domain (CaM-BD) and that can 
lower Pmca affinity for Ca2+ from 20µM to 1µM (Brodin et al., 1992). Interestingly, the most potent 
activator of Pmca is phosphatidylinositol biphosphate (PIP2), the only acidic phospholipid whose 
concentration in the plasma membrane may change rapidly in response to external stimulation (Carafoli 
and Zurini, 1982; Choquette et al., 1984). Pmca can also be constitutively activated by calpain cleavage 
that definitely removes CaM-BD (James et al., 1989). All the mechanism cooperate to lower Pmca Kd to 
values as low as about 100-200nM (Di Leva et al., 2008).  
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AIM  
 
Despite many efforts, the mechanisms underlying the pathophysiology of neurodegenerative disorders 
have not been clarified, yet, though a crucial point seems to be represented by metals and protein 
aggregation (Bush, 2000). Understanding the physiological function of the involved proteins represents 
a central question, since this is fundamental to characterize the pathological mechanisms, as well as to 
find a curative strategy. A peculiar case is represented by prion diseases, also known as Transmissible 
Spongiform Encephalopathies (TSEs). In fact, besides having genetic and sporadic origins, like the 
other neurodegenerative disorders, prion diseases are transmissible (Prusiner, 2001). In 1982, Prusiner 
defined the concept of prions, stating that the disorder causative infective agent has exclusively 
proteinaceous properties (Prusiner, 1982). This etiological agent derives from PrPC, the endogenously 
encoded protein (Oesch et al., 1985), that triggers the pathology upon conformational conversion, 
giving rise to the prion, or PrPSc, enriched in β-sheets and prone to aggregate (Caughey and Raymond, 
1991; Gasset et al., 1993). Despite being highly conserved among species, PrPC physiological function 
has not been completely defined (Aguzzi et al., 2008). A striking property of PrPC is its high affinity 
binding for divalent cations, in particular Cu, but also Zn and Mn (Jackson et al., 2001; Singh et al., 
2010; Stockel et al., 1998). Concerning Cu ion, PrPC is also able to support the ion reduction, being able 
of binding both Cu(I) and Cu(II) (Liu et al., 2011). To unveil PrPC function, several knockout and 
transgenic murine lines for the Prnp gene have been created. These knockout lines are viable and fertile, 
showing no gross disturbancies (Bueler et al., 1992; Manson et al., 1994). However, a few phenotypic 
traits have been identified, suggesting a role for PrPC in synapses. In fact, PrP null mice show increased 
excitability (Maglio et al., 2004) and reduced afterhyperpolarizarion potentials in hippocampal neurons 
(Mallucci et al., 2002), together with a slowed deactivation kinetic of NMDARs currents, likely due to 
PrPC-bound Cu ions (Khosravani et al., 2008b; You et al., 2012). Moreover, PrP ablation provokes high 
neuronal cell death upon excitotoxic insults, such as in vitro kainate or NMDA tratements and in vivo 
stroke (Rangel et al., 2007; Spudich et al., 2005; You et al., 2012). It has been proposed that PrPC 
functions in hippocampal glutamatergic synapses–where it is highly expressed–as an inhibitory 
modulator of NMDA receptors (NMDARs) activity, and this role seems to be crucial in stressful 
conditions. However, the precise mechanism through which PrPC carries on this function has not been 
defined. Can PrPC role in glutamatergic synapses, as well as in stressful conditions, be due to its metal 
ion binding property? Metal ions are essential for many biochemical reactions and they play key roles in 
embryonic, fetal and postnatal development in higher eukaryotes central nervous system. In the brain, 
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different mechanisms have developed to sense and regulate tightly transition metals concentration. 
Alteration in metal ion homeostasis, due to altered supply or protein loss of function, strongly impairs 
neuronal functionality: deficiencies during prenatal or early postnatal life result in profound 
development disturbances, while accumulation or dyshomeostasis is toxic because metal ions support 
Fenton reaction leading to free radicals production (Kambe et al., 2008). Essential metals are crucial 
synaptic function regulators: for example, Zn and Cu, released in the synaptic cleft, modulate 
NMDARs (Choi and Lipton, 1999; Fayyazuddin et al., 2000; Low et al., 2000; Paoletti et al., 2000; 
Vlachova et al., 1996). Besides being a metal binding protein, increasing evidences suggest that PrPC is 
involved in metal ion homeostasis maintenance and in their metabolism (Brown, 2003; Brown et al., 
2001; Singh et al., 2009a; Singh et al., 2009b; Singh et al., 2010). Moreover, Prnp0/0 mice show 
impairments in synaptic functionality and neuronal excitability in the hippocampus, increased 
susceptibility in stressful conditions, as well as demyelination in aging, and metal ions play fundamental 
roles in all these cellular mechanisms. The aim of the first part of this project was the characterization 
of PrPC role in metal ions metabolism and homeostasis. To do this, Prnp+/+ and Prnp0/0 brains and 
hippocampi have been compared concerning their Cu, Fe, Zn and Mn content, as well as the 
expression levels of the major proteins involved in their metabolism. The hippocampus has been 
chosen as a brain area of major interest for two reasons: first, it displays very high levels of PrPC 
expression (Benvegnu et al., 2010; Sales et al., 1998); second, many hippocampal impairments have 
been observed in Prnp0/0 mouse models (Colling et al., 1996; Collinge et al., 1994; Criado et al., 2005; 
Khosravani et al., 2008b; Maglio et al., 2004; Mallucci et al., 2002; Rangel et al., 2007). Particular 
attention has been paid to ceruloplasmin (Cp) since it is expressed in two isoforms–i.e. a secreted one 
and a membrane-anchored one–that allow Cp to be at the same time the major Cu carrier in the serum 
and a Cu-dependent oxidase with key functions in Fe and Mn absorption and distribution (Harris et al., 
1995). The aim of the second part of the project was the understanding of the exact mechanism 
through which PrPC inhibits NMDARs, exerting a neuroprotective role in stressful conditions. PrPC is 
localized in lipid rafts of the postsynaptic terminal, close to NMDARs (Fournier et al., 2000; Haeberle 
et al., 2000; Herms et al., 1999; Linden et al., 2008; Naslavsky et al., 1997; Sales et al., 1998). Their 
opening, upon glutamate release from the presynaptic bouton, activates the protein of the trans-Golgi 
network: the Cu transporter Atp7a is one of them. This event provokes the release of Cu into the 
synaptic cleft, reaching 100µM concentration (Schlief et al., 2005; Schlief et al., 2006). Released Cu ions 
are able to modulate NMDARs activity, but the precise mechanism has not been understood and no 
binding sites have been identified, yet (Vlachova et al., 1996). Ca2+ influx through NMDARs activates 
also neuronal nitric oxide synthase (nNOS). The produced NO can cross plasma membrane and play 
functions in the synaptic cleft, for example it can modulate proteins by mean of cysteine residues S-
nitrosylation (Jaffrey and Snyder, 2001; Lipton et al., 2002). NMDAR subunits GluN1 and GluN2A are 
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S-nitrosylated on extracellular cysteines and this reaction is always inhibitory (Choi et al., 2000). This 
posttranslational modification requires an electron acceptor that is reduced upon cysteine thiol 
oxidation: this electron acceptor is usually Cu. As above described, a high amount of Cu ions is 
available in the synaptic cleft after NMDARs opening. However, to prevent Fenton reaction and 
oxidative stress production, Cu is immediately bound by metal-binding proteins: one of them is PrPC 
that can bind both Cu(II) and Cu(I) and even supports the reduction. Moreover, it has been published 
that PrPC-bound Cu ions support the S-nitrosylation of another membrane protein (Mani et al., 2003) 
and that PrPC modulation of NMDARs is dependent on Cu ions (You et al., 2012). To summarize, the 
aim of the project was to study the neuroprotective role of PrPC in glutamatergic synapses mediated by 
the inhibitory S-nitrosylation of NMDARs. First, the enhanced susceptibility to excitotoxic stimulus in 
a Prnp0/0 murine model was studied in organotypic hippocampal cultures treated with NMDA by 
comparing neuronal death, as the appearance of pyknotic nuclei, in three different regions: Cornu 
Ammonis 1 (CA1), Cornu Ammonis 3 (CA3) and the Dentate Gyrus (DG). Second, the expression levels 
of proteins involved in the excitotoxic mechanism was established (Dong et al., 2006), in particular, 
NMDA receptor subunits GluN1, GluN2A and GluN2B, nNOS, Casp3 and calcium transporters, 
Ncx1, Pmca and Serca2 (the isoforms Ncx1 and Serca2 were chosen according to their expression 
pattern in the CNS). Since some alterations in Ncx1, Pmca and Serca2 expression have been detected, 
Ca2+ concentration was measured and compared to establish whether PrP null mice increased 
susceptibility was due to Ca2+ overload in the CNS. Third, GluN1 and GluN2A S-nitrosylation levels 
were compared in Prnp+/+ and Prnp0/0 hippocampi from adult mice. To do this, the biotin switch assay 
was set up (Jaffrey and Snyder, 2001).  
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MATERIALS AND METHODS 
 
ANIMALS 
Inbred FVB/N Prnp+/+ and FVB Prnp0/0 mice were used in these experiments. The FVB Prnp0/0 mice 
were obtained by backcrossing the original Prnp0/0 mice (ZurichI (Bueler et al., 1992)) to FVB/N inbred 
mice for more than 20 generations (Lledo et al., 1996).  All experiments were carried out in accordance 
with European regulations [European Community Council Directive, November 24, 1986 
(86/609/EEC)] and were approved by the local authority veterinary service. After the animal sacrifice, 
brains were extracted and hippocampi were isolated in phosphate buffered saline pH 7.4 (PBS).  
Dissected structures were immediately frozen in liquid nitrogen and stored at -80°C. Samples were 
collected at the following developmental stages: P1 (post-natal day 1), P7, P30, P90, P180, P365. P1 
and P7 were considered early developmental stages, P30 the end of synaptogenesis, P90 adulthood, 
P180 late adulthood, P365 aging. 
PROTEIN EXPRESSION ANALYSIS 
Proteins expression was measured by Western blot (WB). Brains and ippocampi, extracted from male 
mice, were homogenized and briefly sonicated in lysis buffer containing: 50mM TrisHCl pH 7.5, 
150mM NaCl, 1mM EDTA, 0.5% 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
(CHAPS, Sigma-Aldrich, St Louis, MO, USA), 10% glycerol, proteases inhibitors cocktail (Inhibitor 
complete mini, Roche Diagnostics Corp., Mannheim, Germany). After samples cleaning by 
centrifugation (10 min, 2000g, 4°C), protein concentration was determined by bicinchoninic acid (BCA) 
assay (Pierce, Rockford, IL, USA). For each sample, the same protein amount (30-60µg) was separated 
on SDS–PAGE. On each gel, Prnp+/+ and Prnp0/0samples of the same age were loaded, in order to 
compare them. Commonly, proteins were boiled in loading buffer (10% glycerol, 50mM TrisHCl pH 
6.8, 2% w/v SDS, 4M Urea, 0.005% bromophenol blue). However, for a few proteins analysis (Ncx, 
Serca2, Pmca), denaturation was performed at 30°C for 30 min with a different loading buffer (72mM 
NaCl, 1.9M Urea, 5mM DTT, 3% w/v SDS, 10% w/v glycerol, 62.5mM TrisHCl pH 6.8, 0.004% 
bromophenol blue). The acrylamide concentration was chosen depending on the protein molecular 
weight (MW). Proteins were transferred on nitrocellulose and after 1h in blocking solution membranes 
were incubated overnight at 4°C with the primary antibody, except anti-β-Tubulin III, anti-β-Actin, 
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anti-PrP, anti-Atp7b and anti-Fp1, which were incubated 1h at room temperature. After incubation 
with the secondary antibody, membranes were developed with ECL detection reagent (GE Healthcare, 
Waukesha, WI, USA) and recorded by the digital imaging system Alliance 4.7 (UVITEC, Cambridge, 
UK). Bands quantification was performed with Uviband 15.0 software (UVITEC, Cambridge, UK). 
Each protein signal was normalized against either β-Actin or β-Tubulin III, depending on the protein 
MW, the signal intensity and the secondary antibody.  
ANTIBODIES 
The following primary antibodies were used in TBST + 5% milk: monoclonal [5F10] to Calcium Pump 
pan Pmca ATPase 1:2000 (ab2825 Abcam, Cambridge, UK); anti-Ctr1 1:500 (ab123105 Abcam); anti-
Sod1 1:1000 (ab13499 Abcam); anti-ZnT3 1:1000 (197002 Synaptic System, Goettingen, Germany); 
monoclonal anti-PrP SHA31 1µg/ml (A03213 BertinPharma, Montigny le Bretonneux, France); Fab 
D18 fragment raised against PrP 1µg/ml, InPro Biotech; anti-Atp7b 1:1000 (NB100-360 Novus 
Biologicals, Littleton, CO, USA); anti-nNOS 1:1000 (4234 Cell Signaling, Beverly, MA, USA); anti-
GluN2A 1:1000 (ab1555 Millipore, Billerica, MA, USA); anti-TfR1 1:500 (13-6800 Invitrogen, Paisley, 
UK); anti-Sod2 1:1000 (SAB2102261 Sigma-Aldrich); anti-β-Tubulin III 1:5000 (T2200 Sigma-Aldrich); 
anti-β-Actin Peroxidase (AC-15) 1:10000 (A3854 Sigma-Aldrich); anti-GluN1 1:2000 (G8913 Sigma-
Aldrich); anti-GluN2A 1:2000 (G9038 Sigma-Aldrich); anti-Steap3 1:3000 (AV43515 Sigma-Aldrich); 
anti-Atp7a 1:2000 (AV33797 Sigma-Aldrich); anti-Ccs (FL-274) 1:400 (sc-20141 Santa Cruz 
Biotechnology, CA, USA); anti-Ncx (H-300) 1:200 (sc-32881 Santa Cruz); anti-GluN2B (C-20) 1:200 
(sc-1469 Santa Cruz).  
The following primary antibodies were used in TBST + 5% BSA: anti-Cp 1:250 (611488 BD 
Transduction Laboratories, Milan, Italy); anti-Tf 1:2000 (GTX21223 GeneTex, Texas, USA); anti-
human ferritin 1:1000 (F5012 Sigma-Aldrich); anti-ferritin heavy chain (H-53) 1:200 (sc-25617 Santa 
Cruz); anti-Metallothionein (FL-61) 1:200 (sc-11377 Santa Cruz). 
The following primary antibodies were used in TBST + 3% BSA + 5% milk: anti-Fp1 1:1000 (NBP1-
21502 Novus Biologicals); anti-Serca2 (N-19) 1:500 (sc-8095 Santa Cruz). 
METAL IONS MEASUREMENTS 
Brains and ippocampi from male mice were dissected in bidistilled water (ddH2O), to maximally reduce 
metal ions contamination, and completely dried in vacuum conditions before weighing them. Samples 
were dissolved in 5 volumes of 65% nitric acid (30709, Sigma Aldrich) overnight at 70°C, except P1 
and P7 hippocampi which were dissolved in 10 volumes of 65% nitric acid. Calcium content was 
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measured by a Perkin-Elmer atomic absorption spectrophotometer (model AAnalyst 100), while 
copper, iron, manganese and zinc were measured by inductively coupled plasma mass spectroscopy 
(ICP-MS, NexION 300D, PerkinElmer). 
CERULOPLASMIN ACTIVITY 
Ceruloplasmin is a Cu-dependent ferroxidase and the major Cu transporter in the blood. Its enzymatic 
activity was measured from Prnp+/+ and Prnp0/0serum. Serum samples were prepared as follows: male 
mice were deeply anesthetized with 2g/kg urethane (Sigma-Aldrich), blood was taken directly from the 
heart and was left 30 min at room temperature to finally isolate serum by centrifugation at 900g for 10 
minutes. Cp activity was measured following the protocol published by (Schosinsky et al., 1974). 
Briefly, 50µl serum (50µl ddH2O for the blank) were added to 750µl acetate buffer (100mM sodium 
acetate∙3H2O, pH 5) and heated for 5 min at 30°C. The substrate, o-dianisidine dihydrochloride 
(D3252, Sigma-Aldrich), was prepared 7.88mM in ddH2O and heated at 30°C for 5 min. 200µl 7.88mM 
o-dianisidine were added to the each tube and the reaction was stopped and stabilized adding 2ml 9M 
sulfuric acid. Differently from the published protocol, set up on human serum, in which the reaction 
was stopped after 15 minutes, in our experimental conditions this timing was not enough to get a good 
absorbance (Abs) peak at 540nm. Performing a reaction time course, we observed that the peak signal 
was strong and not at plateau after 2.5 hours reaction (Figure 15). So 2.5 hours was the reaction time 
used for the comparison between Prnp+/+ and Prnp0/0serum samples Cp activity. The enzymatic activity 
of ceruloplasmin is expressed in International Units, in terms of substrate consumed: Ceruloplasmin 
oxidase activity = Abs x 0.416 U/ml. The factor 0,0416 was obtained as follows: Concn of substrate 
oxidized = (absorbance x 3 x 20)/(9. 6 x 150) µmol/ml per minute, where: 9.6 is the molar absorptivity 
of colored solution in terms of substrate consumed (ml µmol-1 cm-1); 3.0 = correction factor for the 
final measured solution volume; 20 correction for serum volume used (0.05 ml); and 150 incubation 
time (min) (Schosinsky et al., 1974). 
 
Figure 15. Cp activity reaction time-course.   
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RNA EXTRACTION AND REAL TIME PCR 
To check Cp mRNA levels, hippocampi from P15 male mice were investigated. This developmental 
stage was chosen because it is in the middle between P7 and P30, which are two ages showing high 
protein level difference between Prnp+/+ and Prnp0/0. Four Prnp+/+ and four Prnp0/0hippocampi  were 
immediately taken after sacrifice into TRIzol reagent (15596018, Invitrogen), frozen in liquid nitrogen 
and  stored at -80°C. Total RNA from the samples was extracted following the TRIzol reagent 
manufacturer's instructions. To limit genomic DNA contamination, samples were treated with RNase 
free DNase set (79254, Qiagen, Germantown, MD, USA) and purified using the RNeasy mini kit 
(74104, Qiagen). Total RNA quality was assessed by observing on 1% agarose gel the two characteristic 
bands corresponding respectively to 28S, 18S rRNA, together with a lower and less intense band likely 
corresponding to tRNA and 5S rRNA. RNA quantification was performed using an ND-1000 
Nanodrop spectrophotometer (Thermoscientific). For each sample, 4μg of RNA were retrotranscribed 
by using SuperScriptIII RT (18080, Invitrogen) and oligodT primer (5′-GCT GTC AAC GAT ACG 
CTA CGT AAC GGC ATG ACA GTG(T)24-3′).  
To check genomic contamination, RT- reactions were performed, i.e. retrotranscription reaction 
without the SuperScriptIII RT enzyme. Quantitative real time PCR was performed using iQ SYBR 
Green Supermix (170-8880, Bio-Rad, Hercules, USA) and an iCycler IQ Real Time PCR System (Bio-
Rad). Expression of the gene of interest was normalized to housekeeping gene βIII-Tubulin and 
glyceraldehyde 3-phosphate dehydrogenase (Gapdh), and the initial amount of the template of each 
sample was determined as relative expression versus housekeeping gene chosen as reference. The 
relative expression of each sample was calculated by the formula 2exp-∆∆Ct (User Bulletin 2 of the ABI 
Prism 7700 Sequence Detection System) (Livak and Schmittgen, 2001). Housekeeping gene expression 
is not modified under the present experimental conditions (data not shown). Primer sequences for 
secreted Cp (sec_Cp), GPI-anchored Cp (GPI_Cp), βIII-Tubulin (βTub) and Gapdh are shown in 
Table 4. Real time PCR products were also analyzed on a 2% agarose gel. 
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Table 4. Experimental parameters used for real time PCR experiments 
BIOTIN SWITCH ASSAY 
The biotin switch assay was performed as described by Jaffrey and Snyder (Jaffrey and Snyder, 2001) 
with a few modifications. Hippocampal samples were collected as described above from adult male 
mice and homogenized in 400µl HEN buffer (250mM HEPES pH 7.5, 1mM EDTA, 0.1mM 
Neocuproine (Sigma-Aldrich) containing proteases inhibitors and centrifuged at 2000g, 10 minutes at 
4°C. Protein concentration in the supernatant was determined by BCA assay. For each sample, 1mg of 
proteins was used for the further steps of the protocol. Samples were diluted to 0.8µg/µl in HEN 
buffer + 0.4% CHAPS (Sigma Aldrich) and incubated in 4 volumes of blocking solution (9 volume of 
HEN, 1 volume of 25% w/v SDS in ddH2O, 20mM methyl methanthiosulfonate (MMTS, Sigma-
Aldrich) from the 2M stock solution in dimethylformamide (DMF)) at 50°C for 1 hour. MMTS was 
removed by acetone-precipitation and the protein pellet was resuspended in 100µl of HENS buffer 
(HEN+1%SDS). 30mM ascorbate was added to samples and the reaction was carried out for 3 hours 
at 25°C (Giustarini et al., 2008). Ascorbate was removed by acetone-precipitation and the protein pellet 
was resuspended in 100µl of HENS buffer. EZ-Link HPDP-biotin (Thermoscientific, Waltham, MA, 
USA) was added 1:3 to the samples. After 1 hour incubation at 25°C, HPDP-biotin was removed by 
dialysis in HENS buffer. To purify biotinilated proteins, 2 volumes of neutralization buffer (20mM 
HEPES pH 7.5, 100mM NaCl, 1mM EDTA, 0.5% Triton X-100) and 15µl of Immobilized 
NeutrAvidin Protein (Thermoscientific) were added to the samples and incubated for 2 hours at room 
temperature. Resin was washed 5 times with neutralization buffer adjust to 600mM NaCl, biotinilated 
proteins were eluted directly in SDS-PAGE sample buffer boiled and loaded on 8% acrylamide gel for 
protein immunodetection.  
!
Primer  Primer sequence (5’ -3’)  Base 
pairs 
Anneal ing 
temperature 
(°C) 
Access ion 
no.  
Reference  
sec_Cp sense TCCCTGGAACATACCAAACC 60 NM_007752  
 antisense ATTTATTTCATTCAGCCAGACTTAG  
157 
  
(Stasi et 
al., 2007) 
GPI_Cp sense TCCCTGGAACATACCAAACC 60 
 antisense CCAGGTCATCCTGTAACTCTGA  
158 
 
AK086999  
AK043248 
(Stasi et 
al., 2007) 
!Tub sense CGCCTTTGGACACCTATTC  60 NM_023279  
 antisense TACTCCTCACGCACCTTG  
240 
  
(Simonetti 
et al., 
2008) 
Gapdh sense TTCACCACCATGGAGAAGGC  60 NM_008084  
 antisense GGCATGGACTGTGGTCATGA  
236 
  
(Chen et 
al., 2003) 
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ORGANOTYPIC HIPPOCAMPAL CULTURES PREPARATION 
Organotypic hippocampal culture (OHC) preparation protocol was set up based on Gahwiler 
(Gahwiler et al., 1997). Briefly, in aseptic condition P5 mice hippocampi were dissected in dissection 
medium (Gey’s balanced salt solution, 5.6mM D-Glucose, 1mM kynurenic acid) and sliced by means of 
a tissue chopper into 300µm thick sections. After washing in dissection medium for 40 min at 4°C, 
slices showing an intact hippocampal cytoarchitecture were selected, singularly attached to a coverslip 
by embedding in a chicken plasma (Sigma-Aldrich) and thrombin (Aurogene, UK) cloth and 
maintained at 37°C in roller tubes with a medium composed by 50% basal medium Eagle (BME, 
Gibco, Life Technologies, UK), 25% horse serum (Gibco), 25% Hank’s balanced salt solution (Gibco), 
5.6mM D-Glucose, 2mM L-Glutamine.  
EXCITOTOXIC TREATMENT  
To compare susceptibility to excitotoxicity in Prnp+/+ and Prnp0/0cultures, after 13 days in vitro (DIV) 
OHCs were treated in serum-free medium for 3h with 5µM NMDA (Tocris biosciences, UK). NMDA 
was dissolved 1mM in sterile ddH2O and stored at -20°C. In control slices, serum-free medium was 
added with corresponding volume of ddH2O. One slice for each group was taken after the treatment to 
assess the immediate effect, while the remaining slices were in left 24h wash out in culture medium. 
Afterwards, all the slices were processed for immunofluorescence. 
IMMUNOFLUORESCENCE 
To evaluate neuronal cell death, slices were fixed in 4% paraformaldehyde (PFA, Sigma Aldrich) in PBS 
pH 7.4 overnight at 4°C. To improve the nuclear staining, slices were treated as follows: 5 min for 3 
times washing in PBS-1% TritonX-100, 10 min in 0.1N HCl at 4°C, 10 min in 0.2N HCl at room 
temperature, 20 min in 0.2N HCl at 37°C, 12 min in borate buffer pH 8.4 (77mM boric acid, 6.6mM 
borax) at room temperature, 5 min for 3 times washing in PBS-1%TritonX-100. Slices were incubated 
for 2h at room temperature in blocking solution (1M glycin, 5% normal goat serum, PBS-1%TritonX-
100) and overnight at 4°C with anti-Neuronal Nuclei antibody 1:500 (NeuN clone A60mab377 
Millipore) in blocking solution. After washing 5 min for 3 times in PBS-1%TritonX-100, slices were 
incubated with Alexa Fluorophore-conjugated secondary antibodies (1:500) and 4',6-diamidino-2-
phenylindole (DAPI, 1:500) in blocking solution for 2h at room temperature. Slices were washed in 
PBS, rinsed in water, and mounted with VectaShield (Vector Laboratories, Burlingame, CA, USA). 
To evaluate PrP distribution, sliceswere fixed in 4% PFA in PBS pH 7.4 for 30 min at room 
temperature, cryoprotected in 10% sucrose in PBS for 1h at room temperature and in 20% sucrose in 
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PBS overnight at 4°C. To expose the antigen, slices were frozen (5 min) and thawed (5 min) 3 times in 
100% ethanol using dry ice. Slices were incubated in blocking solution (10% BSA, 5% normal goat 
serum, PBS-0.1 % TritonX-100) 4h at room temperature, then overnight at 4°C with anti-PrP SHA31 
1:500 in 5% BSA, 0.1% Triton X-100, 1% normal goat serum, PBS/tween 0.05%. After washing 30 
min in 5% BSA, 1% normal goat serum in PBS, slices were incubated 3h at room temperature with 
Alexa Fluorophore-conjugated secondary antibodies (1:500) and DAPI (1:500) in the same solution 
used for the primary antibody. Slices were washed in PBS, rinsed in water, and mounted with 
VectaShield (Vector Laboratories). 
CONFOCAL MICROSCOPY AND IMAGE ANALYSIS 
Hippocampal cultures were examined on a Leica DMIRE2 confocal microscope (Leica Microsystem 
GmbH, Germany) equipped with DIC and fluorescent optics, Diode laser 405nm, Ar/ArKr 488nm 
and He/Ne 543/594nm lasers. The fluorescence images (1024x1024 pixels) were acquired with either a 
63×1.4 NA or a 40×1.4 NA oil immersion objective additionally zoomed 1.5-fold, with 200Hz 
acquisition speed. Stacks of z-sections with an interval of 3µm were sequentially scanned. The CA1, 
CA3 and DG were the regions selected for the analysis (Figure 16). 
 
Figure 16. Scheme of hippocampus architecture (modified from Santiago Ramón and Cajal, 1911). 
The total nuclei number was evaluated in singular frames (1 each 6µm) with DAPI staining using the 
Volocity 5.4 3D imaging software (PerkinElmer, Coventry, UK). Pyknotic nuclei were counted in the 
same frames by mean of ImageJ software by W. Rasband (developed at the U.S. National Institutes of 
Health and available at http://rsbweb.nih.gov/ij/).  
STATISTICAL ANALYSES 
Metal ion content, WB, Cp activity, real time PCR and pyknotic nuclei count results were compared 
between Prnp+/+ and Prnp0/0 samples performing the Student’s T test setting two-tailed distribution and 
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two-sample unequal variance. For OHC experiments, each culture preparation (resulting from 3 mice 
dissection) was considered as one sample, so the average neuronal cell death percentage was calculated 
and compared by mean of the T test with the other culture preparations, for a final sample size of 
three. Concerning the biotin switch assay, in each experiment one Prnp+/+ and one Prnp0/0 sample were 
contemporary processed. Therefore, the statistics of all the experiments was performed by the paired 
Student’s T test setting two-tailed distribution.  
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RESULTS 
 
PrPC ROLE IN ESSENTIAL METAL IONS HOMEOSTASIS 
MAINTENANCE 
ESSENTIAL METALS CONTENT 
The total content of essential metal ions (Cu, Mn, Zn and Fe) was measured in both brains and 
hippocampi of Prnp+/+ and Prnp0/0 mice at different developmental stages: P1 (newborn), P7 (early post-
natal), P30 (end of synaptogenesis), P90 (adulthood), P180 (late adulthood), P365 (aging). These 
measurements allowed comparing trace metal ions content both in corresponding ages and in their 
developmental trend in Prnp+/+ and Prnp0/0 conditions. 
Figure 17 shows metal ions content in total brain extracts, while Figure 18 illustrates results in the 
hippocampus. In the brain, copper content is quite constant in both wild-type and PrP null mouse 
conditions and rises in aging (Figure 17A). Compared to Prnp+/+ samples, Prnp0/0 brains show many 
alterations in Cu content, in particular at P1 their Cu content is half the wild-type’s one. In both Prnp+/+ 
and Prnp0/0 samples, Mn trend decreases from P1 to P30, then it is kept almost constant (Figure 17B). 
However, its content is lower in PrP null samples at early post-natal stage and again at P180, whileit is 
higher at P30. Similarly to Mn, Zn content decreases from P1 to P30, then it is almost constant (Figure 
17C). Also Zn concentration is lowered by PrP ablation at P1 and P180, while it is higher al P30. 
Concerning Fe, its content also decreases from P1 to P30, then it is constant in the adulthood and it 
slightly rises in aging (Figure 17D). Concerning Prnp0/0 brains, Fe content is lower at P1 and P7, then 
higher at P30.  In the hippocampus, Cu content increases during the development, but Prnp0/0 samples 
have a lower content at the different stages with the exception of P90 (Figure 18A). Considering Mn, 
its concentration is lower at P180 in Prnp0/0 samples (Figure 18B). Similarly to Cu, Zn content is 
lowered by PrP ablation at P1 and P180, but it is higher at P90 (Figure 18C). Like in the brain, Fe 
content show a slightly decreasing trend between P1 and P30, then it is constant and it rises in the 
aging. Prnp0/0 samples show lower levels at P7 and P180, but a higher level at P90 compared to 
Prnp+/+(Figure 18D). 
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Figure 17. Transition metals content in Prnp+/+ and Prnp0/0 brains at different developmental stages. Filled circles (●) 
represent Prnp+/+ values, while empty circles (○) indicate Prnp0/0 values. (A) Copper; (B) Manganese; (C) Zinc; (D) Iron. 
Sample size: P1 n=4; P7 n=4; P30 n=6; P90 n=5; P180 n=6; P365 n=4. * p<0.05; ** p<0.01; *** p<0.001. 
 
Figure 18. Transition metals content in Prnp+/+ and Prnp0/0 hippocampal samples at different developmental stages. Filled 
circles (●) represent Prnp+/+ values, while empty circles (○) indicate Prnp0/0 values. (A) Copper; (B) Manganese; (C) Zinc; (D) 
Iron. Sample size: P1 n=4; P7 n=4; P30 n=6; P90 n=5; P180 n=6; P365 n=4.. * p<0.05; ** p<0.01; *** p<0.001. 
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ESSENTIAL METALS HOMEOSTASIS PROTEINS EXPRESSION ANALYSIS 
The expression of proteins with a relevant role in metal ions metabolism was analyzed in both Prnp+/+ 
and Prnp0/0 brains and hippocampi. β-III Tubulin and β-Actin were chosen as housekeeping proteins 
after verifying no differences in their expression levels between Prnp+/+ and Prnp0/0samples at the 
different considered developmental stages (Figure 19). 
Concerning copper metabolism and homeostasis, the following proteins were measured: Ceruloplasmin 
(Cp), Six-Transmembrane Epithelial Antigen of Prostate 3 (Steap3), Cu,Zn-Superoxide Dismutase 
(Sod1), Copper chaperon for Sod1 (Ccs),  Copper Transporter 1 (Ctr1), Atp7a and Atp7b. In Figure 20, 
representative images of bands obtained from WB experiments in brain and hippocampus are shown 
for each protein, including housekeeping proteins and PrP. Considering brain samples, in Figure 21 
graphs representing proteins expression in Prnp+/+ and Prnp0/0 mice at the different developmental 
stages are reported. During development Cp expression rises and in PrP null conditions its presence is 
increased (Figure 21A). Steap3 expression decreases during the development but PrP absence does not 
affect its levels (Figure 21B). The expression of Sod1 increases with the age, but without differences 
induced by PrP ablation (Figure 21C). Concerning Ccs expression, it increases with the age and in 
Prnp0/0 samples it has lower levels at P1 and P365 (Figure 21D). Considering three Cu transporters, the 
expression levels of Ctr1 (Figure 21E), Atp7a (Figure 21F) and Atp7b (Figure 21G) are generally not 
affected by PrP absence, though a increased Atp7b level in P1 mice. In Figure 22 graphs showing 
proteins expression in Prnp+/+ and Prnp0/0 hippocampal samples at the different developmental stages 
are shown. Cp expression increases during development, but in the hippocampus PrP absence generally 
lowers its levels compared to Prnp+/+, though at P1 and at P365 no differences were detected (Figure 
22A). As in the brain, Steap3 expression broadly decreases during the development and it does not 
show differences in PrP null conditions compared to Prnp+/+ (Figure 22B). Again similarly to the brain, 
Sod1 expression increases with the age without differences between Prnp+/+ and Prnp0/0 samples (Figure 
22C). On the contrary, Ccs expression in Prnp0/0 hippocampi is lowered at some developmental stages: 
P1, P30 and P90 (Figure 22D). Concerning Cu transporters, Ctr1 and Atp7a expression levels rise with 
the age and both are generally higher in Prnp0/0 samples, while, as in the brain, Atp7b expression is 
increased by PrP ablation just at P1 (Figure 22E-G).  
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Figure 19. Comparison of housekeeping genes –β-III Tubulin and β-Actin – expression levels between Prnp+/+ and Prnp0/0 
brain and hippocampus. (A) Top: from left to right, Ponceau staining of Prnp+/+ and Prnp0/0 brain and hippocampus blots, 
lines from 1 to 5 represent respectively P7, P30, P90, P180, P365 mouse ages; Bottom: from left to right, immunodetection 
of β-III Tubulin, β-Actin and PrP in Prnp+/+ and Prnp0/0 brains and hippocampi; (B) Graphs showing β-III Tubulin and β-
Actin optical density normalized on total proteins (Ponceau staining optical density) in Prnp+/+ and Prnp0/0 brain (n=3); (C) 
Graphs showing β-III Tubulin and β-Actin optical density normalized on total proteins (Ponceau staining optical density) in 
Prnp+/+ and Prnp0/0 hippocampus (n=3). 
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Figure 20. Copper metabolism proteins. Representative immunoblot of each analyzed protein in the whole brain and in the 
hippocampus in Prnp+/+ and Prnp0/0 mice. Housekeeping proteins – β-III Tubulin and β-Actin – are also shown. Prnp+/+ and 
Prnp0/0 genotypes were confirmed by PrP immunodetection.  
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Figure 21. Copper-binding proteins expression levels in Prnp+/+ and Prnp0/0 brains at different developmental stages. For 
each protein, the optical density value was normalized on a housekeeping protein. Filled circles (●) represent Prnp+/+ values, 
while empty circles (○) indicate Prnp0/0 values. (A) Ceruloplasmin (Cp); (B) Six-Transmembrane Epithelial Antigen of 
Prostate 3 (Steap3); (C) Cu,Zn-Superoxide Dismutase (Sod1); (D) Copper chaperone for Sod1 (Ccs); (E) Copper 
Transporter 1 (Ctr1); (F) Atp7a; (G) Atp7b. Minimum sample size: n=4; * p<0.05, ** p<0.01, *** p<0.001 
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Figure 22. Copper-binding proteins expression levels in Prnp+/+ and Prnp0/0 hippocampi at different developmental stages. 
For each protein, the optical density value was normalized on a housekeeping protein. Filled circles (●) represent Prnp+/+ 
values, while empty circles (○) indicate Prnp0/0 values. (A) Ceruloplasmin (Cp); (B) Six-Transmembrane Epithelial Antigen of 
Prostate 3 (Steap3); (C) Cu,Zn-Superoxide Dismutase (Sod1); (D) Copper chaperone for Sod1 (Ccs); (E) Copper 
Transporter 1 (Ctr1); (F) Atp7a; (G) Atp7b. Minimum sample size: n=4; * p<0.05, ** p<0.01, *** p<0.001 
 
To study Fe metabolism alterations due to PrP ablation, the following proteins were analyzed: Cp, 
Steap3, Transferrin (Tf), Transferrin Receptor 1 (TfR1). Ferroportin 1 (Fpn1), Ferritin heavy chain 
(FtH), Ferritin light chain (FtL). Figure 23 shows representative images of bands obtained from WB 
experiments in brain and hippocampus for each protein, including housekeeping proteins and PrP to 
confirm its absence in PrP null mice. In Figure 24, graphs representing proteins expression in Prnp+/+ 
and Prnp0/0 brains at the different developmental stages are reported. Though reported also in Figure 
24A,B to facilitate a comprehensive analysis, brain Cp and Steap3 expression patterns were described in 
the previous paragraph. PrP null mice show higher expression levels of Fe uptake proteins, Tf and 
TfR1 at all the developmental stages analysed, with exception of P1 TfR1 which is lower in PrP null 
samples (Figure 24C,D). On the contrary, Fpn1 levels are lowered in Prnp0/0samples starting from P30 
0,3 
3 
P1 P7 P30 P90 P180 P365 
S
te
ap
3/
!
II
I-
T
u
b
u
lin
 
Mouse age 
0,0 
0,0 
0,4 
P1 P7 P30 P90 P180 P365 
C
tr
1/
!
-A
ct
in
 
Mouse age 
Ctr1 
0,1 
1 
10 
P1 P7 P30 P90 P180 P365 
A
tp
7b
/
!
-A
ct
in
 
Mouse age 
* 
Atp7b 
0,0 
0,2 
P1 P7 P30 P90 P180 P365 
A
tp
7a
/
!
-I
II
 T
u
b
u
lin
  
Mouse age 
Atp7a 
* 
* 
* * * 
* 
* * * 
0,2 
2 
P1 P7 P30 P90 P180 P365 
C
cs
/
!
-A
ct
in
 
Mouse age 
* 
* 
* 
Ccs 
0,2 
2 
P1 P7 P30 P90 P180 P365 
S
o
d
1/
!
-A
ct
in
 
Mouse age 
Sod1 
0,04 
0,4 
P1 P7 P30 P90 P180 P365 
C
p
/
!
-A
ct
in
 
Mouse age 
Cp 
* 
* 
* 
* 
Steap3 A B 
D C 
E F G 
  63 
(Figure 24E), while FtH levels are lowered from P1 to P30 and then slightly higher at P180 and P365 
(Figure 24F). Concerning FtL expressions, no alterations were observed in Prnp0/0 brains compared to 
Prnp+/+ (Figure 24G). Figure 25 shows graphs corresponding to the expression patterns of the analyzed 
proteins at the different developmental stages in Prnp+/+ and Prnp0/0 hippocampi. Figure 25A-B shows 
Cp and Steap3 trends already described in the previous paragraph. As in the brain, Tf and TfR1 
expression levels are broadly increases in PrP absence (Figure 25C,D). Differently from the brain, Fpn1 
levels are not altered in PrP null hippocampi (Figure 25E), while FtL expression is lowered from P1 to 
P90 (Figure 25G). Concerning FtH expression, similarly to the brain, it is lower in Prnp0/0 from P1 to 
P90 and at P180 and P365 slightly increased (Figure 25F).  
 
Figure 23. Iron metabolism proteins. Representative immunoblot of each analyzed protein in the whole brain and in the 
hippocampus in Prnp+/+ and Prnp0/0 mice. Housekeeping proteins – β-III Tubulin and β-Actin – are also shown. Prnp+/+ and 
Prnp0/0 genotypes were confirmed by PrP immunodetection.  
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Figure 24. Expression levels of iron metabolism proteins in Prnp+/+ and Prnp0/0 brains at different developmental stages. 
For each protein, the optical density value was normalized on a housekeeping protein. Filled circles (●) represent Prnp+/+  
alues, while empty circles (○) indicate Prnp0/0 values. (A) Ceruloplasmin (Cp); (B) Six-Transmembrane Epithelial Antigen of 
Prostate 3 (Steap3); (C) Transferrin (Tf); (D) Transferrin Receptor 1 (TfR1); (E) Ferroportin 1 (Fpn1); (F) Ferritin heavy 
chain (FtH); (G) Ferritin light chain (FtL). Minimum sample size: n=4; * p<0.05, ** p<0.01, *** p<0.001 
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Figure 25. Expression levels of iron metabolism proteins in Prnp+/+ and Prnp0/0 hippocampi at different developmental 
stages. For each protein, the optical density value was normalized on a housekeeping protein. Filled circles (●) represent 
Prnp+/+ values, while empty circles (○) indicate Prnp0/0 values. (A) Ceruloplasmin (Cp); (B) Six-Transmembrane Epithelial 
Antigen of Prostate 3 (Steap3); (C) Transferrin (Tf); (D) Transferrin Receptor 1 (TfR1); (E) Ferroportin 1 (Fpn1); (F) 
Ferritin heavy chain (FtH); (G) Ferritin light chain (FtL). Minimum sample size: n=4; * p<0.05, ** p<0.01, *** p<0.001 
 
To characterize Zn metabolism in PrP absence, the expression of the following protein was analyzed: 
Sod1, Metallothioneins (Mt) and Zn transporter 3 (ZnT3). Figure 26 shows representative bands 
obtained from WB experiments of brains and hippocampi for each protein including housekeeping and 
PrP to confirm Prnp+/+ and Prnp0/0 samples. In Figure 27 graphs displaying Zn metabolism proteins 
expression in Prnp+/+ and Prnp0/0 brains at the different developmental stages are reported. As 
previously reported for Cu metabolism, Sod1 expression is not altered in PrP null condition (Figure 
27A). Concerning Mt expression, though a lower level in Prnp0/0 at P7, it is quite constant during 
development then it decreases in the aging. However, at P180 and P365 PrP absence keeps Mt levels 
slightly higher compared to Prnp+/+ (Figure 27B). ZnT3 expression rises during development reaching a 
plateau at the end of synaptogenesis without showing any difference between Prnp+/+ and Prnp0/0 brains 
(Figure 27C). Figure 28 reports graphs describing Zn metabolism proteins expression at the different 
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ages in Prnp+/+ and Prnp0/0 in hippocampal samples. Figure 28A reports the same Sod1 pattern already 
described for Cu metabolism. Mt and ZnT3 expression levels increase from P1 to P30 where they 
reach a peak and then Mt decreases towards aging while ZnT3 is constant, both without revealing any 
difference in PrP null conditions compared to Prnp+/+ (Figure 28B,C). 
 
 
Figure 26. Zinc metabolism proteins. Representative immunoblot of each analyzed protein in the whole brain and in the 
hippocampus in Prnp+/+ and Prnp0/0 mice. Housekeeping proteins – β-III Tubulin and β-Actin – are also shown. Prnp+/+ and 
Prnp0/0 genotypes were confirmed by PrP immunodetection.  
 
 
Figure 27. Zinc-binding proteins expression levels in Prnp+/+ and Prnp0/0 brains at different developmental stages. For each 
protein, the optical density value was normalized on a housekeeping protein. Filled circles (●) represent Prnp+/+ values, 
while empty circles (○) indicate Prnp0/0 values. (A) Cu,Zn-Superoxide Dismutase (Sod1); (B) Metallothioneins (Mt); (C) Zinc 
Transporter 3 (ZnT3). Sample size: n=4; * p<0.05, ** p<0.01, *** p<0.001 
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Figure 28. Zinc-binding proteins expression levels in Prnp+/+ and Prnp0/0 hippocampi at different developmental stages. For 
each protein, the optical density value was normalized on a housekeeping protein. Filled circles (●) represent Prnp+/+ values, 
while empty circles (○) indicate Prnp0/0 values. (A) Cu,Zn-Superoxide Dismutase (Sod1); (B) Metallothioneins (Mt); (C) Zinc 
Transporter 3 (ZnT3). Sample size: n=4; * p<0.05, ** p<0.01, *** p<0.001 
 
Concerning Mn metabolism, just Mn, Superoxide dismutase (Sod2) expression was evaluated. Figure 29 
shows representative bands obtained from brain and hippocampus protein extracts WB after detection 
of Sod2, the housekeeping and PrP to confirm Prnp+/+ and Prnp0/0 samples. In Figure 30A,B graphs 
displaying Sod2 expression levels in Prnp+/+ and Prnp0/0 brains and hippocampi at the different 
developmental stages are reported. In the brain, Sod2 expression increases up to P30 then it slowly 
decreases (Figure 30A), while in the hippocampus it increases with the age (Figure 30B). No differences 
between Prnp+/+ and Prnp0/0 samples were detected with exception of a little increase in P90 brain in 
Prnp0/0.  
 
Figure 29. Manganese metabolism protein. Representative immunoblot of Sod2 in the whole brain and in the hippocampus 
in Prnp+/+ and Prnp0/0 mice. Housekeeping protein – β-III Tubulin – is also shown. Prnp+/+ and Prnp0/0 genotypes were 
confirmed by PrP immunodetection.  
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Figure 30. Manganese-binding protein expression levels in Prnp+/+ and Prnp0/0 brains and hippocampi at different 
developmental stages. For Sod2, the optical density value was normalized on a housekeeping protein – β-III Tubulin-. Filled 
circles (●) represent Prnp+/+ values, while empty circles (○) indicate Prnp0/0 values. (A) brain samples; (B) hippocampus 
samples. Sample size: n=4; * p<0.05, ** p<0.01, *** p<0.001  
CERULOPLASMIN TRANSCRIPTION AND FUNCTIONALITY  
As it has been described in the previous section, Prnp0/0 mice showed alterated Cp levels compared to 
Prnp+/+, and, in particular, they exhibit lower Cp presence in the hippocampus. To understand if this 
was due to a transcriptional regulation, real time PCR experiments were performed on hippocampal 
total RNA, extracted from mice showing altered protein levels, measuring both the secrete and the 
GPI-anchored form of the protein which were differentiated using specific primers (Stasi et al., 2007). 
The results were normalized on two housekeeping genes (GAPDH and βIII-Tubulin) whose 
expression levels are not different in Prnp+/+ and Prnp0/0 samples (data not shown). Figure 31 reports a 
representative image of the real time PCR amplification products agarose gel. The non template control 
(NTC) did not give any amplification result, as well as the reaction performed using RT- template.  
 
Figure 31. Real time PCR amplification products bands visualized on a 2% agarose gel. Starting from the left: non template 
control (NTC) amplification products for all the used primers; GAPDH, βTub, sec_Cp, GPI_Cp amplification products 
from Prnp+/+RT+ and RT- templates; GAPDH, βTub, sec_Cp, GPI_Cp amplification products from Prnp0/0RT+ and RT- 
templates.  
 
As can be seen from Figure 32, no differences between Prnp+/+ and Prnp0/0were detected both for the 
secreted and the GPI-anchored form of Cp. The same result was obtained normalizing either with 
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GAPDH or βIII-Tubulin. So, different Cp protein levels in brains and hippocampi of Prnp+/+and 
Prnp0/0 mice are not due to differential transcriptional regulation. 
 
Figure 32. Cp mRNA levels comparison between Prnp+/+ and Prnp0/0 samples. In the graph, the results normalized against 
both the housekeeping genes are shown for secreted and GPI-anchored Cp mRNA. The relative expression of each sample 
was calculated by the formula 2exp-∆∆Ct the fold change values are reported on the top of each column. Sample size n=4. 
Biosynthesis of liver-secreted Cp does not seem to depend on the availability of copper, which is 
evidenced by the presence of apo-Cp in plasma under conditions of copper deficiency or when some 
protein needed to provide copper for biosynthesis of Cp is invalid, as in the case of mutated Atp7b 
Wilson’s disease (Vassiliev et al., 2005). However, if Cu ions are not properly loaded on Cp, its 
ferroxidase activity is impaired (Vassiliev et al., 2005). Circulating Cp Cu-loading and ferroxidase 
activity are independent to astrocytes- and neurons-synthetised Cp ones, since they derive from two 
different systems. However, if plasma circulating Cp ferroxidase activity is impaired, it results in 
increased oxidative stress levels that can lead to neurodegeneration. Plasma Cp ferroxidase activity was 
measured following the protocol published in (Schosinsky et al., 1974), and adapted to mice. As can be 
seen in Figure 33, in normal conditions serum Cp activity increases with the age, while in PrP absence 
this increase is not detected. In fact, Prnp0/0 sera show  impaired Cp ferroxidase activity and the 
difference increases with the age (p<0.05 at P15 and P180, p<0.01 at P365).  The similar level observed 
at P30 can be reconducted to a general different situation of metal ion homeostasis, previosly described 
concerning metal content. At P90, impairments in PrP null serum Cp activity are detectable, though not 
statistically significant (p=0.075).  
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Figure 33. Cp functionality comparison between Prnp+/+ and Prnp0/0 samples. The graph shows the results obtained from 
sera samples of different mouse ages (P15, P30, P90, P180 and P365). Cp activity was calculated as U/ml according to 
Schosinsky et al. in 1974. Sample size: P15, P30, P180 n=4; P90, P365 n=3. * p<0.05; ** p<0.01. 
PrPC NEUROPROTECTIVE ROLE IN EXCITOTOXICITY: NMDARS 
ACTIVITY REGULATION.  
EXCITOTOXICITY IN Prnp+/+ AND Prnp0/0 ORGANOTYPIC HIPPOCAMPAL 
CULTURES  
To study PrP role in excitotoxic conditions, OHCs were prepared from Prnp+/+ and Prnp0/0 pups. OHCs 
were treated after 13 DIV, since at this stage cultures appear flattened, thin and with a well-defined 
cytoarchitecture. Figure 34 shows an example of a control slice, after 13 DIV, stained with DAPI and 
NeuN, a neuronal nuclei marker that better highlights hippocampal regions CA1, CA3 and DG.  
 
Figure 34. Organotypic hippocampal cultures at 13 DIV stained with DAPI (blue) and NeuN antibody (green). The three 
hippocampal regions analysed in the following experiments are highlighted: Cornu Ammonis 1 (CA1), Cornu Ammonis 3 (CA3), 
Dentate Gyrus (DG).  
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PrPC expression was assesed in OHCs: a strong staining was observed in both CA1 and CA3 areas and 
a mild staining was detected in the DG (Figure 35, top row). In Prnp0/0 OHCs no immunoreactivity for 
PrPC was observed, confirming the specificity of the antibody (Figure 35, bottom row). 
 
Figure 34. PrPC immunofluorescent staining using PrP SHA31 antibody on OHCs. Confocal microscope fluorescence 
images were acquired using a 40×1.4 NA oil immersion objective. SHA31 is displayed in green and DAPI in blue. Staining 
for Prnp+/+ and Prnp0/0 OHCs is shown respectively in top and bottom row.  
 
After 13 DIV, cultures were treated for 3 hours with 5µM NMDA and processed for 
immunofluorescence after 24 hours wash out. The combination of NeuN and DAPI staining resulted 
to be a good experimental procedure to evaluate neuronal cell death, as it is shown in Figure 36: DAPI 
staining allows discriminating healthy nuclei, which are big and contain distinguishable nucleoli, from 
pyknotic ones, which are smaller and fully condensed; NeuN immunostaining is localized in the nucleus 
in healthy neurons, while it is dispersed around condensed chromatin or completely lost in pyknotic 
nuclei. The NeuN staining was not quantified, but it was used on a quality level, mergd with DAPI 
stainig, to verify that counted pyknotic nuclei corresponded to neuronal cells (Figure 36). 
Prnp+/+ Prnp+/+ Prnp+/+ 
Prnp0/0 Prnp0/0 Prnp0/0 
DAPI     PrP SHA31 
Prnp+/+ Prnp+/+ Prnp+/+ 
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Figure 36. Combination of NeuN and DAPI immunostaining to evaluate neuronal cell death. Confocal microscope 
fluorescence images were acquired using a 63×1.4 NA oil immersion objective. In A-C panels healthy nuclei from untreated 
OHCs are shown: (A) DAPI staining, (B) NeuN immunostaining, (C) merge. In D-F panels pyknotic nuclei from NMDA 
treated OHCs are shown: (D) DAPI staining, (E) NeuN immunostaining, (F) merge. Solid arrows indicate neuronal nuclei; 
dashed arrows indicate glial nuclei. In the merge images, NeuN staining is displayed in green and DAPI one in red. 
The NMDA treatment (5µM for 3 hours) was chosen based on results published in literature (Bunk et 
al., 2010; Kristensen et al., 2001). This NMDA stimulation turned out to be optimal for comparing 
susceptibility between Prnp+/+ and Prnp0/0 cultures since in Prnp+/+ it induced low levels of neuronal cell 
death, but high levels in Prnp0/0preparations. As it can be seen in Figure 37, 3 hours 5µM NMDA 
triggers spread neuronal cell death just in CA1 region in Prnp+/+ OHCs, but not in the CA3 and in the 
DG. On the other hand, in PrP null preparations neuronal cell death was observed at high levels also in 
the CA3 and in the DG. These observations were confirmed by quantification (Figure 38). In fact, the 
statistical analysis revealed that 3 hours 5µM NMDA induced significant neuronal cell death in Prnp+/+ 
CA1 (p<0.05), as well as in Prnp0/0 CA1 (p<0.05), but with higher levels in PrP absence (p<0.05). 
Considering CA3 and DG, the treatment was not able to induce significant neuronal cell death in 
Prnp+/+ OHCs, but it did on Prnp0/0 samples (both p<0.05). So, CA3 and DG neuronal cell death in PrP 
null condition was significantly higher compared to Prnp+/+  (both p<0.01). 
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Figure 37. Comparison between Prnp+/+ and Prnp0/0 OHCs regional susceptibility to NMDA treatment. Confocal 
microscope fluorescence images were acquired using a 40×1.4 NA oil immersion objective. In rows, three different 
hippocampal regions are shown: (A-D) CA1, (E-H) CA3, (I-L) DG. In columns, four different experimental conditions are 
shown: (A, E, I) Prnp+/+ control, (B, F, J) Prnp+/+ 5µM NMDA, (C, G, K) Prnp0/0 control, (D, H, L) Prnp0/0 5µM NMDA. 
NeuN staining is displayed in green and DAPI one in red.  
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Figure 38. Comparison between Prnp+/+ and Prnp0/0 OHCs regional susceptibility to NMDA treatment. Quantification was 
calculated as the percentage of neuronal pyknotic nuclei on the total cell number considering separately three hippocampal 
areas: (A) CA1, (B) CA3, (C) DG.  Sample size: n=3, i.e. 3 independent experiments, each one prepared from 3 mice 
dissection resulting in an average number of 15 control cultures and 15 NMDA-treated cultures. * p<0.05; ** p<0.01 
EXCITOTOXICITY MAJOR PLAYERS ANALYSIS 
To understand the reason why in Prnp0/0neurons are more susceptible to excitotoxic conditions, the 
expression levels of proteins involved in the molecular mechanism underlying NMDA toxic effect was 
analyzed in Prnp+/+ and Prnp0/0 samples at different ages (P30, P90, P180, P365). In the same samples, 
total calcium content was measured.  Concerning proteins, the expression levels of NMDA receptor 
mostly esxpressed subunits, nNOS and Casp3 were assessed in the hippocampus, while calcium pumps 
and calcium content were measured both in the hippocampus and in the brain. Figures 39 and 41 show 
representative images of Western blotting experiments for each protein. For the NMDAR subunits 
GluN1, GluN2A and GluN2B expression levels, in general Prnp0/0 hippocampi showed higher levels, in 
particular from adulthood to aging (Figure 40). Regarding nNOS expression levels, generally PrP 
ablation does not play a role, except for a minor difference at P30 (Figure 40D). Caspase3 expression 
analysis revealed a lower level at P30 but a higher one at P365 in Prnp0/0 mice (Figure 40E).  
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
%
 p
yk
n
o
ti
c 
n
u
cl
ei
 
DG 
Pr
np
+/
+ 
Ct
rl Pr
np
+/
+ 
5!
M
 N
M
DA
 
Pr
np
0/
0 
5!
M
 N
M
DA
 
Pr
np
0/
0 
Ct
rl 
0 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
%
 p
yk
n
o
ti
c 
n
u
cl
ei
 
CA3 
Pr
np
+/
+ 
Ct
rl Pr
np
+/
+ 
5!
M
 N
M
DA
 
Pr
np
0/
0 
5!
M
 N
M
DA
 
Pr
np
0/
0 
Ct
rl 
B 
C 
* 
** 
* 
** 
0 
5 
10 
15 
20 
25 
30 
35 
40 
45 
50 
%
 p
yc
n
o
ti
c 
n
u
cl
ei
 
CA1 A 
* 
* 
* 
Pr
np
+/
+ 
Ct
rl Pr
np
+/
+ 
5!
M
 N
M
DA
 
Pr
np
0/
0 
5!
M
 N
M
DA
 
Pr
np
0/
0 
Ct
rl 
  75 
 
Figure 39. Expression levels of some proteins involved in excitotoxicity. Representative immunoblot of each analyzed 
protein in Prnp+/+ and Prnp0/0 hippocampus. Housekeeping protein – β-Actin – is also shown. Prnp+/+ and Prnp0/0 genotypes 
were confirmed by PrP immunodetection.  
 
Figure 40. Expression levels of some proteins involved in excitotoxicity in Prnp+/+ and Prnp0/0 hippocampi at different 
developmental stages. For each protein, the optical density value was normalized on a housekeeping protein – β-Actin-. 
Filled circles (●) represent Prnp+/+ values, while empty circles (○) indicate Prnp0/0 values. (A) NMDA receptor subunit 1 
(GluN1); (B) NMDA receptor subunit 2A (GluN2A); (C) NMDA receptor subunit 2B (GluN2B); (D) neuronal nitric oxide 
synthase (nNOS); (E) Caspase 3. Sample size: n=4; * p<0.05, ** p<0.01, *** p<0.001 
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Calcium pumps expression in Prnp0/0 resulted to be peculiar. In fact, in both brain and hippocampus, as 
shown in Figures 42A and 43A, the expression of the pump with low affinity but high capacity of 
transport, Ncx1, is increased just in the early post-natal stages P1 and P7, while the expression of 
pumps with high affinity and low capacity, Pmca and Serca2, is differently regulated. In the brain, Pmca 
expression is increased in PrP null mice from adulthood to aging (Figure 42B), while Serca2 is not 
affected except a marked increase at P1 (Figure 42C). In the hippocampus, Pmca expression is 
increased starting from P30; at P1 and P7 it is even lower compared to Prnp+/+ (Figure 43B). A similar 
behavior was detected also for Serca2: diminished levels at P7, and increased levels starting from P30 in 
Prnp0/0 compared to Prnp+/+(Figure 43C).  
 
Figure 41. Calcium pumps expression levels. Representative immunoblot of each analyzed protein in Prnp+/+ and Prnp0/0 
hippocampus. Housekeeping protein – β-Actin – is also shown. Prnp+/+ and Prnp0/0 genotypes were confirmed by PrP 
immunodetection.  
 
Figure 42. Calcium pumps expression levels in Prnp+/+ and Prnp0/0 brains at different developmental stages. For each 
protein, the optical density value was normalized on a housekeeping protein – β-Actin-. Filled circles (●) represent Prnp+/+ 
values, while empty circles (○) indicate Prnp0/0 values. (A) Na+/Ca2+ exchanger 1 (Ncx1); (B) Plasma Membrane Calcium 
ATPase (Pmca); (C) Sarco(Endo)plasmic Reticulum Calcium ATPase 2 (Serca2). Minimum sample size: n=4; * p<0.05, ** 
p<0.01, *** p<0.001 
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Figure 43. Calcium pumps expression levels in Prnp+/+ and Prnp0/0 hippocampi at different developmental stages. For each 
protein, the optical density value was normalized on a housekeeping protein – β-Actin-. Filled circles (●) represent Prnp+/+ 
values, while empty circles (○) indicate Prnp0/0 values. (A) Na+/Ca2+ exchanger 1 (Ncx1); (B) Plasma Membrane Calcium 
ATPase (Pmca); (C) Sarco(Endo)plasmic Reticulum Calcium ATPase 2 (Serca2). Minimum sample size: n=4; * p<0.05, ** 
p<0.01, *** p<0.001 
 
To understand whether this different expression of calcium transporters, occurring in the hippocampus 
and brain of Prnp0/0, was due to maintainance of calcium to wild-type levels, Ca2+ ions concentration 
was measured in both brain and hippocampus during the development. The results are shown in Figure 
44A,B. In the brain of Prnp+/+ and Prnp0/0 the same Ca2+ concentration is present, except at P30 in 
Prnp0/0. In the hippocampus, no differences were observed up to P180. In fact, from late adulthood to 
aging Ca2+ homeostasis appears impaired, since oscillations occur affecting the total calcium content.   
 
 
Figure 44. Calcium content Prnp+/+ and Prnp0/0 samples at different developmental stages. Filled circles (●) represent 
Prnp+/+ values, while empty circles (○) indicate Prnp0/0 values. (A) brain; (B) hippocampus. Minimum sample size n=5. * 
p<0.05; ** p<0.01; *** p<0.001. 
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NMDAR SUBUNITS S-NITROSYLATION LEVELS IN Prnp+/+AND Prnp0/0 
HIPPOCAMPI 
To determine whether PrP neuroprotective function upon NMDA induced toxicity is due to a direct 
modulation of NMDARs by mediating the inhibitory S-nitrosylation reaction, SNO levels of NMDAR 
subunits GluN1 and GluN2A were measured. To this end, the biotin switch assay was applied to 
hippocampal protein extracts from adult Prnp+/+ and Prnp0/0 mice. In Figure 45A-B, the biotin switch 
assay output for SNO-GluN1 measurement is shown. In particular, Figure 45A displays the SNO 
fraction of both GluN1 and β-Actin in Prnp+/+ and Prnp0/0 samples, as well as in the control without 
biotin. As controls, GluN1, β-Actin and PrP were immunodetected also in the starting material (input) 
and in the supernatant after incubation with the Neutravidin resin (Figure 45B).  In Figure 45C, a table 
reports the values obtained for SNO-GluN1 O.D. signal normalized on SNO-β-Actin from Prnp+/+ and 
Prnp0/0 samples for each experiment. In the same table, the p value indicating the statistical significance 
of the difference between Prnp+/+ and Prnp0/0 in the entire experimental set is reported (p=0.0002).  
 
Figure 45. SNO-GluN1 levels in Prnp+/+ and Prnp0/0 hippocampal samples. The biotin switch assay was performed to detect 
SNO-proteins levels starting from 1mg protein extract. (A) SNO-GluN1 and SNO-β-Actin in Prnp+/+ and Prnp0/0 
hippocampi and in the control without biotin; (B) GluN1, β-Actin and PrP immunodetection in the starting material (input) 
and in the supernatant after incubation with the Neutravidin resin (not bound); (C) table reporting the values of SNO-
GluN1 normalized on SNO-β-Actin obtained for each experiment performed in Prnp+/+ and Prnp0/0 samples and the p value 
calculated with the paired T test formula.  
ratio SNO-GluN1/SNO-!-actin p value 
Prnp+/+ 0.320 0.316 0.346 0.134 0.316 0.187 0.373 
0.0002 
Prnp0/0 0.145 0.086 0.182 0.039 0.086 0.047 0.098 
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Considering SNO-GluN2A detection and measurement, Figure 46A-C reports as example the biotin 
switch assay output. In particular, Figure 46A shows the SNO fraction of GluN2A and β-Actin in two 
Prnp+/+ and two Prnp0/0 samples, as well as in the control without biotin. To check samples quality, 
Figure 46B display the result of the immunodetection of GluN2A, β-Actin and PrP in the supernatant 
after incubation with the Neutravidin resin, while Figure 46C shows the same on the input material. 
The table in Figure 46D reports the quantification values for SNO-GluN2A, normalized on SNO-β-
Actin, obtained in each experiment with Prnp+/+ and Prnp0/0 samples. The resulting p value indicating 
the significance of the difference between Prnp+/+ and Prnp0/0 condition is also reported (p=0.0368).  
 
 
Figure 46. SNO-GluN2A levels in Prnp+/+ and Prnp0/0 hippocampal samples. The biotin switch assay was performed to 
detect SNO-proteins levels starting from 1mg protein extract. (A) SNO-GluN2A and SNO-β-Actin in Prnp+/+ and Prnp0/0 
hippocampi and in the control without biotin; (B) GluN2A, β-Actin and PrP immunodetection in the fraction that did not 
reacted with Neutravidin resin; (C) GluN2A, β-Actin and PrP immunodetection  in the starting material (input); (D) table 
reporting the values of SNO-GluN2A normalized on SNO-β-Actin obtained for each experiment performed in Prnp+/+ and 
Prnp0/0 samples and the p value calculated with the paired T test formula.  
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Prnp0/0 0.002 0.054 0.088 0.084 0.232 0.173 
  80 
DISCUSSION 
 
Among different neurodegenerative diseases, altered concentration in metal ions, protein aggregation, 
RNS and ROS have been identified as common traits (Bush, 2000). However, the precise mechanism 
that gives rise to these pathologies has not been defined. Table 1 shows the neurodegeneration 
characteristics of aggregating proteins, like Aβ, Sod1 and PrP, that share a crucial property of being 
metal-binding proteins. The focus of this study has been PrPC.  This endogenously encoded protein has 
a wide range of interesting characteristics. The protein is very well conserved in different mammalian 
species, although its ablation in several knockout mouse models seem to compromise neither vitality 
nor fertility and does not produce gross phenotypic disturbances (Bueler et al., 1992; Manson et al., 
1994). The protein is expressed in different tissues, showing the highest level in the CNS synapses, in 
particular in the hippocampus (Benvegnu et al., 2010; Fournier et al., 1998; Horiuchi et al., 1995; 
Linden et al., 2008). The polypeptide is GPI-anchored to plasma membrane and targeted to lipid rafts, 
like most of the GPI-anchored proteins (Naslavsky et al., 1997; Simons and Ikonen, 1997). The PrPC is 
able to bind divalent cations with higher affinity for Cu and lower for Mn and Zn (Jackson et al., 2001; 
Singh et al., 2010; Stockel et al., 1998), it supports the reduction of Cu(II) to Cu(I) and, upon this 
reaction, it is internalized, so that it can pass Cu(I) to Cu transporters and chaperons (Liu et al., 2011). 
Different processes have been found to be affected by PrPC ablation: synaptic formation and 
functionality, myelin sheets formation and maintenance, metal ions absorption and distribution, 
oxidative stress control, among others (Aguzzi et al., 2008; Bremer et al., 2010). However, its cellular 
function has not been established. To define the pathological mechanism leading to prion 
neurodegeneration, it is very important to understand PrPC mechanism of action in physiological 
conditions. In fact, the loss-of-function of PrPC is likely implied in prion diseases, since aggregates 
spreading removes functional PrPC molecules.  
The first part of the project has been dedicated to understanding the influence that PrPC exerts on 
metal ions metabolism through the characterization of alterations occurring when PrPC is absent. Metal 
ions are crucial elements for cellular processes, since they are involved as co-factors in many protein 
functions, but at the same they are potentially dangerous for the cell itself because they can give rise to 
Fenton reaction and oxidative/nitrosative stress. For these reasons, they are subjected to a strictly 
regulated homeostasis and metabolism in each district, but in particular in the brain. In fact, since brain 
activity has the highest metabolic rate of all organs and depends predominantly on oxidative 
metabolism for its energy, it has developed fine mechanisms to compartmentalize, distribute, uptake, 
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excrete and control the different ionic species it contains. Both in development and in aging, alterations 
in one of the mechanism listed above can easily provoke great neuronal damages, and maybe 
neurodegenerative disorders. Metal ions are a common denominator to all the cellular pathways in 
which PrPC seems to be actively involved, for example ionotropic receptor modulation and response to 
stressful conditions and excitotoxic insults.  
First, Cu, Zn, Fe and Mn total concentrations were measured in brains and hippocampi. Prnp0/0 mouse 
samples were compared to Prnp+/+ ones at different developmental stages: neonatal (P1), early postnatal 
(P7), synaptogenesis completion (P30), adulthood (P90), late adulthood (P180), aging (P365). Table 5 
summarises the results obtained concerning brain measurements, showed in detail in Figure 17. Zn and 
Fe brain total content seem to be less affected by PrP ablation. In fact, Prnp+/+ and Prnp0/0 show similar 
decreasing trend during the development. The only main difference occurs at P1, where Prnp0/0 mice 
reveal a striking lower content compared to Prnp+/+ brains. This observation suggests that PrPC role in 
Zn and Fe metabolism is predominant at this developmental stage and other mechanisms cannot 
compensate. Cu and Mn concentrations are more altered by PrP ablation. In Prnp+/+ brains, Cu 
concentration decreases from the early postnatal stages to the end of synaptogenesis, then it increases 
up to aging. In Prnp0/0, instead, Cu content is much lower in P1 samples, it is kept almost constant with 
slight variations up to P180, then it suddenly rises, although at not statistically significant levels due to 
biological variance of the samples. Mn concentration shows completely different trends in Prnp+/+and 
Prnp0/0. In normal conditions, Mn content decreases from the early postnatal stages to synaptogenesis 
completion, afterwards it is quite constant. In Prnp0/0 brains, Mn concentration has a similar general 
trend, but at P1 and P7 it is lower compared to Prnp+/+ and from P30 to the aging the values oscillate 
around the Prnp+/+ ones, likely because compensatory mechanisms continuously need to arrange and 
re-organize to balance PrPC absence.  
 
 
Table 5. Summary of brain metal content measurements results. (-): Prnp0/0 metal content is significantly lower than 
Prnp+/+; (+): Prnp0/0 metal content is significantly higher than Prnp+/+; (#): no statistically significant difference. 
 
Table 6 summarizes the results obtained from hippocampal samples and showed in detail in Figure 18. 
PrP ablation highly affects Cu and Fe concentrations, which are lower at both P7 and P180, critical 
P1 P7 P30 P90 P180 P365
Cu - - # ++ # - #
Mn # - - ++ # - #
Zn - - # ++ # - #
Fe - - + + # # #
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stages that seem to be particularly susceptible to PrPC function, while in adulthood their content is 
brought to normal levels by compensatory mechanism. In both Prnp+/+ and Prnp0/0, Zn and Mn 
contents have not a well-defined trend in the development. However, they both are decreased by PrP 
absence at P180 that is confirmed to be a stage in which PrPC function is particularly predominant over 
the other mechanisms. 
 
 
Table 6. Summary of hippocampus metal content measurements results. (-): Prnp0/0 metal content is significantly lower than 
Prnp+/+; (+): Prnp0/0 metal content is significantly higher than Prnp+/+; (#): no statistically significant difference. 
 
For each analyzed transition metal, the major proteins responsible for its metabolism regulation were 
characterized according to their expression levels in the development and the results of the comparison 
have been schematised in Table 7. 
Ceruloplasmin (Cp) can be expressed in two forms, a secreted one and a GPI-anchored one, by the 
liver, which provides for the higher portion, but also by the brain, lung, spleen and testis (Aldred et al., 
1987; Fleming and Gitlin, 1990; Klomp and Gitlin, 1996). The GPI-anchored form is present on 
astrocytes and leptomeningeal cells (Mittal et al., 2003; Patel and David, 1997). Cp is a α2-globulin that 
carries 95% of serum copper (Harris and Gitlin, 1996). It functions as a Cu-dependent ferroxidase and 
in its GPI-anchored form provides for Fe mobilization promoting, for example, Fe efflux from 
astrocytes (Hellman et al., 2002; Jeong and David, 2003). In fact, in case of Cp hypofunctionality, Fe 
accumulates inside astrocytes. The ferroxidase activity confers Cp an antioxidant function (Goldstein et 
al., 1979a, b). GPI-anchored Cp is responsible for Fe oxidation that is necessary for loading apo-Tf 
with Fe3+, this allows to prevent Fenton reaction as well as to transport Fe to neurons (Patel and David, 
1997). Cp expression is not dependent upon Cu availability, as checked by apo-Cp presence in the 
serum of patients affected by Wilson’s disease, a pathology in which copper is accumulated but not 
available (Vassiliev et al., 2005).  
The six-transmembrane epithelial antigen of the prostate 3 (Steap3) belongs to the family of Steap 
protein. Steap3 is expressed in a wide range of tissues as a transmembrane metalloreductase. It seems to 
P1 P7 P30 P90 P180 P365
Cu # - - # + - - #
Fe # - - # + - #
Zn - # # ++ - - - #
Mn # # # # - - #
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be the most important metalloreductase of the Steap family, playing crucial role in both Fe and Cu 
uptake (Knutson, 2007). In particular, its function is linked to the Tf/TfR cycle.  
 The Cu,Zn-Superoxide Dismutase (Sod1) catalyzes the disproportionation of superoxide anion to 
oxygen and hydrogen peroxide (McCord and Fridovich, 1969). Each unit contains a Cu ion and a Zn 
ion, the latter is not essential for the dismutation reaction, but stabilyzes the protein (Furukawa et al., 
2004). To function, Sod1 requires to be loaded with metal ions by Ccs, since this reaction cannot be 
achieved spontaneously in the cell (Culotta et al., 1997). If the posttranslational activation of Sod1, 
including Cu and Zn, binding is defective, Sod1 can even be toxic producing aggregates, like in ALS 
(Banci et al., 2010).  
The copper chaperone for superoxide dismutase (Ccs) contains a Cu binding domain that serves to 
load Sod1 with the Cu ion it requires for functioning. Moreover, Ccs contains also a Zn binding site 
that is not essential but contributes to protein stabilization, as for Sod1. Actually, it has been proposed 
that Ccs can function also as a Zn chaperone, but this mechanism has not been proved, yet (Banci et 
al., 2010). Ccs seems to be the preferred route of Sod1 activation, but it is not the only one.  
Copper transporter 1 (Ctr1) is a plasma membrane protein with a homotrimeric pore essential for Cu(I) 
uptake in all cells. Cu(II) is thought to be reduced to Cu(I) by various Steap proteins on the cell surface 
before uptake by Ctr1. Cu uptake by Ctr1 is (i) energy dependent, (ii) stimulated by acidic extracellular 
pH and high K+ concentrations, and (iii) time dependent and saturable (Gaggelli et al., 2006). Evidence 
suggests that Ctr1 may be posttranslationally regulated by intracellular Cu availability. Elevated 
intracellular Cu levels stimulate the rapid endocytosis and degradation of Ctr1 from the cell membrane, 
resulting in attenuated Cu uptake and thus preventing the cellular overload (Gaggelli et al., 2006). Ctr1 
has been shown to be present in the BBB, choroid plexus, as well as the brain parenchyma (Choi and 
Zheng, 2009; Kuo et al., 2006). Recent data show that chronic exposure to Mn in rats leads to the 
subcellular relocation of Ctr1, rendering a highly concentrated Ctr1 in the apical brush boarder of the 
choroidal epithelia facing the cerebrospinal fluid (CSF). The exact implication of this intracellular 
trafficking of Ctr1 in response to Mn exposure remains to be determined. However, it seems that in the 
brain Ctr1 uptake function is predominantly from the CSF and minor from the blood (Kuo et al., 
2006). 
Two intracellular ATPases, Atp7a and Atp7b, are involved in ATP-dependent transport of Cu across 
the brain barriers. Genes that encode for these proteins are mutated in the inherited disorders of Cu 
metabolism, Menkes and Wilson diseases. Menkes disease is a fatal X-linked Cu deficiency syndrome 
that arises from defective Atp7a-driven transport of Cu from the intestine into the portal circulation, 
and aberrant distribution of Cu in the body. Wilson disease is an autosomal recessive Cu toxicity 
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disorder that results from disruption of Atp7b-mediated Cu export from liver hepatocytes into bile, and 
consequently liver and brain Cu accumulation. Atp7a is expressed in the majority of tissues except for 
the liver. Atp7b expression is more restricted, with highest expression in the liver. Both proteins 
possess eight transmembrane domains and contain six Met–X–Cys–X–X–Cys Cu binding motifs at the 
N-terminus (Lutsenko et al., 2007). Both are expressed in the brain capillary endothelial cells, in the 
choroidal epithelial cells (Choi and Zheng, 2009; Nishihara et al., 1998), in the BBB and in blood CSF 
barrier. Both ATPases are localized to the TGN, where they are utilized in the Cu secretory pathway, 
delivering Cu for incorporation into cuproenzymes. When intracellular Cu levels rise, both Atp7a and 
Atp7b are translocate from the TGN and carry Cu to the cellular membrane for efflux from the cell. 
This function is not only necessary for Cu trans-barrier transport, but also important for preventing 
excess Cu accumulation inside the barrier cells. The same mechanism, mediated by Atp7a, is activated 
in the postsynaptic terminal upon activation of NMDAR leading to Cu release in the synaptic cleft 
(Schlief et al., 2006). The localization, regulation and directional trafficking of both these Cu exporters 
at the brain barriers, and their respective roles in CNS Cu homeostasis, remain largely unknown. 
Transferrin (Tf) binds Fe3+ in the circulation and brings it to the different site of use. Fe release from 
holo-Tf occurs after binding to its receptor, internalization in vesicles, acidification of the vesicles and 
reduction Fe3+ to Fe2+ by Steap3. The protein is essentially synthesized in hepatocytes, but also in 
Sertoli cells, in the epithelial cells of the choroid plexus in rodents and in oligodendrocytes (Zakin et al., 
2002). Tf expression is regulated also by the hypoxia-inducible factor-1(HIF-1)/hereditary 
hemochromatosis gene product interaction (Rolfs et al., 1997).  Moreover, diferric Tf levels have been 
suggested to modulate the expression of other proteins involved in Fe metabolism (Anderson et al., 
2007).  
Transferrin receptor 1 (TfR1) is a disulfide bonded, homodimeric receptor that is found on the surface 
of most body cells. TfR1 deficiency leads to embryonic lethality in mice, an indication of its 
physiological essentiality (Levy et al., 1999). The receptor binds diferric Tf with 10-fold higher affinity 
than monoferric Tf at physiological pH, and 2,000-fold higher affinity than apo-Tf. Since Tf binds Fe 
with such a high affinity, it is likely that Fe release also requires reduction, and takes advantage of a 
conformational change in Tf that accompanies its binding to TfR1 (Bali et al., 1991; Tsunoo and 
Sussman, 1983; Watkins et al., 1992). TfR1 expression is modulated in response to Fe abundance as 
described in Figure 47 (Zecca et al., 2004).  
Ferroportin 1 (Fpn1) is a plasma membrane Fe export protein. Fpn is expressed at particularly high 
levels on the surface of cells with a high capacity to export iron, such as macrophages and enterocytes, 
but it appears to be present on almost all cells. Mutations in the Fpn gene create severe alterations in Fe 
metabolism: tissue Fe overloading occurs, but a systemic anemia is induced as reduced Fe export into 
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the plasma means reduced Fe supply to erythroid progenitors. Fpn deletion is not compatible with 
postnatal life. Its mechanism is not properly characterized, but it is known that it binds Fe2+. GPI-
anchored Cp is devoted to the oxidation of Fe2+ exported by Fpn to load Fe3+ on apo-Tf. Fpn 
transcription regulation occurs with the same mechanism described for ferritin in Figure 47, so in low 
Fe conditions its expression is diminished (Anderson et al., 2007).  
The storage protein ferritin (Ft) is a 24-subunit protein shell enclosing a hollow interior, in which large 
Fe amounts are stored in a soluble, non-toxic, but bioavailable form. Mammalian Ft contains variable 
amounts of two types of polypeptide chain, heavy (H) and light (L), which have different functions. 
FtH chains have a ferroxidase centre, which can catalyse the rapid oxidation from Fe2+ to Fe3+, whereas 
FtL chains are thought to function in the nucleation of the mineral core within the protein shell. L-rich 
Ft is associated to Fe storage, while H-rich Ft is associated to stress response (Zecca et al., 2004). Ft 
expression is regulated according to Fe availability in the opposing way with respect to TfR1 expression 
(Figure 47). 
 
Figure 47. Production of the transferrin receptor (TfR) and ferritin is regulated at the level of mRNA by iron 
regulatory proteins (IRPs), which bind to iron response elements (IREs) on the 3'- and 5'- untranslated regions 
of their respective mRNAs. (a) In iron deficiency, the IRPs bind to the IREs, protecting the TfR mRNA from 
nuclease digestion and preventing the synthesis of ferritin. (b) When iron is abundant, the modified IRP no 
longer binds to the IREs — in IRP1 the IRE binding site is blocked by a 4Fe–4S cluster (green rectangle), 
whereas in IRP2 the protein is targeted for destruction in the proteasome — allowing TfR mRNA to be 
destroyed and allowing the expression of ferritin (Zecca et al., 2004). 
Metallothioneins (Mt) are very small proteins containing highly conserved cystene residues that allow 
them to bind seven divalent metal ions (e.g. Zn) and up to twelve monovalent Cu ions (Bogumil et al., 
1998; Faller et al., 1999). Mt expression is regulated in response to a range of stimuli, including metals, 
hormones, cytokines, oxidative agents, inflammation and stress. This complex regulation is mediated by 
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metal responsive elements, glucocorticoid responsive element, antioxidant response elements. Mt 
expression occurs in both CNS and PNS, particularly in reactive astrocytes. In neurons Mt promote 
neuronal survival and regeneration upon injury (Chung et al., 2007; Chung and West, 2004). There are a 
number of ways that MtI/II potentially enhance the ability of astrocytes to promote neuronal 
regeneration, for example by Zn binding, with roles in metal homeostasis or free radicals scavenging 
(Hidalgo et al., 2001; West et al., 2004). Mt likely acts within astrocytes, maybe to handle toxic 
intermediates. Moreover MtI/II and MtIII expressions are differently regulated in response to brain 
insults (West et al., 2008). Mt proteins also represent a source of Zn ions. In fact, they can rapidly 
release it by nitrosylation or oxidation of the thiol ligands (Maret, 1994, 2000). MtIII Zn release in the 
CA1 region of the hippocampus contributes to cell injury (Lee et al., 2003), but the opposite effect is 
observed in the CA3 where presynaptic release of Zn is neuroprotective (Takeda et al., 1999).  
Zinc transporter proteins (ZnT) are responsible for Zn export and sequestration. Eight ZnT types have 
been characterized (Lovell, 2009). ZnT3 was analyzed in this project because it is the one responsible 
for Zn sequestration into vesicles in the hippocampal dentate granule cells, pyramidal and intraneurons 
(Palmiter et al., 1996). These vesicles contain Zn that is released with glutamate and that modulates 
NMDAR activity. 
Specifically concerning Mn metabolism, just Mn-superoxide dismutase (Sod2) was analyzed in this 
study. It has been shown by Fridovich and colleagues that Sod2 is a ubiquitous metalloenzyme, 
essential for the survival of all aerobic organisms from bacteria to humans (Fridovich, 1974, 1995). Like 
Sod1, Sod2 catalyses the dismutation of superoxide anion radical to hydrogen peroxide and molecular 
oxygen. Sod2 is encoded by a nuclear gene and is transported across two mitochondrial membranes to 
the matrix. In mice, the lack of Sod2, or the complete elimination of its expression, causes dilated 
cardiomyopathy and neurodegeneration leading to early postnatal death. Sod2 is able to modulate some 
gene transcription through the HIF-1: at lower levels of Sod2, HIF-1α levels are elevated, but are 
suppressed at higher Sod2 levels. The biphasic influence of Sod2 on activation of HIF-1α is H2O2-
dependent, as removal of peroxides reverses the effect (Miriyala et al., 2012).  
Table 7 summarises all the obtained results concerning both metal ion content and protein expression 
measurements. As described in the Introduction, essential metals metabolisms cannot be considered 
individually: they are strictly interconnected and an alteration occurring in one of them is likely to alter 
all the others. As an example, if Cu content is altered or if it is miscompartimentalized, Fe uptake and 
distribution will be impaired, since Fe metabolism is regulated by Cu-dependent oxidases and 
reductases.  
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Table 7. Summary of Cu metabolism proteins expression comparison between Prnp+/+ and Prnp0/0.  The results are 
reported as Prnp0/0 Vs Prnp+/+. (-): significantly lower; (+): significantly higher; (#): no statistically significant difference. 
 
To characterize essential metal metabolism in PrP null condition, for each metal ion both membrane 
transporters and cytosolic binding proteins expression has been investigated. Observing all the obtained 
data, it emerges that transporters and metal uptake proteins are generally upregulated in PrP absence, 
while exporters and storage proteins are downregulated. These overall protein expression re-
arrangement is in agreement with metal ion levels measured in Prnp0/0 brains and hippocampi, which 
resulted to be decreased compared to wild-type in particular in the early postnatal stages. In fact, Fe, 
and also Mn, uptake proteins (TfR1 and Tf) are generally increased in Prnp0/0 brains and hippocampi, as 
well as Fe exporter (Fpn1) and storage proteins (FtH and FtL) are broadly decreased, in agreement with 
the results already published (Singh et al., 2009b). However, from late adulthood to aging, FtH 
expression is increased and this is likely to represent a response to a stressful condition (Zecca et al., 
P1 P7 P30 P90 P180 P365 P1 P7 P30 P90 P180 P365
Cu - - # ++ # - # Cu # - - # + - - - #
Cp # # + + + + Cp # - - - - #
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Sod1 # # # # # # Sod1 # # # # # #
Ccs - # # # # - Ccs - # - - - #
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Atp7b + # # # # # Atp7b + # # # # #
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Fe - - - + # # # Fe # - # + - #
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2004). This does not agree with what previously published (Singh et al., 2009b), since their results show 
lower FtH levels in 6 months-old mouse brains. The same modulation can be observed concerning Cu 
binding proteins, though mainly in the hippocampus. In fact, Cu transporters (Ctr1 and Atp7a) are 
generally upregulated, while cytosolic proteins (Sod1 and Ccs) are either not affected or downregulated.  
A protein showing strong expression alterations in PrP null samples is Cp, whose levels are increased in 
the brain and decreased in the hippocapus of Prnp0/0 mice. Since the ratio between blood and brain 
volumes is very low, it is likely that the Cp revealed in the measurements is mainly synthetised by 
neurons and astrocytes. No Cp transcriptional regulation in response to Cu concentration has been 
described in literature and the same was confirmed by real time PCR on hippocampal mRNA extracts 
results reported in Figure 33. However, its degradation rate might be affected by Cu concentration, 
delivery and availability, thus resulting in the different Cp levels detected in brain and hippocampus. 
Considering the observed Fe metabolic situation in PrP null brains, how can this global reorganization 
be justified in lack of a Cu-binding protein, like PrPC is? In the finely tuned and very well orchestrated 
metal ion homeostasis mechanism, PrPC functions as a player whose role, even if not strictly essential, 
needs to be compensated, in case of absence, through a deep reorganization of the other players, to 
reach the final goal which corresponds to homeostasis. This is confirmed also on Mn metabolism. In 
fact, as Fe and Zn, Mn levels are lowered in Prnp0/0 brains in the early postnatal stages, while they are 
increased at P30. Mn shares with Fe the same transporters, in particular TfR1 and Fpn1. So, the 
rearranged TfR1 and Fpn1 expressions, beside rising Fe levels, likely increase Mn content. Moreover, 
since Tf and Cp are increased, a higher portion of Mn should be bound to Tf, since, as previously 
described, Mn oxidation operated by Cp promotes its binding to Tf, slowering its clearance. So, as for 
Cu and Fe, after P30 Mn content alterations are diminished and, though oscillation, mechanisms 
continue to re-organize maintaining its homeostasis as close to wild-type conditions as possible. 
Though a slight increase at P90, Sod2 expression is not altered. Since it was reported that in PrP 
absence Sod2 activity is triggered to face and prevent ROS formation (Brown and Besinger, 1998; 
Kralovicova et al., 2009), it is possible that the increased expression in adulthood is due to an increased 
requirement of Sod2 activity in particular in this stage. However, if really Sod2 activity is increased, it 
means that Mn homeostasis and metabolism are efficiently balanced in PrP null conditions, so Mn ions 
are effectively delivered to Sod2, otherwise it would not be able to catalyse the dismutase reaction. The 
content of Zn ions is lower in P1 PrP null brains compared to wild-type ones, it increases at P30 and it 
is again lowered at P180. So, it seems that Zn content follows more or less the same trend of Cu, Fe 
and Mn. It may be that transporters that were not analyzed in this study are subjected to expression 
modulations in Prnp0/0 brains. Interestingly, Mt expression is increase from P180 to P365: this may 
represent a response to a stressful condition, as it was supposed for FtH.  
  89 
In the hippocampus, Cu content is highly affected by PrP absence at P7 and at P180, stages showing a 
great lowering of its concentration. Differently from brain samples, alterations in Cu transporters 
expressions occur. At P7, both Ctr1 and Atp7a expressions are increased: this modulation may be 
caused by low Cu content. Impairments in Cu metabolism may also induce Cp decreased levels: if Cu is 
not properly stored or delivered in PrP null conditions, it cannot be load on Cp, resulting in lower Cp 
levels maybe due to apo-Cp higher degradation rate. In fact, as real time PCR results show in Figure 33, 
lower Cp levels are not consequent to decreased transcription.  
The hypothesis of a condition of Cu miscompartmentalization, affecting the entire organism, thus, 
leading to impaired Cu loading on Cp, was assessed and confirmed by measuring Cp activity in sera. 
Circulating Cp is produced and Cu-loaded in the liver, and it represents the major Cu carrier in the 
entire body. So, its Cu-dependent ferroxidase activity is a good marker of Cu availability and 
homeostasis. Different ages were tested, P15, P30, P90, P180 and P365, revealing that Cp activity 
increases with age. However, this is true for Prnp+/+ mice, but not for Prnp0/0 ones. In fact, Prnp0/0 Cp 
activity is lower compared to wild-type one, and the difference increases in the aging. This means that, 
at the systemic level, Cu homeostasis is impaired in such a way that its availability for Cp loading 
cannot be increased after a certain level, resulting in decreased ferroxidase activity. The peculiarity of 
P30 metal ion condition is confirmed also in this experiment where P30 results to be the only stage 
with comparable levels of Cp activity in wild-type and PrP null mice: given the importance of 
synaptogenesys completion, it is likely that many compensatory effect occur in this stage to maintain 
metal ion homeostasis and metal-dependent enzymes functionality. It would be interesting to measure 
Fe plasma levels at P365. In fact, it has been published that PrP null 6 months-old mice show mild 
anemia (Singh et al., 2009b). This, according to the results here shown, can be consequent to lower Cp 
activity that triggers lower plasma Fe levels, inducing anemia. If this is the case, anemia should increase 
in aging, with Cp activity becoming lower and lower. According to what has been observed in Wilson’s 
disease and aceruloplasminemia conditions, diminished Cp functionality should cause brain Fe 
accumulation (Qian and Wang, 1998). In the results previously showed, this was not strikingly detected 
because in the aging brain Fe levels increases in Prnp0/0 mice, but the difference with Prnp+/+ samples is 
not significant - maybe the gap can get more pronounced in further aging stages -, while in the aging 
hippocampus, Fe concentration increases in both Prnp+/+ and Prnp0/0 mice in the same manner. Going 
back to the other analysed proteins, also in the hippocampus Sod1 expression is not impaired, but it is 
likely less functional (Brown and Besinger, 1998; Kralovicova et al., 2009), also because lower Ccs levels 
were detected at different developmental stage, maybe due to impairments in Cu delivery pathways. 
Though the existence of others mechanisms that deliver Cu to Sod1, this is the prevalent one, so its 
decrease must contribute to the diminished Sod1 functionality. Concerning Fe homeostasis, the same 
phenotype observed in the brain, typical of Fe deficiency conditions, was confirmed in the 
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hippocampus of PrP null mice. In fact, Fe uptake proteins Tf and TfR1 showed increased expression 
levels, though a lower Tf level at P7 was detected concomitant with the major drop in Fe 
concentration. Moreover, FtH was decreased up to adulthood, confirming the transcriptional regulation 
model in Figure 47, but going towards aging, like in the brain, FtH is increased, confirming that a stress 
condition is occurring at higher levels compared to wild-type hippocampi. Moreover, since Ft is 
expressed in oligodendrocytes, being the major Fe source, the occurring stressful conditions may be 
related to a demyelinating phenomenon (Todorich et al., 2011). Differently from the brain, Fpn1 
expression was not affected, indicating either that Fe metabolic impairment in PrP null hippocampi is 
less pronounced compared to the entire brain or that it cannot be rescued decreasing the export. 
Another difference, suggesting a different situation compared to the brain, is the lower FtL expression 
detected in the hippocampus. These findings suggest that Fe homeostasis compensation occurs with 
different mechanism in the hippocampus with respect to the total brain. It may be that these 
differences between PrP null brains and hippocampi regulation of Fe metabolism are linked to the 
lower Cp levels observed in the hippocampus. The same considerations done about Mn homeostasis in 
the brain can be transposed to the hippocampus. Largely sharing the same transporters and the same 
Tf-loading upon Cp oxidation, Mn concentration is affected by PrP ablation in a way similar to Fe one. 
However, at P180 its content is lowered in a more pronounced manner compared to Fe. This suggests 
that, in Cp deficiency conditions, Mn oxidation is more affected than Fe one. Concerning Zn 
metabolism, though its concentrations was affected by PrP ablation, in particular at P1 and P180, the 
latter one showing an astonishing reduced content, the proteins analysed did not reveal any difference 
compared to wild-type hippocampal samples, indicating that, if some protein expression alteration 
occurs, it involves others Zn metabolic pathway players.   
In general, known that many transporters and enzymes function for different cations, metal ions 
occupancy of binding sites is dependent on both the relative abundance of the competitor ions and the 
protein binding site affinity for each ion. So, if one metal exceeds, the binding, as well as the uptake, the 
distribution and the availability, of the others ions will be diminished. This corresponds, for example, to 
the situation theoretically occurring in case of Fe or Mn excess: if Fe overload occurs, Mn content will 
be likely decreased, and vice versa, since they share transporters, like TfR1 and Dmt1, but also 
oxidation by Cp is required for both ionic species homeostasis. On the contrary, in Fe deficiency, Mn 
uptake is likely to be increased, and vice versa.  However, in case of Cu deficiency, consequences on 
other metals are completely different. In fact, instead of being a competitor for transporter sites, Cu is 
essential for other Mn and Fe uptake since it is the cofactor of oxidases (Cp) and reductases (Steap) 
responsible for Mn and Fe loading on, passage among and release from transporters. According to 
what emerges from the results here presented, this is likely the situation induced by PrP absence. PrP 
binds metal ions, like Cu, Zn, Mn and also Fe. However, its affinity for Cu is definitely higher, 
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especially in biological conditions (Chattopadhyay et al., 2005; Liu et al., 2011). It is likely that the PrP-
bound Cu represent a prominent fraction of the total Cu content. As a consequence, in PrP absence, at 
the absorption sites, Cu can occupy proteins not primarily devoted to its metabolism. This can have 
different consequences: first, alteration in Cu absorption itself; second, interferences with other cations 
absorption, impairing it; third, altered compartmentalization of Cu ions, which will not be as available 
as they are in normal conditions for enzymes loading and cofactor functioning. Both these 
consequences lead to diminished cations absorption and distribution. However, metal ions pathways 
can be so finely regulated, by transcriptional, translational, posttranslational and translocation regulation 
of soluble and membrane transporters, that a compensation occurs, even though just partial. This is the 
reason why, in Prnp0/0 mice, even if not dramatically, metal ions content is altered: this is likely to be the 
common denominator to the phenotypes observed in Prnp0/0 mouse CNS, for example demyelination, 
which has been reported in PrP null conditions (Bremer et al., 2010) and which is caused by Cu and Fe 
impaired metabolism (Benetti et al., 2010; Skripuletz et al., 2008), and also impaired synaptic plasticity 
and alteration in oxidative stress response.  
In Prnp0/0 mice, phenotypes related to synaptic functionality impairments have been reported (Criado 
et al., 2005; Maglio et al., 2004; Mallucci et al., 2002). In particular, excitatory glutamatergic synapses 
appear to be the major site in which PrPC plays an important role. In fact, it has been reported in 
literature that NMDAR currents are altered upon PrP ablation: NMDARs show slowed deactivation 
kinetics (Khosravani et al., 2008a), as well as a large non-desensitizing steady-state (You et al., 2012). 
This increased steady-state length, of course, damages neurons: in fact, Prnp0/0 neurons are more 
susceptible to excitotoxic insult. The alteration of NMDAR activity observed in PrPC absence can be 
induced in wild-type conditions adding a Cu chelator, on the contrary, PrPC null neurons can approach 
the wild-type current upon Cu addition (You et al., 2012). How PrPC-bound Cu can inhibit NMDAR 
was not clarified, neither it has been described in literature the general mechanism through which Cu 
inhibits NMDARs (Vlachova et al., 1996). However, it is known that NMDARs can be modulated by 
extracellular cysteines S-nitrosylation and that this reaction is always inhibitory (Choi and Lipton, 2000; 
Choi et al., 2000; Lipton et al., 2002). As described in Box1 in the Introduction, S-nitrosylation reaction 
requires one-electron oxidation from the free radical NO to NO+ that is mediated by a transition metal, 
in particular Cu. Since PrPC can bind up to five Cu ions and supports its reduction, it can represent the 
link between free synaptic Cu and NO+ production. In fact, Cu is released by TGN vesicles after 
glutamatergic stimulation of NMDAR and Ca2+ intracellular influx, as well as nNOS is activated to 
produce NO. Therefore, PrPC-bound Cu could contribute to NMDAR inhibition promoting S-
nitrosylation of extracellular cysteines, as it does for glypican-1 (Mani et al., 2003). To validate this 
hypothesis, first the increased susceptibility to NMDA stimulation in our murine model was assessed 
by mean of OHCs: a very potent system that allows to operate in vitro maintaining the organ 
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cytoarchitecture. Treating OHCs with 5µM NMDA for three hours induced very low neuronal cell 
death levels in Prnp+/+ hippocampus, allowing an easier comparison with Prnp0/0 cultures. The results 
obtained confirmed that Prnp0/0 hippocampus is more susceptible to excitotoxic treatment. As shown in 
Figures 37 and 38, Prnp+/+ neurons were affected by the treatment in a significant manner almost only 
in the CA1 region, which is known to be the first responding to insults (Bunk et al., 2010; Kristensen et 
al., 2001), while in the CA3 and in the DG neuronal cell death levels were very low. On the contrary, 
Prnp0/0 hippocampus, beside showing a higher death levels in the CA1 compared to Prnp+/+, revealed 
significant pyknotic nuclei percentages also in the CA3 and in the DG, confirming what previously 
published with propidium iodide staining on OHCs (Rangel et al., 2007). Moreover, neuronal cell death 
was accompanied by loss of NeuN staining, which appeared fading around pyknotic nuclei. By 
expression analysis of the proteins playing major roles in excitotoxicity, it was observed that no 
alterations occur in nNOS expression, meaning that RNS should not be increased in Prnp0/0 
hippocampus because of an increased enzyme expression level. The analysis of Casp3 expression levels 
revealed that it is expressed at lower levels at P30 and at higher levels at P365. The decrease at P30 may 
be one cause of the impairments in learning and memory processes observed in PrP ablated mice 
(Criado et al., 2005). In fact, during the CNS developlment, Casp3, has non-apoptotic functions in 
neurons and, if mutated, provokes synaptic alterations including learning and memory deficits 
(D'Amelio et al., 2010). Casp3 higher expression at P365 may be due to increased stress condition 
occurring in aging Prnp0/0 hippocampus: in fact, it has been shown that Casp3 mRNA and protein levels 
are increased after apoptosis-promoting insults, like ischemia (Chen et al., 1998). However, NMDAR 
subunits expression was highly increased in PrP null conditions: GluN2A, GluN2B, as well as the 
ubiquitous GluN1 showed higher expression levels, confirming what previously published in literature 
(Maglio et al., 2004). The reason why this alteration occurs cannot be explained in light of the data 
collected in this work. An increased expression in NMDARs, whether functional, may lead to impaired 
Ca2+ homeostasis. To address this point, Ca2+ transporters were analysed according to their expression. 
Alterations in Ncx1, Pmca and Serca2 were detected both in the brain and in the hippocampus of 
Prnp0/0 mice. In general, it came out that in the early postnatal stages Prnp0/0 mice upregulate the 
expression of transporters with low affinity, but high capacity (Ncx1), likely to move huge amount of 
Ca2+. In adulthood and aging, on the contrary, the expression of pumps with high affinity, but low 
capacity (Pmca and Serca2) was enhanced, indicating that a finer regulation is required, maybe to sense 
small Ca2+ concentration oscillations. To check whether these alterations were aimed to maintain Ca2+ 
homeostasis, or whether, on the contrary, these modifications induced impairments in the homeostasis, 
Ca2+ total content was measured in both brain and hippocampus at the different developmental stages. 
Results showed that Ca2+ is almost not affected by PrP ablation, suggesting that modulation of Ca2+ 
transporters likely occurs to solve a situation in which Ca2+ homeostasis would be impaired. Taken 
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together these results explain neither why Prnp0/0 hippocampus is more susceptible to excitotoxicity nor 
how PrPC-bound Cu ions modulate NMDAR functionality. The measurements of S-nitrosylation levels 
of GluN1 and GluN2A subunits provided the answer. In fact, in Prnp0/0 hippocampus both the 
subunits showed lower S-nitrosylation levels compared to Prnp+/+ samples. This result explains why 
NMDAR currents are altered by PrP ablation, as well as why PrP null mice are more susceptible to 
excitotoxic insults. The model in Figure 48, confirmed by these results, describes the neurochemical 
mechanism through which PrPC exerts its neuroprotective function: upon Cu binding in the synaptic 
cleft, PrPC bring the electron acceptor that supports the inhibitory S-nitrosylation of NMDARs.  
 
 
Figure 48. Mechanism of PrPC-medited inhibition of NMDA receptor.   
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CONCLUSIONS 
 
Define the physiological function of the proteins involved in neurodegenerative disorder is crucial  for  
understanding pathological mechanisms underlying these disorders. Concerning proteins that aggregate 
in neurodegenerating neurons, like PrP, their function may be lost upon oligomerization, and this could 
contribute to the disease progression. 
The work described in this thesis has been focused on PrPC physiological function in the context of 
CNS metal ions homeostasis and glutamatergic synapses regulation. What links these two apparently 
separated aspects is PrPC ability to bind metal ions. Copper is an essential metal with the highest 
binding affinity for PrPC and an interesting point is represented by PrPC ability to support its reduction. 
Results obtained studying PrP null mice indicate that the essential metals homeostasis is affected by 
PrP ablation mainly in the early postnatal stages. Starting from synaptogenesis completion, the set of 
pathways devoted to metals metabolism rearrange the expression, the activity and, likely, the 
localization of transporters and enzymes in order to re-establish a condition as much close to normal 
one as possible. PrPC absence corresponds to the lack of a protein that is so widely and highly 
expressed that likely binds a high percentage of copper ions. This induces copper dys-homeostasis, 
triggering two main consequences: (i) alteration in the binding rate of the others divalent cations, 
impairing their absorption, delivery and excretion; (ii) not proper copper delivery and 
compartmentalisation. Copper miscompartmentalisation can occur for two reasons: (i) the binding to 
other proteins will bring it to other cellular district; (ii) the delivery, occurring when PrPC-mediated 
reduction of Cu(II) to Cu(I) induce endocytosis and Cu(I) passes to other transporters, is completely 
missing. Even if in adulthood and aging the metal ions content is almost re-established, these set of 
results do not indicate where ions are localized, where they are stored and which proteins they are 
bound to.  As a consequence, loading on copper-dependent enzymes will be impaired: an example is 
ceruloplasmin, which shows decreased ferroxidase activity, consequently impairing Fe homeostasis. 
Being metal ions so important in the organism physiology, these set of alterations, even if not 
apparently so huge, triggers consequences, as the demyelination observed in aged mice. Concerning the 
exact PrPC role in metal ions homeostasis, the situation here presented suggests that PrPC is an 
important copper buffering protein and that PrPC-mediated copper uptake in the cell and delivery to 
intracellular transporters is necessary for the correct functioning of all essential metals homeostasis 
pathways.  
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Copper binding confers PrPC another important function that in this work has been clarified. Evidence 
reported in literature describe NMDAR activity and regulation impairments in PrP null conditions, as 
well as an increased susceptibility to excitotoxic stimuli, such as NMDA and kainate treatment. Both 
NMDARs current alteration and neuronal cell death upon insult were rescued by copper adding, or, on 
the contrary, were induced in wild-type hippocampus upon copper chelator adding, suggesting that 
PrPC-mediated modulation of NMDARs is mediated by copper. In this work, a more detailed 
characterization of hippocampal susceptibility to NMDA treatment was described using OHCs as a 
system and evaluating neuronal cell death by pyknotic nuclei counting and neuronal marker staining, 
instead of primary hippocampal cultures or propidium iodide staining. The results obtained show that, 
while in wild-type sample low NMDA exposure (5µM for three hours) can induce significant neuronal 
cell death just in the CA1 region, in PrP absence high pyknosis levels are triggered also in the CA3 and 
in the DG, beside having enhanced mortality in the CA1. Excitotoxicity major players expression levels 
were measured in PrP null hippocampi, revealing the more interesting differences in calcium 
transporters. In fact, the results show that, to properly maintain calcium homoestasis, PrP null mice 
require a specific up-regulation of the transporters: (i) high capacity but low affinity transporters (Ncx1) 
are over-expressed in the early postnatal stages, likely because massive movements of calcium are 
required in these stages; (ii) high affinity but low capacity calcium pumps (Pmca and Serca2) are up-
regulated from adulthood to aging, likely because a finest sensing of calcium concentration oscillations 
is required in these stages. Increased NMDAR subunits expression was also revealed in PrP null 
hippocampus; however, a higher expression cannot account for the slowed deactivation kinetics and 
the increased steady-states reported in literature. The mechanism here hypothesised and also confirmed 
claims that PrPC mediates NMDAR inhibition bringing the copper ion that functions as electron 
acceptor for the S-nitrosylation of GluN1 and GluN2A extracellular cysteines. In fact, in PrP null 
hippocampus lower levels of S-nitrosylated GluN1 and GluN2A were detected, meaning that PrPC 
promotes this inhibitory reaction that occurs at lower levels in its absence. This explains, also, at least 
one way of copper-mediated inhibition of NMDARs, since, even if this modulation has been described 
many years ago, no binding sites have been detected and no mechanisms have been described.  
These results highlight the importance of metal ions homeostasis in the CNS and in glutamatergic 
synapses, as well as the central role PrPC plays in maintaining the homeostasis and in bringing copper 
ions where they are required and in the oxidation state they are required in synapse. 
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Importance of the field: Despite many recent advances in prion research, the
molecular mechanisms by which prions cause neurodegeneration have not
been established. In fact, the complexity and the novelty characterizing this
class of disorders pose a huge challenge to drug discovery. Pharmacogenomics
has recently adopted high-throughput transcriptome analyses to predict
potential drug target candidates, with promising results in various fields
of medicine.
Areas covered in this review: The present work offers an overview of the
transcriptional alterations induced by prion infection in different biological
systems. Hereafter, therapeutic approaches are discussed in light of the
identified altered processes.
What the reader will gain: This review offers readers a detailed overview on
microarray analyses, taking into account their advantages and limitations.
Our work can help readers, from many research areas, to design a suitable
microarray experiment.
Take home message: So far, drugs acting on the pathways identified by
microarray analysis have not been found to be effective in prion diseases
therapy. An integration of gene expression profiling, proteomics and
physiology should be applied to pursue this aim.
Keywords: drug, gene expression, microarray, prion
Expert Opin. Drug Discov. (2010) 5(2):177-202
1. Introduction
Prion diseases or transmissible spongiform encephalopathies (TSEs) are a class of
fatal neurodegenerative disorders characterized by the spongy appearance of brain
tissue, synaptic degeneration, microglia and astrocytes activation and neuronal
loss [1]. They can be distinguished in sporadic, genetic and infectious disorders.
TSEs include: Creutzfeldt-Jakob disease (CJD), Gerstmann-Stra¨ussler-Scheinker
syndrome, fatal familial insomnia and kuru in humans, bovine spongiform
encephalopathy (BSE) in cattle, scrapie in sheep and goats and chronic wasting
disease in elk and deer [2]. Like other neurodegenerative pathologies, such as
Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis
and Huntington’s disease, prion diseases are commonly characterized by abnormal
protein aggregates and amyloid deposits. The hypothesis that an infectious
proteinaceous particle was responsible of TSE transmissibility was first proposed
in the early 1980s by Stanley B. Prusiner [1] and later widely confirmed and
accepted [3]. The agent responsible for the onset and propagation of TSE is a
pathogenic conformational isoform (PrPSc) of the cellular prion protein (PrPC) that
in humans is encoded by the gene PRNP. These two conformational isoforms can
10.1517/17460440903544449 © 2010 Informa UK Ltd ISSN 1746-0441 177
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be distinguished in view of their different biochemical
properties, such as proteases resistance and insolubility in
non-denaturing detergents [1,4,5].
The transmission of the disease is related to the autocat-
alytic ability of PrPSc to act as a template converting PrPC into
the pathogenic isoform [6,7]. Mutations in the PRNP gene
favor the misfolding of PrPC, increasing the propensity to the
disease onset [8]. Despite the many advances made in recent
years, neither the molecular mechanism by which prions
determine TSEs nor the physiological function/s of PrPC
have been established. Current studies propose prion protein
(PrP) involvement in several biological processes such as
neuritogenesis [9-13], apoptosis prevention [14-17], protection
against oxidative stress [18], cell adhesion [19,20], hormone regu-
lation [21-23], transcriptional regulation [24], myelinogenesis [25]
and copper endocytosis [26].
The complexity of this class of neurodegenerative diseases
as well as the novelty of their molecular mechanisms pose a
huge challenge to biology and drug discovery. Presently,
biomarkers for early diagnosis and effective therapeutic
treatments have not been identified. Global expression anal-
ysis platforms, such as oligonucleotide microarrays, offer
unique tools to deal with neurodegenerative disorders.
This technology has become robust for both the identifica-
tion of co-regulated and differentially expressed genes
(DEGs) and of novel drug targets [27-29]. Therefore, phar-
macogenomics has adopted high-throughput gene express-
ion analysis to predict a flood of potential drug candidates
and accelerate drug discovery and development.
Gene expression analysis in the field of prion biology
has been mostly used to compare the expression and regu-
lation of genes in healthy and diseased systems. In particular,
genome-wide analysis has been carried out to explain the
transcriptional changes induced by prion strains at different
disease stages. Comprehensive transcriptome profiles of the
early disease symptoms might reveal the optimal path for
drug discovery, from target to lead compound.
In this paper, we present a comprehensive review of the
results obtained investigating the transcriptional changes in
different prion-infected systems, and then relate these studies
to therapeutic applications.
2. Gene expression profiling using subtractive
hybridization approaches
First attempts to study the gene expression modulations
induced by scrapie infection with a large-scale approach
were performed by Duguid et al. [30-32]. The authors analyzed
transcriptome variations in scrapie strain 263K-infected ham-
ster brains, performing a subtractive hybridization of cDNA
libraries. Their results, confirmed by RNA blotting, evidenced
an expression increase of mRNAs encoding glial fibrillary
acidic protein (GFAP), metallothionein II (MTII), B-chain
of a-crystallin, sulfated glycoprotein 2 (SGP-2), transferrin,
b-2 microglobulin and two unknown non-coding sequences.
GFAP is an astrocyte-specific marker. Its deficiency causes
Alexander’s disease, characterized by progressive failure of
central myelination, ataxia, bulbar signs and spasticity and
a slowly progressive course [33-38]. Duguid and Trzepacz
revealed an upregulation of b-2 microglobulin and both
classes of MHC genes as well as the class II-associated
invariant chain [39]. MTII selectively binds zinc ions and
its regulation strongly depends on the availability of this
micro-element, suggesting a dysmetabolism of this metal
during prion propagation, as in the case of PD and
AD [40,41]. SGP-2 neurobiology encompasses the subjects of
cell death, synaptic remodeling and neuroendocrinology [42].
Its upregulation has been also described in AD [42]. Finally,
the role of transferrin in neurodegeneration has been
demonstrated in patients with macular degeneration [43,44].
Alterations of MTII and transferrin denote a dysmetabolism
of micro-elements in prion diseases. Moreover, transcripts
previously related to AD, such as SGP-2 and GFAP, highlight
possible common mechanisms in both diseases.
The same approach was also applied by Diedrich et al. to
analyze scrapie-infected mouse brain transcripts [45]. The main
mRNAvariations, confirmedby in situhybridization and immu-
nocytochemistry on both mouse and AD patient brains, were
associated with the upregulation of apolipoprotein E (apoE) and
cathepsin D (CD). ApoE and CD upregulation were primarily
localized in activated astrocytes. Again, these results confirm
neuropathological similarities between prion diseases and AD.
The cDNA library differential screen was performed on
scrapie-infected murine neuroblastoma cells [46]. Doh-ura
et al. identified and confirmed by northern blotting 11
DEGs. Among the annotated ones, chromogranin B, intra-
cisternal A-particle-related retroviral envelope gene, heat
shock protein (hsp) 70, ornithine decarboxylase antizyme
and ribosomal protein S2 were upregulated, while a-enolase,
eIF-4A and hsp90 were downregulated.
Article highlights.
. Pharmacogenomics has adopted gene expression analysis
to predict drug targets.
. In prion biology, gene expression analyses have been
performed to compare infected and healthy systems.
. Gene expression analyses using subtractive hybridization
approaches have been carried out on both in vitro and
in vivo systems.
. Though the main purpose of gene expression profiling in
the prion field is the identification of drug targets, no
effective remedies have been found against prion diseases
among clinically tested compounds.
. The action mechanisms of some drugs and their efficacy
have been correlated with the altered pathways
evidenced by microarray analyses.
. In order to select the best target for therapeutic
treatments, gene expression profiling must be associated
with functional proteomics and physiology.
This box summarises key points contained in the article.
Gene expression profiling to identify druggable targets in prion diseases
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More recently, a subtractive suppressive hybridization
(SSH) was carried out by Cosseddu et al. on mixed midbrain,
thalamus, cerebellum and temporal cortex RNAs from a
clinically scrapie-affected and healthy sheep brain [47]. The
first animal carried out the susceptible scrapie genotype
VRQ/VRQ, while the second one had the resistant genotype
ARR/ARR. The SSH procedure revealed the following
altered transcripts: three short interspersed elements or
satellite sheep DNA, the mitochondrial cytochrome c
oxidase subunit 1, the brain GTPase-activating protein chi-
merin 1, the phosphatase 2A catalytic subunit, leucine-rich
and fibronectine type III domain containing 5 and the Ser/
Thr calcium/calmodulin-dependent protein kinase II a
required for hippocampal long-term potentiation and
spatial learning.
3. Gene expression profiles on cell cultures
Several works have reported gene expression studies performed
on scrapie-infected neuronal cell cultures. Sample homoge-
neity and higher signal:noise ratio compared to the whole
brain allow the identification of tissue specific transcriptional
changes. Baker and Manuelidis performed a microarray study
on microglia cells isolated from CJD-infected mice brains [48].
The CJD-specificity of DEGs was checked through compar-
ison against lipopolysaccharide-, IFN-g or protease-resistant
PrP-treated microglia cells. These results highlighted the
following affected pathways: inflammation, IFN and comple-
ment pathways, intercellular communication, chemotaxis
and migration, antibody receptor, proteases and protease
inhibitors, cell differentiation, lipid metabolism, matrix
and cytoskeleton.
Greenwood et al. performed a gene-expression profile on
murine cell culture models persistently infected with mouse-
adapted scrapie strains [49]. They used neuronal origin cells
N2a and GT1, which showed a different phenotype in
response to prion infection. Both cell types revealed the
upregulation of transport proteins, ATP-binding and cal-
cium-binding proteins. However, N2a evidenced an increase
in transcripts involved in cytoskeletal functions. The down-
regulated genes were mainly related to ATP-binding in GT1,
while in N2a they were ribosomal-associated genes.
To investigate prion-induced effects on human neuronal
cell cultures directly, Martinez and Pascual analyzed the
differential gene expression regulation induced by a neuro-
toxic prion fragment, PrP106-126, on SH-SY5Y neuroblas-
toma cells [50]. Similar to human post-mortem brain tissues
analyses [51], almost 90% of the DEGs were downregulated.
The altered biological processes were involved in metabolism,
folding and transport of proteins, cell cycle regulation,
transcriptional regulation and mitochondrial functions.
On the contrary, genes involved in microglia activation as
well as inflammation were not highly deregulated in isolated
neurons. Although microglia plays a central role in prion
pathologies establishment and development, prions could
exploit other mechanisms to induce neuronal death
and neurodegeneration.
Julius et al. evaluated the transcriptional response to per-
sistent RML infection on three distinct murine cell lines:
N2aPK1, CAD and GT1 [52]. Surprisingly, they did not find
any altered genes and hypothesized that alterations in gene
expression represent secondary effects of the infection. Bach
et al., by performing microarray analysis on murine N2a cells
infected with prion strain 22L, observed upregulated genes of
the cholesterol pathway with a subsequent increase of total and
free cholesterol levels [53]. Upregulation of cholesterogenic
genes – hydroxymethylglutaryl-CoA synthase and reductase,
mevalonate kinase, isopentenyl diphosphate isomerase, squa-
lene synthase, cytochrome P450, family 51 and C4-sterol
methyl oxidase – was probably due to an increase in the
amount and activity of the sterol regulatory element-binding
protein Srebp2. In order to test the upregulation of cholesterol
pathway on different neuronal cells, the authors analyzed, by
using real time PCR, the expression levels of Srebp2, C4-sterol
methyl oxidase and low-density lipoprotein receptor in
RML-infected GT1 cells. The three genes were found upre-
gulated in this case as well. On the contrary, RML- and
22L-infected BV-2 microglia cells revealed a downregulation
of cholesterogenic genes.
4. Gene expression profiles on mouse brain
areas
Few studies have been performed on specific mouse brain areas
to determine the characteristic effects of prion infection on the
different brain regions. Brown et al. collected the total hippo-
campus RNA at the terminal stage of the disease from ME7/
CV-infected mice and hybridized it on Clontech Atlas arrays
containing > 2300 annotated genes [54]. Statistical analysis
identified nine genes with differential expression: six previ-
ously reported as upregulated by prion infection (GFAP,
vimentin, clusterin, CD and complement component 1q a
and b polypeptides) and three not previously identified
(cystatin C, defender against cell death (DAD) and amino
terminal enhancer of split (AES)). DAD and AES only
appeared to be downregulated, but the results were not
confirmed by real time PCR. Most of the genes identified
were involved in microglia activation, a process that occurs in
the late stages of the disease. This process probably does not
induce neuronal loss, but masks the alteration of its earlier
stages. Within the infected hippocampi, CA1 neuronal death
occurs between 160 and 180 days post-inoculation (DPI). To
elucidate the molecular events causing the neuronal loss,
Brown et al. analyzed the gene expression profile of ME7-
infected murine hippocampus at 170 DPI using Affymetrix
high-density oligonucleotide arrays [55]. The hierarchical clus-
tering of the array revealed a clear segregation of control and
scrapie-infected samples. Statistical analysis identified 65 up
and 13 downregulated genes. The processes mainly affected
were oxidative stress-response, endoplasmic reticulum
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homeostasis (increased expression of Reticulon 3, calnexin, ER
chaperons FK506 binding protein 2), mitochondrial apopto-
tic pathway (upregulation of the mitochondrial cloride chan-
nel mtCLIC4, ring finger protein 7, 2 members of the acidic
nuclear phosphoprotein 32 family), protein degradation
(induction of proteasome subunit b5, ring finger proteins
with ubiquitin E3 ligase activity, a-mannosidase 2 and
ATPase, H+ transporting V1 subunit D) and trafficking
(upregulation of signal recognition pattern 9, Golgi-localized
short coiled-coil protein, VAMP4 and AP1s1), cholesterol and
lipid biosynthesis and metabolism (sterol-C5-desaturase,
sterol-C4-methyl oxidase, acetyl-CoA acyltransferase 1, sorti-
lin-related receptor, ecithin cholesterol acyltransferase and
very-low-density lipoprotein receptor), and transcription
and chromatin architecture regulation (for instance, C/EBP
d and IFN consensus sequence binding protein). In the early
stages of disease, cholesterol and lipid biosynthesis-related
genes were found upregulated in scrapie-infected samples,
while appearing downregulated in the later stages [56,57].
The authors related these discrepancies to neuronal tissue
loss occurring mainly in the later stages. Surprisingly, only
few DEGs were involved in inflammation.
Other brain areas expression profiles were analyzed in
the work published by Riemer et al. in 2004 [56]. They
performed microarray analysis of the total RNA extracted
from cortex, medulla and pons of 139A-infected mice
identifying 114 DEGs, 86 up and 28 downregulated.
Most of the upregulated genes are involved in inflamma-
tory reactions, immune and stress responses. The increased
mRNAs were those coding for complement system pro-
teins, enzymes that generate cytotoxic superoxide anion
radicals, cathepsins, acute phase proteins (serine proteinase
inhibitor 2, a2-macroglobulin and lipocalin 24p3) and
transcription factors (CCAAT/enhancer-binding protein d,
IFN consensus sequence binding protein and LRG-21).
Interestingly, as shown in the late stage of the disease
[56,57], most of the downregulated genes play a significant
role in cholesterol biosynthesis.
5. Gene expression profiles on mouse
whole brain
To identify DEGs in early and terminal stages of the disease,
high-density microarray approaches in whole-brain murine
scrapie models have been extensively used. The use of
mock-inoculated age-matched mice as controls allows dis-
criminating expression alterations due to aging rather than
prion infection. In addition to clinical and late stages of
the disease, authors often selected one preclinical time
point with minor detectable neuropathological changes.
This comparative analysis may reveal biomarkers for prion
detection at an early stage.
In 2004, Booth et al. studied two strains of mouse-adapted
scrapie, ME7 and 79a, to characterize the overall general
response to prion infection [58]. Analyzing the whole brain
mRNA at the appearance of clinical signs, they were able to
select 138 up and 20 downregulated genes. This analysis
evidenced a generic fingerprint to damage rather than a
prion-specific response. In particular, they observed the upre-
gulation of genes involved in protease/peptideolysis, lysosomal
functions, lipid binding, defense and immunity, cell commu-
nication, cell death, cell differentiation, cell growth regulation,
cell organization and biogenesis, hormone metabolism, ion
transport, microtubule-based process and oxygen transport.
To gain deeper insights into the early variations of gene
expression, the authors collected samples both at preclinical
and clinical disease stages. The time-course study revealed
genes involved in the initial acute response to prion agent.
Cluster analysis of the 217 DEGs produced four main groups:
i) genes upregulated at 21 DPI; ii) genes downregulated at 21
DPI; iii) genes downregulated throughout the course of the
disease; and iv) genes upregulated at the midpoint in the
disease process. Genes belonging to clusters 1 and 2 evidenced
an early disruption of development and differentiation
regulation as well as neuronal senescence leading to apoptosis.
On the other hand, 50% of the third cluster genes belonged
to the hematopoietic system (hemoglobin Y, b-like,
hemoglobin-a, NCK-associated protein1) and were proposed
as preclinical biomarkers.
The same group published an analysis of the gene expres-
sion modifications in the brains of two inbred mice back-
grounds, C57BL/6 and VM, infected with three different
scrapie strains (22A, ME7 and 79a) [59]. The most repre-
sented functional groups in the ‘prion-related genes’ list were:
lipid metabolism, nervous system function and synaptic
transmission, cytoskeleton organization and biogenesis, pro-
tein biosynthesis and folding, lysosome organization and
biogenesis, proteolysis, apoptosis, immune cell activation
and inflammatory response. Subsequently, using the Inge-
nuity Pathways Analysis tool, they identified 22 networks
such as tissue development, cell death, endocrine system;
behavior, cellular movement, cell cycle; inflammatory disease,
connective tissue disorders, infectious disease; cancer, cell
death, tumor morphology; and cellular assembly and orga-
nization, neurological disease, and tissue morphology.
Because astrocytosis is a prominent feature of prion diseases
and numerous affected pathways were probably involved in
glia origin, the DEGs were annotated in terms of cell-type,
comparing astrocytes and microglia versus neurons. Glia-
associated DEGs were mainly involved in cell proliferation
and growth, cellular migration and inflammation, lysosomal
activity, lipid metabolism and transport. The upregulation of
these pathways supports the astrocytes activation in the
damaged areas of the brain. On the other hand, proteins
involved in synaptic functions, signaling pathways, choles-
terol metabolism, calcium signaling and long-term potenti-
ation were downregulated in neurons, in agreement with the
induced neuronal death during prion disease.
Skinner et al. reported the gene expression alterations in
brains of C57BL/6 mice infected with three different scrapie
Gene expression profiling to identify druggable targets in prion diseases
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strains: ME7, 22L and RML [60]. Microarray analyses were
performed at both preclinical and clinical time points. Over
400 DEGs were detected at the clinical stage of the disease.
Bioinformatics analysis revealed the functional categories
associated: protein folding and degradation, endosome/
lysosome functions, immune response, cytoskeleton organi-
zation, metal ion binding, calcium regulation, pumps and ion
channels, signaling cascade, transcription/translation, mito-
chondria functions, carbohydrate processing, lipid metabo-
lism and synapse function. Genes involved in the endosome/
lysosome system may function as cofactors in PrP misfolding
and accumulation, while the altered gene expressions of the
other pathways are probably crucial for microglia activation
and neuronal degeneration. At the preclinical stage, only
22 genes were deregulated, revealing no massive brain dis-
ruption. To identify prion strain-specific gene patterns, the
authors compared among each other mice infected with the
three prion isolates. This comparison revealed several
genes differentially modulated by the various prion strains,
probably underlying distinct infection mechanisms and
degeneration processes.
Kretzschmar’s group compared the transcriptome of
C57BL/6 mice inoculated with two different prion strains
(ME7 and RML) [61]. They identified 121 genes common to
both prion strains. These genes encode proteins mainly
involved in proteolysis, protease inhibition, cell growth and
maintenance, immune response, signal transduction, cell
adhesion and molecular metabolism. The transcriptional
activity generally showed upregulation of these genes from
120 DPI for ME7-inoculated mouse brains and from 90 DPI
for RML-inoculated mouse brains. The onset of upregulation
was temporally correlated with PrPSc appearance, glia activa-
tion and neuronal cell death. Among the 67 genes upregulated
in ME7-infected mice, many were downregulated in RML-
inoculated mice. However, none of the genes showing a
discordant prion strain-variation were validated through
real time PCR. The high percentage of genes involved in
the immune response raises the possibility that complement
proteins, inflammatory factors and astrocytes associated genes
may play a primary role in prion diseases. These results may be
related to the later stages of the disease without being essential
to prion propagation.
In another study by the same group performing
time-course experiments, 430 DEGs were identified [57].
The time-dependent expression profiles revealed a down-
regulation of cholesterol metabolism-related genes, in addition
to an enhanced activation of the immune system and other
categories such as translational terminators, cofactors and
ubiquinone metabolism. Cholesterol synthesis inhibition sug-
gested a correlation between cholesterol depletion and
synaptic degeneration.
To identify pre-symptomatic biomarkers for prion infec-
tion diagnosis, Miele et al. applied microarray analysis on
inbred C57BL/6 mice inoculated with RML prion strain [62].
The authors performed a transcriptional analysis of
intraperitoneally prion-infected mouse brains looking for
highly upregulated transcripts containing a secretory leader
peptide. The microarray analysis revealed 77 DEGs. In par-
ticular, a1-antichymotrypsin was increased in urine and cere-
brospinal fluid of prion-affected patients, suggesting its
potential use as preclinical biomarker.
In a more recent study, a huge effort to perform a global
systematic approach has been carried out. Hwang and cow-
orkers collected > 400 Affymetrix chips to monitor the
disease progression associated with different mice background
(FVB, B6 and B6.I) and prion strains (RML and
301V) [63,64]. A total of 333 DEGs, common to the five
prion-mouse combinations, were identified and integrated
with the known protein–protein interaction networks. More-
over, transgenic mice expressing different PrP levels were
used (Tg4053, Prnp0/+ and Prnp0/0) and their DEGs inves-
tigated. PrPC expression levels affected both the onset of
symptoms and the transcriptional regulation. High PrPC
content, as in eightfold PrP expressing Tg4053 mice, showed
vast transcription alteration associated with earlier onset of
symptoms. On the other hand, heterozygous mice (Prnp0/+)
revealed a transcriptional program similar to wild-type mice
during early stages of neuropathological changes and devel-
oped the disease later. Prnp knockout mice (Prnp0/0) did not
develop prion disease and, therefore, showed no statistically
significant DEGs.
Hwang and collaborators identified a stereotypical set of
steps leading to neurodegeneration. Microglia, astrocytes
activation and increase of lysosomal protease were detected
within 10 weeks from inoculation, followed by alteration in
cholesterol, glycosaminoglycan and androgen metabolism, in
addition to iron homeostasis and prostaglandin metabolism.
Perturbation of androgen metabolism was related to glia
activation and neurosteroid metabolism, further linked to
cholesterol metabolism. Iron homeostasis and heme metabo-
lism were associated with their potential role in demyelination,
while the biosynthesis of protoinflammatory prostlaglandins
and leukotrimers was deemed to explain the overproduction of
pro-inflammatory metabolites.
Because most DEGs in TSE infection, as in many other
brain disorders, are related to neuroinflammation, Moody
et al. analyzed the transcriptome changes specifically associated
with prion neuropathology, adopting a different approach [65].
They compared gene expression profiles of RML-infected
and cuprizone-treated mouse brains. Cuprizone is a
copper chelator and induces demyelination in the CNS,
histopathological lesions, inflammation and glia activation
of orally treated mice. The authors analyzed cuprizone-
treated mouse brains to highlight the modulations of
neuroinflammation-associated RNAs and to identify prion-
specific gene expression alterations. Microarray analysis, per-
formed on RML-infected C57BL/6 mice at three time points,
revealed 164 DEGs; the majority of them had not been
previously identified. Upregulated genes are mainly involved
in immune response (probably due to glia proliferation),
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response to stimuli, protein modification, intracellular cellular
signaling, while downregulated genes belong to the ubiquitin
cycle and cellular developmental processes. Cuprizone dose
and time exposure were chosen to obtain prion-like histo-
pathological modifications. The transcriptome analysis of
cuprizone-treated mice detected 319 DEGs. Upregulated
genes are associated with immune response, metabolic
processes, apoptosis (probably related to oligodendrocyte
demyelination), cell communication, cellular adhesion and
localization, while downregulated genes are related to axon
ensheathment. Comparing microarray data from both RML-
and cuprizone-treated mice, 17 genes resulted to be specific for
prion disease. The two major altered pathways in prion disease
were: neuropeptide signaling (agouti-related protein and phos-
pholipase C, e 1) and adipocytokine signaling (agouti-related
protein, solute carrier family 2 member 4 and suppressor of
citokine signaling).
6. Glycosylation-related gene
expression profiles
PrPC is present in the outer leaf of plasma membranes as un-,
mono- or di-glycosylated form. Alterations in the PrP glyco-
pattern have been revealed during prion infection [66]. Barret
et al. discovered the downregulation of chondroitin sulfate
N-acetylgalactosaminyltransferase 1 (ChGn) and carbohy-
drate (N-acetylgalactosamine 4-O) sulfotransferase 8
(Chst8) genes in scrapie Chandler-infected murine GT1-7
cells [67]. ChGn is involved in the initiation of the synthesis of
chondroitin sulfate, while Chst8 in the 4-O-sulfation of
non-reducing N-acetylgalactosamine residues.
Guillerme-Bosselut et al. investigated the expression pat-
terns of 165 glycosylation-related genes in the brain and
spleen of healthy and 127S ovine strain-affected Tg338 mice,
an homozygous transgenic line for the ovine VRQ allele and
expressing 8- to 10-fold PrP more than in sheep [68]. Brain
and spleen play a role in prion replication and present
different glycomes [69,70]. Eight genes encoding for glycosyl-
transferases and glycosidase were found upregulated in the
infected brains. On the contrary, in the spleen there was a
dichotomy in glycosyltransferases behavior.
Because prion diseases cause alterations in the extra-cellular
matrix [71] and both PrPC and PrPSc bind different N-glycans
[72], glycosaminoglycan binding sites could represent a
potential target for therapeutic treatment.
7. Gene expression profiles on BSE-infected
animal brains
Sawiris et al. performed microarray analyses on 301V BSE
strain-inoculated mouse brains in late stage infection and
identified 116 up and 180 downregulated genes [73]. The
functional categories mainly affected were: ubiquitin-mediated
protein degradation, protein folding, apoptosis, zinc and
calcium binding proteins and transcription regulation.
Recently, a time-course transcriptome analysis on BSE
orally-infected cattle brains was published revealing 187
DEGs [74]. Among the annotated ones, 46% were upregulated,
35% downregulated and 19% showed complex expression
patterns. The most affected categories were: metabolism,
transcription and translation, immune response and transport.
The higher degree of difference between healthy and BSE-
infected brains was at 21 months post-inoculation (MPI).
Although some samples did not present any clinical signs at
45 MPI, their gene profiles were highly similar to the
infected samples.
8. Gene expression profiles on CJD patients’
post-mortem brains
Xiang et al. analyzed the transcriptome of sporadic CJD
(sCJD)-affected human post-mortem brains [51]. Most of
the identified DEGs were downregulated, indicating neuronal
dysfunction and degeneration. The major alterations of upre-
gulated pathways include stress and immune responses, as well
as cell cycle and death, while downregulated genes encode for
protein metabolism, ion transport and synaptic proteins.
sCJD brains revealed many similarities to ageing human
brains, both in global expression patterns and in DEGs.
9. Drug target identification by gene
expression profiling of prion-infected samples
The main purpose of a genome-wide analysis on prion-
infected samples is the identification of targets for novel
therapeutic approaches. Currently, no effective cures have
been found against prion diseases, though several anti-
prion compounds have been clinically tested (Table 1) [75].
Here, we briefly correlate the action mechanisms of some
drugs and their efficacy on the altered pathways evidenced by
microarray analyses.
Cholesterol synthesis is one of the most confirmed altered
processes in prion-infected samples. The polyene antibiotics –
amphotericin B, mepartricin and filipin – interact with
cholesterol, inducing alteration of membrane lipid composi-
tion, disruption of cell membrane and modification of raft
domains that are thought to be the site of PrPC conversion
into PrPSc [76,77]. As reviewed by Trevitt and Collinge [78]
and by Sakaguchi [75], these drugs have shown an anti-
prion activity prolonging the incubation time, delaying the
disease onset and inhibiting prion propagation in scrapie-
infected mouse brains and CJD-infected monkeys. However,
the same beneficial effects were not confirmed in CJD
patients [79,80]. Other drugs acting on cholesterol, such as
statins, were used. Statins decrease cholesterol levels by
inhibiting its biosynthesis [81]. Lovastatin and squalestatin
were tested on scrapie-infected cells reducing PrPSc
levels [82,83]. The blood-brain barrier permeable simvastatin
instead showed weak effects on prion-infected mice [84,85].
Gene expression profiling to identify druggable targets in prion diseases
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Table 2. List of DEGs collected from reviewed publications.
Gene symbol Gene name No. of citations
CTSS Cathepsin s 12
CTSH Cathepsin h 10
GFAP Glial fibrillary acidic protein 10
C1QA Complement component 1, q subcomponent, alpha polypeptide 9
C1QB Complement component 1, q subcomponent, beta polypeptide 9
HEXB Hexosaminidase b 9
ABCA1 Atp-binding cassette, sub-family a (abc1), member 1 8
B2M Beta-2 microglobulin 8
FCER1G Fc receptor, ige, high affinity i, gamma polypeptide 8
GRN Granulin 8
IFIT3 Interferon-induced protein with tetratricopeptide repeats 3 8
LY86 Lymphocyte antigen 86 8
APOD Apolipoprotein d 7
CD53 Cd53 antigen 7
CD68 Cd68 antigen 7
CLU Clusterin 7
CNN3 Calponin 3, acidic 7
CST3 Cystatin c 7
CST7 Cystatin f (leukocystatin) 7
DBI Diazepam binding inhibitor 7
DHRS1 Dehydrogenase/reductase (sdr family) member 1 7
FCGR2B Fc receptor, igg, low affinity iib 7
H2-D1 Histocompatibility 2, d region locus 1 7
LAPTM5 Lysosomal-associated protein transmembrane 5 7
LGALS3BP Lectin, galactoside-binding, soluble, 3 binding protein 7
SERPINA3N Serine (or cysteine) peptidase inhibitor, clade a, member 3n 7
TYROBP Tyro protein tyrosine kinase binding protein 7
VIM Vimentin 7
CD52 Cd52 antigen 6
CD9 Cd9 antigen 6
CTSC Cathepsin c 6
FXYD1 Fxyd domain-containing ion transport regulator 1 6
HMGCS1 3-hydroxy-3-methylglutaryl-coenzyme a synthase 1 6
MPEG1 Macrophage expressed gene 1 6
S100A6 S100 calcium binding protein a6 (calcyclin) 6
SGK Serum/glucocorticoid regulated kinase 6
SOX9 Sry-box containing gene 9 6
AQP4 Aquaporin 4 5
C4B Complement component 4b (childo blood group) 5
CAPG Capping protein (actin filament), gelsolin-like 5
CCL9 Chemokine (c-c motif) ligand 9 5
CD84 Cd84 antigen 5
CEBPD Ccaat/enhancer binding protein (c/ebp), delta 5
CHI3L1 Chitinase 3-like 1 5
Cited genes have been found in at least three studies.
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Table 2. List of DEGs collected from reviewed publications (continued).
Gene symbol Gene name No. of citations
CSF1R Colony stimulating factor 1 receptor 5
CTSD Cathepsin d 5
CTSZ Cathepsin z 5
CXCL10 Chemokine (c-x-c motif) ligand 10 5
CYBA Cytochrome b-245, alpha polypeptide 5
EGR1 Early growth response 1 5
H2-K1 Histocompatibility 2, k1, k region 5
HPGD Hydroxyprostaglandin dehydrogenase 15 (nad) 5
IFITM3 Interferon induced transmembrane protein 3 5
ITGB2 Integrin beta 2 5
LAMP2 Lysosomal membrane glycoprotein 2 5
LMNA Lamin a 5
MDH1 Malate dehydrogenase 1, nad (soluble) 5
MSR2 Macrophage scavenger receptor 2 5
NUPR1 Nuclear protein 1 5
OSMR Oncostatin m receptor 5
PRDX6 Peroxiredoxin 6 5
SC4MOL Sterol-c4-methyl oxidase-like 5
SLC25A18 Solute carrier family 25 (mitochondrial carrier), member 18 5
SPARC Secreted acidic cysteine rich glycoprotein 5
TRF Transferrin 5
A2M Alpha-2-macroglobulin 4
ALDOC Aldolase 3, c isoform 4
ANXA3 Annexin a3 4
APOE Apolipoprotein e 4
AU020206 Expressed sequence au020206 4
BCL2A1A B-cell leukemia/lymphoma 2 related protein a1a 4
BLNK B-cell linker 4
C1QC Complement component 1, q subcomponent, c chain 4
C3AR1 Complement component 3a receptor 1 4
CD14 Cd14 antigen 4
CD48 Cd48 antigen 4
CD86 Cd86 antigen 4
CLEC7A C-type lectin domain family 7, member a 4
CRYAB Alpha crystallin B chain 4
CTSB Cathepsin b 4
CTSL Cathepsin l 4
DNAJA1 Dnaj (hsp40) homolog, subfamily a, member 1 4
FCGR3 Fc receptor, igg, low affinity iii 4
FYB Fyn binding protein 4
GP49A Glycoprotein 49 a 4
GPNMB Glycoprotein (transmembrane) nmb 4
HBA-A1 Hemoglobin alpha, adult chain 1 4
HMGCR 3-hydroxy-3-methylglutaryl-coenzyme a reductase 4
IDI1 Isopentenyl-diphosphate delta isomerase 4
Cited genes have been found in at least three studies.
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Table 2. List of DEGs collected from reviewed publications (continued).
Gene symbol Gene name No. of citations
IRF8 Interferon regulatory factor 8 4
ITGAX Integrin alpha x 4
LCN2 Lipocalin 2 4
LDLR Low density lipoprotein receptor 4
LGALS3 Lectin, galactose binding, soluble 3 4
LILRB4 Leukocyte immunoglobulin-like receptor, subfamily b, member 4 4
LYZS Lysozyme 4
MSN Moesin 4
NEFL Neurofilament, light polypeptide 4
NFKBIA Nuclear factor of kappa light chain gene enhancer in b-cells inhibitor, alpha 4
PLEK Pleckstrin 4
PSMB8 Proteosome (prosome, macropain) subunit, beta type 8 (large multifunctional peptidase 7) 4
PTPRC Protein tyrosine phosphatase, receptor type, c 4
PYCARD Pyd and card domain containing 4
RAB31 Riken cdna 1700093e07 gene 4
RPH3A Rabphilin 3a 4
S100A4 S100 calcium binding protein a4 4
SPP1 Secreted phosphoprotein 1 4
TLR2 Toll-like receptor 2 4
TNFRSF1A Tumor necrosis factor receptor superfamily, member 1a 4
TRIM30 Tripartite motif protein 30 4
TTC3 Tetratricopeptide repeat domain 3 4
TTR Transthyretin 4
ABHD4 Abhydrolase domain containing 4 3
ACTA2 Actin, alpha 2, smooth muscle, aorta 3
ACTB Actin, beta, cytoplasmic 3
ADAM23 A disintegrin and metallopeptidase domain 23 3
ALDH1A1 Aldehyde dehydrogenase family 1, subfamily a1 3
ATP1B1 Atpase, na+/k+ transporting, beta 1 polypeptide 3
ATP1B2 Atpase, na+/k+ transporting, beta 2 polypeptide 3
ATP6V1A Atpase, h+ transporting, lysosomal v1 subunit a 3
BC032204 Expressed sequence c79673 3
BCL2A1D B-cell leukemia/lymphoma 2 related protein a1d 3
C3 Complement component 3 3
CALM3 Calmodulin 1 3
CAMK2B Calcium/calmodulin-dependent protein kinase ii, beta 3
CAR8 Carbonic anhydrase 8 3
CCL12 Chemokine (c-c motif) ligand 12 3
CCL3 Chemokine (c-c motif) ligand 3 3
CCL6 Chemokine (c-c motif) ligand 6 3
CCNC Cyclin c 3
CD44 Cd44 antigen 3
CSF1 Colony stimulating factor 1 (macrophage) 3
CTLA2B Cytotoxic t lymphocyte-associated protein 2 beta 3
CTNNB1 Catenin (cadherin associated protein), beta 1 3
Cited genes have been found in at least three studies.
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Table 2. List of DEGs collected from reviewed publications (continued).
Gene symbol Gene name No. of citations
CTSA Protective protein for beta-galactosidase 3
CTSK Cathepsin k 3
CX3CR1 Chemokine (c-x3-c) receptor 1 3
CYBB Cytochrome b-245, beta polypeptide 3
D12ERTD647E Dna segment, chr 12, erato doi 647, expressed 3
DDR1 Discoidin domain receptor family, member 1 3
EIF5A Eukaryotic translation initiation factor 5a 3
EXT2 Exostoses (multiple) 2 3
FCGR1 Fc receptor, igg, high affinity i 3
GBP2 Guanylate nucleotide binding protein 2 3
GJA1 Gap junction membrane channel protein alpha 1 3
GLUL Glutamate-ammonia ligase (glutamine synthetase) 3
GNB4 Guanine nucleotide binding protein, beta 4 3
GNG5 Guanine nucleotide binding protein (g protein), gamma 5 subunit 3
GSTM1 Glutathione s-transferase, mu 1 3
GUSB Beta-glucuronidase structural 3
HIST1H1C Histone 1, h1c 3
HRSP12 Heat-responsive protein 12 3
HSPB1 Heat shock protein 1 3
IFI30 Interferon gamma inducible protein 30 3
IGFBP5 Insulin-like growth factor binding protein 5 3
IIGP1 Interferon inducible gtpase 1 3
ITGB5 Integrin beta 5 3
LPL Lipoprotein lipase 3
LYN Yamaguchi sarcoma viral (v-yes-1) oncogene homolog 3
LYZ P lysozyme structural 3
MAFB V-maf musculoaponeurotic fibrosarcoma oncogene family, protein b (avian) 3
MAN2B1 Mannosidase 2, alpha b1 3
MBP Myelin basic protein 3
MCOLN1 Mucolipin 1 3
MS4A6D Membrane-spanning 4-domains, subfamily a, member 6d 3
MT2 Metallothionein 2 3
MTAP4 Microtubule-associated protein 4 3
MYH11 Myosin, heavy polypeptide 11, smooth muscle 3
NCALD Neurocalcin delta 3
NCF1 Neutrophil cytosolic factor 1 3
NEFM Neurofilament 3, medium 3
NTRK2 Neurotrophic tyrosine kinase, receptor, type 2 3
OASL2 2¢’-5¢ oligoadenylate synthetase-like 2 3
PARP3 Poly (adp-ribose) polymerase family, member 3 3
PCMT1 Protein-l-isoaspartate (d-aspartate) o-methyltransferase 1 3
PDLIM4 Pdz and lim domain 4 3
PHPT1 Phosphohistidine phosphatase 1 3
PLEKHB2 Riken cdna 2310009m15 gene 3
PMP22 Peripheral myelin protein 3
Cited genes have been found in at least three studies.
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Lysosomes are potential sites for PrPSc conversion and their
activity is altered during prion infection, as revealed by
microarray analyses. Therefore, the lysosomal pathway
represents a potential drug target. Tricyclic compounds, such
as quinacrine and chloroquine, are lysosomotropic factors.
Though modest improvements have been registered in CJD
patients, preclinical and clinical quinacrine tests gave con-
troversial results [75,78,80]. Several DEGs are also involved in
proteolysis. Cysteine preotease inhibitors have been tested on
infected cells reducing PrPSc levels [86].
The immune response and the inflammation are
altered processes in prion disorders. Pentosan polysulfate,
an anti-inflammatory drug, competes with endogenous
glycosaminoglycans for the interaction with PrPC and/or
PrPSc, preventing the conversion and decreasing neuronal
death [26,75,78,80,87].
Another crucial pathway in neurodegeneration, confirmed
by microarray experiments, concerns apoptosis. Pifitrin-a a
p53 inhibitor, causes the decrease of caspase-3. Although
infected cells treated with Pifitrin-a showed a dose-dependent
decrease of prion levels, in vivo studies did not evidence
improvements in incubation time, astrogliosis and spongio-
sis [88]. Flupirtine, a non-opioid analgesic anti-apoptotic drug,
has also been tested on CJD patients. It increases the Bcl-2 and
glutathione synthetase expression levels [89]. Flupirtine
administration to CJD patients brought some benefits to
Table 2. List of DEGs collected from reviewed publications (continued).
Gene symbol Gene name No. of citations
PROS1 Protein s (alpha) 3
PTBP1 Polypyrimidine tract binding protein 1 3
PTPN6 Protein tyrosine phosphatase, non-receptor type 6 3
PTPRZ1 Protein tyrosine phosphatase, receptor type z, polypeptide 1 3
QK Quaking 3
RAB1 Rab1, member ras oncogene family 3
RALGDS Ral guanine nucleotide dissociation stimulator 3
RASA2 Ras p21 protein activator 2 3
RGS2 Regulator of g-protein signaling 2 3
RNASE4 Ribonuclease, rnase a family 4 3
RPL4 Ribosomal protein l4 3
RUNX1 Runt related transcription factor 1 3
S100B S100 protein, beta polypeptide, neural 3
SGPP1 Sphingosine-1-phosphate phosphatase 1 3
SLC11A1 Solute carrier family 11 (proton-coupled divalent metal ion transporters), member 1 3
SLC1A3 Solute carrier family 1 (glial high affinity glutamate transporter), member 3 3
SLC4A4 Solute carrier family 4 (anion exchanger), member 4 3
SOCS3 Suppressor of cytokine signaling 3 3
SORL1 Sortilin-related receptor, ldlr class a repeats-containing 3
SUCLA2 Succinate-coenzyme a ligase, adp-forming, beta subunit 3
TCFCP2L1 Riken cdna 4932442m07 gene 3
TIMP1 Tissue inhibitor of metalloproteinase 1 3
TM2D1 Tm2 domain containing 1 3
TMSB4X Thymosin, beta 4, x chromosome 3
TOB2 Transducer of erbb2, 2 3
TREM2 Triggering receptor expressed on myeloid cells 2c 3
TRPC4 Transient receptor potential cation channel, subfamily c, member 4 3
TSC22D4 Riken cdna 1700023b23 gene 3
UCHL5 Ubiquitin carboxyl-terminal esterase l5 3
UCP2 Uncoupling protein 2 (mitochondrial, proton carrier) 3
VAMP1 Vesicle-associated membrane protein 1 3
Cited genes have been found in at least three studies.
DEG: Differentially expressed gene.
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cognitive functions, less deterioration in the dementia tests,
but no differences in survival [80,90].
Transcriptome analysis of prion-infected samples identified
some DEGs playing a role in oxidative stress, a crucial
pathway in neuronal cell death. Antioxidant compounds –
polyphenolic molecules, coenzyme Q-10, vitamins, NADH,
minerals and others – decrease PrPSc propagation in infected
cells [91]. Administration of these compounds to CJD patients
revealed clinical improvements, including responsiveness,
myoclonus, apnoeic episodes and rigidity [80,92].
10. Expert opinion
Microarray technology has been demonstrated to be a useful
tool to simultaneously monitor the expression levels of
thousandsofgenes andtostudy theeffectsof treatments,diseases
and biological processes on gene expression. In particular, gene
expression profiling can be used to identify altered transcripts in
response to pathogens, such as prions, and to select potential
targets for novel therapeutic approaches.
Although the reviewed studies demonstrate scarce repro-
ducibility between different laboratories and manufacturers,
several overlapping genes and metabolic pathways were found
(Tables 2 and 3). This heterogeneity may be due to various
aspects: different biological systems – cell cultures, mouse
brain areas or mouse whole brains, sheep and CJD patient
post-mortem brains – and genetic background of the host;
prion strain and titer used for inoculation as well as the
inoculation method; microarray platforms, working strategy
and algorithms for analysis and statistical thresholds for
significance selection (Table 4).
Table 3. List of altered pathways obtained using Kyoto encyclopedia of genes and genomes and gene ontology.
Pathway Count p Value Genes
Innate and adaptive
inflammatory host
defenses
38 0.0421 CYBB, MSN, CTNNB1, NCF1, CYBA, ACTB, NFKBIA, PTPN6, FCGR2B, LYN, BLNK,
PTPN6, FCGR3, TYROBP, ITGB2, H2-D1, CD48, FCER1G, CCL3, CX3CR1,
TNFRSF1A, CSF1R, CCL9, CCL12, CSF1, CCL6, CXCL10, OSMR, B2M, CTSL,
H2-K1, IFI30, CTSB, CTSS,SPP1, CD14, CD86, TLR2
Hematopoietic cell
lineage
6 0.0366 CSF1R, FCGR1, CD14, CSF1, CD44, CD9
Alzheimer’s disease 6 0.0003 APOE, C1QC, LPL, C1QB, C1QA, A2M
Complement and
coagulation
cascades
7 0.0046 C1QC, C3, C1QB, C4B, C1QA, A2M, C3AR1
Biosynthesis of
steroids
3 0.0938 HMGCR, IDI1, SC4MOL
Response to stress 37 4.8E-11 DNAJA1, HSPB1, RUNX1, C4B, CRYAB, FCER1G, NCF1, CXCL10, CD9, FCGR2B,
TNFRSF1A, FCGR3, FCGR1, CD14, CCL12, CD44, C1QA, CTSB, LY86, APOE,
PYCARD, C1QC, CLEC7A, PROS1, S100B, GJA1, NEFL, C1QB, C3, TLR2, C3AR1,
TSC22D4, CCL3, SPP1, SERPINA3N, SGK, PRDX6
Proteolysis 22 0.0006 ABHD4, PYCARD, CTSA, C1QC, CTSL, S100B, PSMB8, C1QB, C3, C4B, C3AR1,
CTSS, CTSD, UCHL5, CTSZ, CTSC, TIMP1, CTSK, C1QA, CTSH, CTSB, ADAM23
Cell differentiation 39 0.00111 TM2D1, MYH11, BCL2A1A, BCL2A1D, EIF5A, EXT2, LYZS, LYZ, SOX9, CSF1,
RUNX1, FCER1G, SGPP1, TCFCP2L1, PTPRZ1, TNFRSF1A, FCGR3, FCGR1, EGR1,
S100A6, APOE, PYCARD, NFKBIA, CTNNB1, NEFM, ALDH1A1, S100B, GJA1,
NEFL, LYN, IRF8, NTRK2, PTPRC, QK, SPP1, TIMP1, MAFB, SGK, CLU
Alcohol metabolic
process
12 0.0008 APOE, SORL1, ALDOC, LDLR, MDH1, HMGCR, IDI1, MAN2B1, SC4MOL, SGPP1,
HMGCS1, ABCA1,
Vesicle-mediated
transport
15 0.0016 SORL1, CTNNB1, CLEC7A, C3, FCER1G, MCOLN1, ABCA1, RAB1, FCGR2B,
LDLR, FCGR3, NCALD, FCGR1, RPH3A, VAMP1
Lipid metabolic
process
18 0.0034 APOE, ABHD4, SORL1, GRN, HMGCR, IDI1, NCF1, SC4MOL, SGPP1, ABCA1, QK,
LDLR, TNFRSF1A, HPGD, LPL, HMGCS1, HEXB, PRDX6
Regulation of
apoptosis
14 0.0050 APOE, TM2D1, PYCARD, BCL2A1A, BCL2A1D, S100B, ALDH1A1, SOX9, NEFL,
FCER1G, PTPRC, SPP1, FCGR3, FCGR1
Biological adhesion 17 0.0106 CD84, ITGAX, CLEC7A, CTNNB1, PROS1, DDR1, ATP1B2, SOX9, CSF1, CD9,
ITGB5, GPNMB, SPP1, BC032204, ITGB2, CD44, ADAM23
Ion homeostasis 8 0.0125 APOE, PTPRC, MT2, S100B, TRF, SLC4A4, C3AR1, HEXB
Response to
chemical stimulus
18 0.0002 APOE, NFKBIA, MT2, LYN, HSPB1, TLR2, FCER1G, CXCL10, C3AR1, CCL3, SPP1,
FCGR3, CCL9, CCL12, ITGB2, CCL6, CTSB, PRDX6
Gene expression profiling to identify druggable targets in prion diseases
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Several drugs have been tested for their anti-prion activity.
These compounds, as reported above, act on cholesterol
biosynthesis, lysosomal activity, immune response and inflam-
mation and play a role against oxidative stress (Table 1).
Although these drugs operate on the pathways identified by
microarray analyses (Figure 1), so far, no effective cures have
been found against prion diseases.
Genes belonging to a metabolic or biological process
often share enzymatic reactions with other pathways,
such as ApoE and ApoD. ApoE holds roles in lipid met-
abolic process, regulation of apoptosis, ion homeostasis,
response to chemical stimuli and stress, cell differentiation
and alcohol metabolic process. ApoD occurs in the
macromolecular complex with lecithin–cholesterol acyl-
transferase, transports and binds bilin and other
ligands. Moreover, ApoD inhibits translocation of phos-
phorylated MAPKs into the nucleus [93], altering the
MAPK-dependent transcriptional regulation. Because
MAPK pathways are altered during prion infection [94]
and cellular protein–protein networks are complex, the
trigger remains still unknown. In addition, drugs acting
on cholesterol biosynthesis can disrupt the lipid raft
domains, altering both protein locations and synaptic
functions, and cause significant injuries.
Metal ion homeostasis is yet another altered pathway during
prion infection. Almost all physiological processes are gov-
erned by metal ions – calcium, sodium, magnesium, manga-
nese, iron, copper and zinc – through allosteric and prosthetic
regulations, or electrostatic interactions. Alterations of their
homeostasis affect ATP production, action potential, protein
synthesis and metabolism, vesicle transport, osmotic pressure
and apoptosis. Incorporation of metal ions into apo-proteins
takes place in organs other than the brain, such as the
liver. Metal ions dysmetabolism prompts the coexistence of
multi-factorial events during neurodegeneration.
Many drugs used to cure prion diseases through their direct
action on altered pathways manifest important effects on
unaltered pathways (Table 5). Statins showed weak therapeutic
effects on mice inhibiting endogenous cholesterol production.
They also affect related pathways such as Ras- and Rho-
signaling as well as ubiquinone. D-penicillamine used as
copper chelator acts as an immunosuppressor by reducing
numbers of T-lymphocytes, inhibiting macrophage function,
decreasing IL-1, decreasing rheumatoid factor and preventing
collagen from crosslinking. Quinacrine also acts on histamine
metabolism, muscarinic acetylcholine receptor M1 and ara-
chidonic acid 5-lipoxygenase. ApoE and ApoD are involved in
several other disorders such as PD and AD. The common-
alities among prion diseases and PD and AD disorders
highlight either similar neurodegenerative molecular mechan-
isms or similar pathological secondary events. To establish
suitable drug targets for prion disorders, a more stringent
and specific approach is requested. Comparative analyses of
altered pathways of prion diseases, PD and AD could expose
characteristic gene targets.
Microarray analyses on prion-infected samples evaluate the
transcriptional variations following the onset of prion pathol-
ogy. Because many ligands are required to maintain proteins
in an active form, gene expression profile per se is not sufficient
to fully understand the molecular mechanisms involved in
neurodegeneration. Are those altered genes translated in an
active form? How does metal ions deregulation affect overall
enzymatic activities.
In order to select the best target for therapeutic treatments,
gene expression profiling has to be associated with functional
proteomics and physiology. For instance, it is worth noting
Innate and adaptive inflammatory host defenses: 15%
Hematopoietic cell lineage: 2%
Alzheimer’s disease: 2%
Coagulation cascades: 3%
Biosynthesis of steroids: 1%
Response to stress: 14%
Proteolysis: 8%
Cell differentiation: 15%
Alcohol metabolic process: 5%
Vesicle-mediated transport: 6%
Lipid metabolic process: 7%
Regulation of apoptosis: 5%
Biological adhesion: 7%
Ion homeostasis: 3%
Response to chemical stimulus: 7%
Figure 1. Pie chart of the most altered metabolic pathways, as reported in Table 3.
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that most of known enzymatic chains have a negative feedback
regulatory mechanism. Rational drug design should be
addressed to restore or modulate the endogenous enzymatic
activity instead of replacing its products.
New experiments focused on understanding of the molec-
ular reasons behind pathways or protein activity alterations
must be performed. Therefore, once an altered pathway is
discovered, it will be crucial to analyze the physiological state
of all its components, assess the damage and design specific
drugs restoring its functionality.
The similarity in symptoms, as for AD and PD, and
multi-factorial events require a multi-disciplinary approach
to neurodegenerative diseases. While microarray analyses
can highlight altered genes and biological pathways,
proteomics and physiology ought to confirm such altera-
tions, and, therefore, ensure the identification of the best
drug targets. However, to achieve synergistic outcomes from
a multi-disciplinary approach to neurodegenerative dis-
orders treatments, new breakthrough bioinformatics tools
capable of integrating and interpreting large amounts of
information will represent a much sought after endeavor in
the coming years.
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Table 5. List of drug targets in prion diseases and their side effects on unaltered pathways.
Drug Target pathway altered
in prion disease
Examples of target pathway not altered in
prion disease
Polyene antibiotics
(methotrexate, amphotericin B,
mepartricin and filipin)
Lipid raft conformation
alteration
Methotrexate: DNA replication, DNA repair and cell cycles
alteration
Amphotericin B: permeability alteration in mammalian cells also
Mepartricin: estrogen biosynthesis
Quinacrine Lysosomal pathway Histamine metabolism (histamine methyltransferase inhibition);
arachidonic acid balance deregulation that induces oxidative stress
and neuroinflammation (phospholipase-A2 inhibition)
Chloroquine Lysosomal pathway Lymphocyte proliferation and phospholipase A inhibition, enzymes
release from lysosomes, reactive oxygen species release from
macrophages, IL-1 production
Leupeptin Lysosomal pathway
(cysteine–protease
inhibitors)
Ion homeostasis, integrin signaling pathway, PTP1B signaling, T-cell
apoptosis, cdk5 deregulation in Alzheimer’s disease
Statins Cholesterol biosynthesis
inhibition
Ras- and Rho-signaling as well as ubiquinone
Pifitrin-a Apoptosis (p53 inhibition,
caspase-3 decrease)
Interference with heat shock and glucocorticoid receptor signaling
D-Penicillamine Ion homeostasis
(copper chelator)
T-lymphocytes reduction, macrophage function inhibition, IL-1 and
rheumatoid factor decrease and collagen crosslinking prevention
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Nervous systemA prion, a protease-resistant conformer of the cellular prion protein (PrPC), is the causative agent of
transmissible spongiform encephalopathies or prion diseases. While this property is well established for the
aberrantly folded protein, the physiological function of PrPC remains elusive. Among different putative
functions, the non-pathogenic protein isoform PrPC is involved in several cellular processes. Here, we show
that PrPC regulates the cleavage of neuregulin-1 proteins (NRG1). Neuregulins provide key axonal signals that
regulate several processes, including glial cells proliferation, survival and myelination. Interestingly, mice
devoid of PrPC (Prnp0/0) were recently shown to have a late-onset demyelinating disease in the peripheral
nervous system (PNS) but not in the central nervous system (CNS). We found that NRG1 processing is
developmentally regulated in the PNS and, by comparing wildtype and Prnp0/0 mice, that PrPC inﬂuences
NRG1 processing in old, but not in young, animals. In addition, we found that also the processing of
neuregulin-3, another neuregulin family member, is altered in the PNS of Prnp0/0 mice. These differences in
neuregulin proteins processing are not paralleled in the CNS, thus suggesting a different cellular function for
PrPC between the CNS and the PNS.of the PrP; TSE, transmissible
protein; BACE1, β-site of APP
NRG1, neuregulin-1 proteins;
TF, carboxy-terminal fragment
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Prion diseases are fatal neurodegenerative diseaseswhose etiology
is linked to the conversion of the cellular form of the prion protein
(PrP), PrPC, to a protease-resistant aberrant conformer, denoted as
prion (Prusiner, 1982). Prion diseases include Creutzfeldt–Jakob
disease, fatal familial insomnia and kuru in humans; bovine spongi-
form encephalopathy and scrapie in cows and sheep, respectively;
and chronicwasting disease in free-ranging cervids including deer, elk
and moose. The physiological function of PrPC still remains enigmatic,
although several putative roles have been proposed for different
cellular functions, including synaptic activity (Herms et al., 1999),
neurite outgrowth (Kanaani et al., 2005; Santuccione et al., 2005),
neuroprotection (Bounhar et al., 2001) and maintenance of myelin-ated sheet (Radovanovic et al., 2005). Recently, mice lacking the PrP-
encoding gene (Prnp0/0) were shown to have a late-onset peripheral
demyelinating polyneuropathy (Bremer et al., 2010) not observed in
the central nervous system (CNS) of the same Prnp0/0 mice.
Myelination and myelin maintenance are different physiological
processes which require distinct axonal molecular signals acting on
glial cells and supporting them at different developmental stages. One
of the most studied molecular signals is mediated by neuregulin-1
proteins (NRG1) (Newbern and Birchmeier, 2010). The NRG1 contain
an epidermal growth factor (EGF)-like domain that signals through
the binding of ErbB receptor tyrosine kinases (Mei and Xiong, 2008).
The best-deﬁned function of NRG1 is the control of myelination in the
peripheral nervous system (PNS), where NRG1 are essential for
neuronal and glial survival (Garratt et al., 2000b; Jessen and Mirsky,
2005; Nave and Salzer, 2006). On the other hand, NRG1 role in the
myelination of the CNS have not yet been established and, despite in
vitro data, neuregulin protein family (NRG) signaling seems to be
dispensable for CNS myelination in vivo, at least during postnatal
stages (Brinkmann et al., 2008). This suggests that NRG1may function
differently in the PNS and CNS.
Gene transcripts encoding at least 14 different NRG1 isoforms have
been identiﬁed (Fischbach and Rosen, 1997). Themost commonNRG1
isoforms in the nervous system are synthesized as transmembrane
pro-proteins and are classiﬁed according to their different N-terminal
domains (Falls, 2003). NRG1 type I and type II possess N-terminal
29S. Benvegnù et al. / Molecular and Cellular Neuroscience 47 (2011) 28–35immunoglobulin-like domains, while NRG1 type III is characterized by
a cysteine-rich domain, which functions as a second transmembrane
domain (Buonanno and Fischbach, 2001). Neuregulin-1 pro-proteins
undergo protease-mediated proteolytic cleavage in the stalk region
(Burgess et al., 1995; Lu et al., 1995; Loeb et al., 1998). Thus, NRG1
types I and II are released from the cell surface and may function as
paracrine signals, while NRG1 type III remains tethered to the cell
membrane after cleavage andmay act as a juxtacrine signal (Nave and
Salzer, 2006). In any case, the EGF-like signaling domain (present in
all NRG1-isoforms) is required and sufﬁcient for binding and
activation of the ErbB transmembrane receptor tyrosine kinases
(Holmes et al., 1992; Lu et al., 1995).
The proteolytic cleavage of NRG1 is catalyzed by different
membrane proteases, including members of the ADAM proteases
family, like ADAM17/TACE (Loeb et al., 1998; Montero et al., 2007)
and ADAM19 (Yokozeki et al., 2007), and the β-site of amyloid
precursor protein (APP) cleaving enzyme, (β-secretase, BACE1) (Hu
et al., 2006; Willem et al., 2006). The BACE1 knockout mice show a
deﬁcit in NRG1 processing in their nervous system and display a
peripheral neuropathy similar to that observed in mice lacking NRG1/
ErbB signaling (Garratt et al., 2000b; Michailov et al., 2004; Taveggia
et al., 2005). Thus, the physiological BACE1-mediated processing of
NRG1 seems to be a key trophic instruction for the normal
development and maintenance of myelin physiology, at least in the
PNS. As PrPC is known to interact and regulate BACE1 activity (Parkin
et al., 2007), we were led to investigate whether PrPC could inﬂuence
the physiological NRG1 processing, both in the CNS and in the PNS.
We found that PrPC positively inﬂuences the processing of NRG1 in
the old, but not young, PNS of the mouse. Aged Prnp0/0 mice show
indeed a signiﬁcant reduction in the levels of NRG1 cleaved fragments,
in contrast to their wildtype littermates. We could also conﬁrm an
inﬂuence of PrPC on the cleavage of neuregulin-3 (NRG3), another
BACE1 substrate and member of the NRG. This inﬂuence of PrPC on
neuregulins processing, however, is not detectable in the CNS. Hence,
our results suggest that the inﬂuence of PrPC on the cleavage of NRG1
(and NRG3) is limited to the PNS of aged mice. These ﬁndings point at
different functional roles of PrPC in the CNS and in the PNS and
conﬁrm an involvement of PrPC in peripheral myelin maintenance
during aging processes.
Results
NRG1 processing is developmentally regulated in sciatic nerves
The NRG1 proteins are one of the major axonal cues acting as
myelination-promoting factor during PNS development (Garratt et al.,
2000a; Jessen and Mirsky, 2005; Nave and Salzer, 2006; Newbern and
Birchmeier, 2010). Alteration in the processing of NRG1 has been
linked to deﬁcit in correct myelination mechanisms (Hu et al., 2006;
Willem et al., 2006), thus showing that the resulting cleaved
fragments, rather than the full length pro-proteins, are the active
key instruction for a physiological myelination process. In order to
analyze the processing of NRG1 during PNS development and
maturation, we undertook a time-course analysis of NRG1 expression
in total protein extracts from mouse sciatic nerves at different ages
(postnatal days P15, P30, P90 and P120) (Fig. 1A). The anti-NRG1
antibody sc-348 that we used recognizes an epitope speciﬁc to the
most common cytoplasmic tail variant in the NRGs expressed in the
nervous system (Wen et al., 1994). In Western blot analyses, two
main proteins at ~140 kDa and ~100 kDa were labeled in sciatic nerve
protein extracts with both the cytoplasmic tail antibody (sc-348)
(Fig. 1A) and the NRG1 N-terminal antibody sc-28916 (data not
shown). Labeling of these proteins by antibodies directed against both
the N-terminal ectodomain and cytoplasmic domain epitope points
that these are NRG1 pro-proteins. Additionally, two ~65- and ~55-kDa
proteins were labeled by the cytoplasmic tail antibody, indicating thatthese proteins are C-terminal fragments (CTFs) resulting from stalk
cleavage of the pro-proteins. The reason why there are C-terminal
fragments with two different electrophoretic mobilities is unknown.
However, the pro-protein and C-terminal fragment sizes that we
observed are consistent with previous analyses of NRG1 processing
(Burgess et al., 1995; Carroll et al., 1997; Loeb et al., 1998; Savonenko
et al., 2008).
We found that, during this time course, the levels of full length
NRG1 pro-proteins (NRG1-FL) signiﬁcantly decrease with age to very
low detectable levels, while the levels of the cleaved C-terminal
fragments of NRG1 (NRG1-CTFs) signiﬁcantly increase up to stage
P90, reaching then a steady-state level (Fig. 1B) which persists at least
till 1 year of age (data not shown). This ﬁnding suggests that active
processing of NRG1 is taking place and increasing during postnatal
development, and once the PNS reaches full maturation, NRG1
bioactive cleaved fragments are constantly produced during
adulthood.
NRG1 cleavage is altered in the PNS of aged, but not young, Prnp0/0 mice
Mice lacking PrP (Prnp0/0 mice, (Bueler et al., 1992)) were
recently shown to manifest a late-onset peripheral demyelinating
polyneuropathy (Bremer et al., 2010). As the deﬁcit in the proteolytic
fragments of NRG1 has been linked to a loss of myelin homeostasis
(Hu et al., 2006; Willem et al., 2006), we compared the levels of
NRG1-CTFs in the sciatic nerves of wildtype mice and of their Prnp0/0
littermates at different ages. According to the authors of this work
(Bremer et al., 2010), we could not identify any signiﬁcant difference
in NRG1 processing during early postnatal development, at P15
(Fig. 2A) and at P30 (Fig. 2B). However, by increasing the age of the
animals under investigation, we could ﬁnd a decreasing level of
NRG1-CTFs at 5 months of age (P150) in Prnp0/0 mice yet not
reaching statistical signiﬁcance (Fig. 2 C). Finally, when we analyzed
1-year-old mice sciatic nerves, we found signiﬁcant lower levels of
the NRG1-CTFs in Prnp0/0 mice compared to their wildtype
counterpart (Fig. 2D). Thus, during early postnatal PNS development
Prnp0/0 and wildtype mice show no differences in NRG1 processing;
in contrast, with aging, Prnp0/0 mice show a chronically defective
processing of NRG1 protein.
PrPC stimulates ectodomain shedding of NRG1 in cell cultures
We have identiﬁed that the lack of PrPC in sciatic nerves reduces
the levels of NRG1-cleaved fragments. In order to verify whether high
levels of PrPC, on the contrary, could enhance the production of NRG1
cleaved fragments, we took advantage of N2a and N2a-CL3 cell lines.
N2a-CL3 cell line consists of N2a cells stably transfected with full-
length mouse PrPC (Ghaemmaghami et al., 2010) to express higher
level of PrPC than normal N2a cells. We conﬁrmed the higher levels of
PrPC in cell lysates of N2a-CL3 cells compared to N2a cells (Fig. 3A).
Then, we checked for NRG1 levels in cell lysates and in the
conditioned medium. We took advantage of the sc-28916 antibody,
raised against the N-terminal domain of NRG1, in the perspective that
the functional bioactive EGF-like containing ectodomain, after
proteolytic cleavage of NRG1 pro-protein, could be detectable also
in the extracellular environment. We could observe that, in N2a-CL3
cell lysates, compared to N2a cell lysates, there was a signiﬁcant lower
amount of total NRG1-FL, in contrast to a higher amount of the NRG1-
N-terminal fragment (NRG1-NTF, ~70 kDa) (Fig. 3A and B). The size of
the NRG1-NTF detected in our Western blots is consistent with
previous studies on cell cultures, brain and spinal cord samples
(Sandrock et al., 1995; Bermingham-McDonogh et al., 1996; Carroll et
al., 1997; Wang et al., 2001). We then checked in the conditioned
medium (CM) of N2a and N2a-CL3 cells for the presence of NRG1-NTF
and we could identify a signiﬁcant higher amount of NRG1-NTF in the
conditioned medium of N2a-CL3 cells compared to the conditioned
Fig. 1. The processing of NRG1 proteins is developmentally regulated in the sciatic nerve. (A) Sciatic nerves were excised frommice at different developmental stage (n=4, for each
age) and protein extract (50 μg/lane) was analyzed for NRG1 content. We used an anti-NRG1-C-terminal antibody, by which we can recognize full length NRG1 pro-proteins and C-
terminal fragments after cleavage (NRG1-CTFs). (B) Quantiﬁcation of the Western blot; values of NRG1 full length and of NRG1-C-terminal fragments were normalized on beta-
tubulin levels, and expressed as percentage of total neuregulin protein. Values are expressed as mean±SD; *p≤0.05; n.s.=not statistically signiﬁcant.
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levels of PrPC potentiate NRG1 cleavage in intracellular compartments
and that, after this processing, the NRG1 N-terminal fragment is
released in the extracellular environment.Fig. 2. The proteolytic cleavage of NRG1 is affected in aged, but not young, Prnp0/0 mice sciatic
(C), and P365 mice (D) from wildtype (Wt) and Prnp0/0 mice. (A) Western blot of sciatic
recognizing the C-terminal fragments after cleavage (NRG-CTFs) of NRG1. Quantiﬁcation o
(B) Western blot of sciatic nerve protein extracts of P30 Prnp0/0 (n=3) and Wt (n=3) mi
of NRG1. Quantiﬁcation of the NRG-CTFs was normalized to the expression levels of beta-t
(n=3) and Wt (n=4) mice using an antibody recognizing the C-terminal fragments a
to the expression levels of beta-tubulin (right panel). (D)Western blot of sciatic nerve protei
C-terminal fragments after cleavage (NRG-CTFs) of NRG1. Quantiﬁcation of the NRG-CTFs wa
as mean±SD; n.s.=not statistically signiﬁcant.Prnp0/0 mice show a defective cleavage also of NRG3
The protein PrPC was previously shown to regulate BACE1-
mediated cleavage of APP, a molecule that plays a central role in thenerves. Comparison between protein extracts of sciatic nerves of P15 (A), P30 (B), P150
nerve protein extracts of P15 Prnp0/0 (n=3) and Wt (n=5) mice using an antibody
f the NRG-CTFs was normalized to the expression levels of beta-tubulin (right panel).
ce using an antibody recognizing the C-terminal fragments after cleavage (NRG-CTFs)
ubulin (right panel). (C) Western blot of sciatic nerve protein extract of P150 Prnp0/0
fter cleavage (NRG-CTFs) of NRG1. Quantiﬁcation of the NRG-CTFs was normalized
n extract of P365 Prnp0/0 (n=5) andWt (n=9)mice using an antibody recognizing the
s normalized to the expression levels of beta-tubulin (right panel). Values are expressed
31S. Benvegnù et al. / Molecular and Cellular Neuroscience 47 (2011) 28–35pathogenesis of Alzheimer's disease (AD) (Parkin et al., 2007). As
BACE1 is known to cleave other different substrates, we were
prompted to verify whether PrPC could regulate the cleavage of
other BACE1 substrates. The protein NRG3 is another member of the
NRG (Zhang et al., 1997) and was shown to share the same BACE1
cleavage site of NRG1 and to be directly processed by BACE1 (Hu et al.,
2008). Thus, we investigated whether the levels of NRG3 could also
change between wildtype and Prnp0/0 mice sciatic nerves. Similarly to
the brains and sciatic nerves of BACE1 null mice (Hu et al., 2008), we
found a signiﬁcant accumulation of unprocessed full length NRG3 in
the sciatic nerves of Prnp0/0 mice, when compared to their wildtype
counterpart (Fig. 4). Thus, we could observe that also NRG3
processing is affected in the PNS of mice lacking PrP.Fyn and ERK kinases signaling pathways are not affected in sciatic
nerves of Prnp0/0 mice
In neuregulin canonical signaling pathways, mature cleaved NRG1
proteins bind to and induce dimerization of ErbB receptors, which in
turn activate auto-phosphorylation of the receptors themselves and
the subsequent downstream activation of intracellular signaling
pathways (Mei and Xiong, 2008). Among these, the extracellular
signal-regulated kinase (ERK) (Si et al., 1996; Tansey et al., 1996) and
Fyn kinase (Bjarnadottir et al., 2007) pathways can be activated.
Moreover, PrPC was also shown to signal through the same signaling
pathways (Mouillet-Richard et al., 2000; Toni et al., 2006). In addition,
Fyn kinase is known to regulate CNS (Umemori et al., 1994) and,
recently, also PNS myelination (Hossain et al., 2010). Nevertheless,
Bremer et al. (2010) could not detect any alteration of Akt and ERK
kinases phosphorylation during PNS myelination (ages P10 and P30).
The convergence of these signaling pathways led us to investigate
whether there could be an aberrant activation of Fyn or ERK kinases in
aged Prnp0/0 mice compared to their wildtype counterpart. However,
we also could not ﬁnd any alteration of ERK or Fyn kinases activation
in the sciatic nerves between aged wildtype and Prnp0/0 mice (Fig. 5).
This ﬁnding suggests that these signaling pathways are still active inFig. 3. The shedding of NRG1 ectodomain is enhanced by overexpression of PrPC in cell lines.
and cellular extract and conditioned medium were prepared and analyzed for the levels of N
on NRG1 after cleavage (NRG1-NTF). (A) Western blots of cell lysates and conditioned med
lysates, compared to N2a cell lysates (upper panel). Cell lysates of N2a-CL3 cells show a reduc
cell lysates (central panel). Conditioned media were also analyzed for the levels of NRG1-NT
(left) and N2a-CL3 (right) cells. Values were normalized to the levels of beta-tubulin, and ex
conditioned medium of N2a (white column) and N2a-CL3 (black column) cells. Values areaged Prnp0/0 mice as in physiologically myelinated nerves and thus are
not inﬂuenced by the lack of PrPC or by a deﬁcit in NRG1 processing.
Neuregulins processing is not altered in the CNS of Prnp0/0 mice
We found a correlation between the lack of PrPC and a defective
processing of NRG1 and NRG3 in the PNS (sciatic nerves) of aged
animals. In order to verify whether this processing was defective also
in the CNS, we analyzed the levels of NRG1 and NRG3 in hippocampal
homogenate from 1-year-old wildtype and Prnp0/0 mice. We failed to
detect any difference in expression and processing of NRG1 and NRG3
in the hippocampus between wildtype and Prnp0/0 mice (Fig. 6). Thus,
we can conclude that the lack of PrPC inﬂuences neuregulins
processing only in the PNS of aged mice, whereas in the CNS this
inﬂuence is not effective.
Discussion
The physiological function of PrPC is still under intense investiga-
tion. The protein PrPC has been shown to inﬂuence several important
aspects of cell biology, including cell adhesion, neurite outgrowth,
protection against oxidative stress, and myelin homeostasis
(reviewed by Aguzzi et al. (2008)). Recently, Prnp0/0 mice were
shown to manifest a late-onset chronic demyelinating polyneuro-
pathy (Bremer et al., 2010). Interestingly, this phenotype was evident
only in the PNS of aged Prnp0/0 mice. Moreover, the demyelination
was recovered by expression of axonal PrPC and not by glial
expression. This suggests an axonal trophic support, mediated by
PrPC neuronal expression, acting in trans to Schwann cells for a
physiological myelin homeostasis. Thus, we were prompted to
investigate for a neuron-speciﬁc key element that could be regulated
by PrPC and is involved in myelin homeostasis. PrPC was previously
shown to interact and regulate the β-site of APP cleaving enzyme
(β-secretase BACE1) (Parkin et al., 2007). The protease BACE1 is
preferentially expressed by neurons (Rossner et al., 2001), and
interestingly, BACE1 null mice show myelin defects in the CNS and the
PNS (Hu et al., 2006; Willem et al., 2006). These defects were bona ﬁdeN2a and N2a-CL3 cells stably overexpressing PrPC were cultured in serum-free medium,
RG1 using an antibody recognizing full length (NRG1-FL) and the N-terminal fragment
ium from N2a and N2a-CL3. We conﬁrmed the overexpression of PrPC in N2a-CL3 cell
ed level of NRG1-FL and a concomitant increased level of NRG1-NTF, if compared to N2a
F (lower panel). (B) Quantiﬁcation of NRG1-FL and NRG1-NTF in the cell lysates of N2a
pressed as percentage of total NRG1 protein. (C) Quantiﬁcation of the NRG1-NTF in the
expressed as mean±SD; *p≤0.05.
Fig. 4. Unprocessed NRG3 accumulates in the sciatic nerves of Prnp0/0 mice. Sciatic nerve protein extracts of 1-year-old wildtype (Wt) (n=9) and Prnp0/0 (n=5) mice were
investigated for the levels of full length NRG3. The amount of full length NRG3 was analyzed quantitatively and normalized to the expression level of beta-tubulin (right panel).
Values are expressed as mean±SD; *p≤0.05.
32 S. Benvegnù et al. / Molecular and Cellular Neuroscience 47 (2011) 28–35linked to a lack of processing of NRG1 proteins, which are BACE1
substrates and key regulators of PNSmyelination (Mei and Xiong, 2008;
Newbern and Birchmeier, 2010). Thus, we investigated whether,
besides regulating BACE1 activity in the cleavage of APP (Parkin et al.,
2007), PrPC could also regulate the cleavage of other BACE1 substrates,
i.e., neuregulins.
Here we demonstrate that Prnp0/0 mice show a defective processing
of NRG1. However, this defect in NRG1 processing is time- and tissue-
deﬁnite. Indeed, we could highlight a difference in NRG1 processing
only in aged Prnp0/0 mice compared to their wildtype counterpart,
whereas in young animalswe could not ﬁnd any difference between the
two genotypes. This ﬁnding hints that during the ﬁrst postnatal
development, i.e., during the initial PNS myelination process, PrPC role
for neuregulin processing is dispensable, whereas it starts to exert its
effects and to be relevant in adult and aged animals. This is suggestive of
a physiological role of PrPC for NRG1 processing during the aging of an
animal. Moreover, Prnp0/0 mice showed altered NRG1 cleavage only in
their PNS, whereas they did not show any difference, if compared to
their wildtype counterpart, in NRG1 processing in the CNS at any age of
investigation. Themolecule PrPC thus seems to fulﬁll different functions
between CNS and PNS, at least for NRG1 processing and, in turn,
possibly for myelin homeostasis.
In order to verify whether PrPC could directly stimulate the
cleavage of NRG1, we used N2a cells stably over-expressing full-
length mouse PrPC and identiﬁed an increase of NRG1-N-terminal
cleaved fragment both in the cell lysates and in the conditioned
medium. This suggests that the cleavage of NRG1, stimulated by PrPC
expression, occurs in intracellular compartments, for example in the
endosomal system, and then the cleaved fragment is released in the
cell medium, probably through a subsequent move of the cleaved
fragment to the protein secretory pathway. The protease BACE1 is
known to cleave its substrate APP in the endosomal pathway and thenFig. 5. ERK and Fyn kinases signaling pathways are not altered in the sciatic nerves of
Prnp0/0 mice. Western blot of protein extracts from sciatic nerves of 1-year-old wildtype
(Wt) (n=9) and Prnp0/0 (n=5)mice. The levels of total Fyn protein, of phosphorylated
Fyn and phosphorylated ERK proteins do not signiﬁcantly change between wildtype
and Prnp0/0 mice.the cleaved fragment is released in the extracellular medium via the
secretory pathway (Koo and Squazzo, 1994; Thinakaran et al., 1996;
Tomita et al., 1998; Marlow et al., 2003). This suggests the need of
acidic compartments (i.e., endosomes and/or late Golgi) for BACE1
activity. This ﬁnding hints that BACE1-mediated cleavage of NRG1
may require the same endocytosis/recycling process as for BACE1-
mediated APP processing.
We also identiﬁed altered processing of NRG3 in Prnp0/0 mice.
NRG3 is another member of the NRG, possesses a similar structural
organization to NRG1, and also activates ErbB receptor (Zhang et al.,
1997). Like NRG1, NRG3 is also substrate of BACE1, and after
proteolytical cleavage it was proposed to bind Schwann cells ErbB
receptors (Hu et al., 2008). We could detect a difference in processing
also for NRG3 only in the PNS of Prnp0/0 mice and not in the CNS if
compared to wildtype animals. Hence, PrPC can stimulate the
processing of neuregulins only in the PNS and not in the CNS.
We also investigated whether two intracellular signaling pathways,
i.e., ERK and Fyn kinases, linked both to PrPC and neuregulins signaling,
could be altered in the sciatic nerves of Prnp0/0 mice, but we could not
highlight any difference from their wildtype counterpart in the
activation of these two signaling cascades. This suggests that other
signaling pathwaysmay be affected by the lack of PrPC and the defective
neuregulin processing. Further studies need to investigate other
intracellular cascades related to both PrPC and neuregulin signaling
(for example, the PI3K pathway (Li et al., 2001; Roffe et al., 2010)).
The age-dependent effect of PrPC on neuregulin processing may be
associated to different cellular mechanisms. Lipid rafts are dynamic
and highly ordered sterol- and sphingolipid-enriched domains that
can concentrate selected subsets of proteins and serve as a platform
for cellular processes, including cell signaling, protein sorting and
trafﬁcking, and extracellular/membrane protein proteolysis (Simons
and Toomre, 2000; Ledesma et al., 2003; Helms and Zurzolo, 2004;
Hancock, 2006). Rafts are continuously endocytosed from cellular
plasma membrane via the endocytic pathway, and either recycled
back to the plasmamembrane or returned to the Golgi apparatus (Puri
et al., 1999; Mukherjee and Maxﬁeld, 2000). Neuregulin (Frenzel and
Falls, 2001), PrPC (Vey et al., 1996) and BACE1 (Riddell et al., 2001) are
all enriched in lipid rafts domains.Moreover, targeting BACE1 lumenal
domain to lipid rafts by the addition of a glycophosphatidylinositol
anchor was shown to increase BACE1-mediated APP processing
(Cordy et al., 2003). This hints at lipid rafts as functional compartment
for BACE1 activity. Besides, PrPC was shown to exert its regulation on
BACE1-mediated APP cleavage only when correctly localized to lipid
rafts domain (Parkin et al., 2007). Although from our experiments we
cannot draw a direct functional link between PrPC and the regulation
of BACE1, our ﬁndings suggest that PrPC could physiologically
inﬂuence also the BACE1-mediated neuregulins cleavage and this
occurring in an endocytosis/secretory pathway-dependent manner.
Lipid rafts however do not maintain the same protein and lipid
composition: with aging and in pathological condition (like in AD),
the ratio between cholesterol, sphingolipid and phospholipid changes
(Prinetti et al., 2001; Palestini et al., 2002; Martin et al., 2010). This in
Fig. 6. Processing of NRG1 and NRG3 is not altered in the hippocampus of Prnp0/0 mice. Hippocampal homogenates from 1-year-old wildtype (Wt) (n=3) and Prnp0/0 (n=3) mice
were analyzed for the levels of NRG1 proteins using antibody against the N-terminus of NRG1 (A) against the C-terminus of NRG1 (B) or against full length NRG3 (C). The Western
blot showed no signiﬁcant difference in expression or processing of both NRG1 and NRG3 proteins between wildtype and Prnp0/0 mice hippocampi. Quantiﬁcation of the Western
blot: values of NRG1 full length, NRG1 terminal fragments and NRG3 were normalized on beta-tubulin levels (lower panels). Values are expressed as mean±SD; *p≤0.05.
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As a consequence of this, the protein composition of the lipid rafts
may dramatically change, and this can consequently modify their
properties as “signaling scaffolds” during different cellular life stages.
Hence, we may suggest that, during early postnatal development, the
lack of PrPC in lipid rafts and the speciﬁc protein/lipid composition
may not destabilize BACE1-mediated NRGs processing, whereas by
changing the biochemical composition of the rafts, i.e., with adulthood
and aging, the lack of PrPC could instead destabilize lipid rafts-
mediated BACE1–NRGs interaction. This in turn could lead to the
observed altered NRGs processing. In this perspective, PrPC may be a
crucial key element in lipid rafts protein homeostasis, composition
and in physiological signaling processes during lifetime, and partic-
ularly during aging.
Moreover, the possible age-dependent inﬂuence of PrPC on BACE1-
mediated neuregulin cleavage may be also due to the opposite
dynamic expression levels between PrPC and BACE1 throughout the
lifespan of the animal. Indeed, PrPC levels were shown to increase
during postnatal development then reaching a plateau of expression
in adulthood (Sales et al., 2002), whereas BACE1 levels are high during
development and then decrease to a low levels in adult animals
(Willem et al., 2006). Thus, PrP inﬂuence could be minimal during
early development when PrPC low levels of expression overlap the
high levels of BACE1; on the contrary, in adult animals, the minimal
expression of BACE1 could be strongly inﬂuenced by the high levels of
PrPC. Accordingly, in Prnp0/0 mice BACE1 activity may not be affected
by the lack of PrPC in young animals, while on the contrary it can be
effectively altered during adulthood and aging of the animals.
The mechanisms responsible for the tissue-dependent inﬂuence of
PrPC on neuregulin processing also are not clear and need furtherinvestigation. We detected altered NRGs processing only in the PNS of
aged Prnp0/0 mice and not in their CNS. This can suggest that some
compensatory mechanism for neuregulin processing may occur in the
CNS, whereas it is not effective in the PNS.
Pharmacological inhibition of BACE1 in adult mice brain was
shown to induce signiﬁcant Aβ-peptide lowering, but it was without
any major effect on brain NRG1 processing (Sankaranarayanan et al.,
2008). The same study suggests differences in BACE1-mediated NRG1
processing only in early development in the brain, as aged (2-years-
old) BACE1 null mice show identical full-length NRG1 and NRG-NTF
levels to their wildtype counterpart. Therefore, BACE1 inhibition in
the brain showed to have an effective impact on the lowering of APP
processing and no alteration on NRG1 processing. Similarly, PrPC was
shown to inhibit BACE1-mediated APP processing in the brain (Parkin
et al., 2007), whereas in our present study we could not detect any
role for PrPC on NRG1 processing in the CNS of aged mice. These
independent ﬁndings are suggestive of a different PrPC inﬂuence on
BACE1 processing activity between the CNS and the PNS.
Taken together, our ﬁndings are indicative of the occurrence of
different age-dependent and tissue-dependent cellular mechanisms
for the regulation of neuregulins processing. We envision that future
studies on NRGs processing and cleavage need to take into deep
account the different ages and tissues of the animals under
investigation, in order to describe a correct spatial and dynamic
frame of neuregulins processing and biological action.
Conclusions
In summary, our study points at PrPC as a positive regulator of
NRGs processing. This effect was manifest as age-dependent (only in
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but not in the CNS). Our results suggest that PrPC could exert different
functions, during development and aging, between the CNS and the
PNS, at least as regards neuregulin processing and possibly myelin
homeostasis. In turn, this ﬁnding could shed new light on the etiology
of the peripheral demyelinating neuropathy affecting aged mice null
for the PrP (Bremer et al., 2010).
Experimental methods
Animals
C57/B6 wildtype, mixed B6/129 wildtype, B6/129 Prnp0/0 (Bueler
et al., 1992), FVB wildtype and FVB Prnp0/0 (Lledo et al., 1996) mice
were used in these experiments. All experiments were carried out in
accordance with European regulations [European Community Council
Directive, November 24, 1986 (86/609/EEC)] and were approved by
the local authority veterinary service. After animal sacriﬁce, tissues
were immediately dissected and processed for protein analysis.
Protein analysis
Mouse hippocampi and sciatic nerves were dissected and
immediately frozen in ice-cold lysis buffer (50 mM Tris–HCl pH 7.5,
150 mM NaCl, 1 mM EDTA, 0.5% CHAPS, 10% glycerol) containing
proteases inhibitors (Inhibitor complete mini, Roche Diagnostics
Corp., Mannheim, Germany) and stored at −80 °C or immediately
homogenized. Hippocampal samples were further cleared by centri-
fugation at +4 °C, 2000g, 10 min. For sciatic nerves of P15 and P30
wildtype and Prnp0/0 mice, nerves from 2 animals were pooled
together in each sample, while for older mice each sample included
sciatic nerves from a single animal. Total protein content was
determined by the bicinchoninic acid (BCA) assay (Pierce), and the
same amount of proteins for each sample (50 μg) was separated either
on gradient SDS–PAGE gels (NuPAGE® Novex 4-12%, Invitrogen) or
on 8% homemade SDS–PAGE gels, and transferred to PVDFmembrane.
Antibodies
We used the following primary antibodies: NRG1 C-Terminal
epitope, C-20 (sc-348, Santa Cruz Biotechnology); NRG1 N-terminal
epitope, H-210 (sc-28916, Santa Cruz Biotechnology); NRG3, H-70
(sc-67002, Santa Cruz Biotechnology); Anti-PrP antibody HRP-
conjugated Fab D13 (Williamson et al., 1998); anti total non-
phosphorylated Fyn, phosphorylated Fyn and phosphorylated ERK
kinases [Src Family Antibody #2109, phospho-Src Family (Tyr416)
antibody #2101, and phospho-p44/42 Map Kinase (Thr202/Tyr204)
Ab #9101, Cell Signaling Technology].
Cell culture
N2a and N2a-CL3 cells, stably transfected with and overexpressing
full-length mouse PrPC, were cultured as previously described
(Ghaemmaghami et al., 2010). Brieﬂy, all cell lines were maintained
in Modiﬁed Eagle's Medium (MEM) supplemented with 10% vol/vol
fetal bovine serum, 1% penicillin–streptomycin, and 1% GlutaMAX
(Invitrogen) at 37 °C in a humidiﬁed atmosphere with 5% CO2.
Preparation of cytosolic extracts and conditioned medium proteins
Cells were grown almost to conﬂuency in 10-cm diameter tissue
culture plates (Corning). Cells were then washed with PBS (3×) and
maintained in serum-depleted MEM for 40 h. Conditioned medium
was then removed, spun at 10,000g, 10 min, 4 °C to remove cell
debris, and then precipitated with 5 volumes of cold acetone. Samples
were incubated at least 2 h at−20 °C, and then spun at 5000g, 20 min,4 °C. Protein pellets were then air dried and resuspended in Laemmli
buffer.
The cell layer remaining in the plate after the incubation period in
serum-free MEMwas washed with PBS (3×) and lysed with 500 μL of
cold lysis buffer (10 mm Tris–HCl, pH 8.0, 150 mm NaCl, 0.5% sodium
deoxycholate, 0.5% Nonidet P-40). Cell lysates were then centrifuged
at 10,000g, 5 min, 4 °C to remove cell debris. The supernatant was
collected and the total protein concentration was measured by using
the bicinchoninic acid assay (Pierce). The conditioned medium and
cell lysates were normalized for total protein based on the cell lysate
protein concentrations, boiled for 5 min, electrophoresed on gradient
SDS–PAGE gels (NuPAGE® Novex 4–12%, Invitrogen) and transferred
to PVDF membrane.
Data and statistical analysis
Image analysis was carried out with Quantity One® software v
4.6.2 (Bio-Rad). In each gel, bands were detected, background was
subtracted and protein bands quantities were deﬁned with the
dedicated functions. We took advantage of the “Volume analysis” tool
provided with the software. For the analysis, we used the adjusted
volume parameter, corresponding to the band volume [i.e., the sum of
the intensities of the pixels inside the volume boundary×area of a
single pixel (in mm2)] minus the background volume. Each value was
then normalized against the b-tubulin value of the same biological
sample. Then, normalized results were analyzed with Student's t test,
with a cutoff value of p≤0.05.
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